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L Stellingen behorend bij het proefschrift 
\.� I 
I�mhnotherapeutic strategies in patients with solid malignancies ,,Qrtsing the line between scientific possibility and clinical reality" 
j Caroline J. Voskens -------1. Immobilized Fe enhances the expression of CD137 on IL-2 stimulated human NK cells and expression levels are dependent on patterns of Fe glycosylation (this thesis) 
2. CD137 expressing human NK cells play a role in immunomodulation rather than exhibiting direct cytotoxic functions (this thesis) 
3. CD137-CD137L interactions promote human B cell proliferation and survival (this thesis) 
4. Ex vivo NK cell expansion in the presence of exogenous IL-2 and CD137L/IL-15 expressing K562 cells turns the NK receptor balance towards activation resulting in natural cytotoxicity and ADCC against autologous gastric tumor cells (this thesis) 
5. Polymorphisms at amino acid position 158 of the Fe receptor are associated with antigen-dependent and antigen-independent NK cell mediated cytotoxicity (this thesis) 
6. The disparity of CD137 expression and function between human and murine NK and B cells challenges the use of murine-based disease models for the evaluation of CD 13 7 mediated immune regulation (this thesis) 
7. Applying immune-related response criteria on previously conducted clinical studies will likely re-identify various immunotherapeutic strategies with proven favorable toxicity profiles and potential benefit for patients with solid tumors 
8. ,,It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change" Attributed to Charles R. Darwin 
9. "Pride: Having it makes giving anything less than your best an impossibility. Conversely, knowing you have given your best makes the failure bearable" Marshall Strome 
10. Vasthouden betekent loslaten 
11. "The future belongs to those who can see opportunities before they get obvious" Oscar Wilde 
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Chapter 1 Introduction 
Cancer immunotherapy is a form of cancer treatment, which holds great promise. 
Its main premise is to stimulate natural occurring immune responses or to facilitate 
de nova immune responses directed against tumor cells. Despite their recognized 
therapeutic potential in murine models, most immunotherapeutic strategies have 
demonstrated little clinical efficacy when tested in phase I/II clinical trials ( 1 ). 
Recent reviews have reported that objective tumor regression in cancer patients is 
rare when measured by strict Response Evaluation Criteria In Solid Tumors 
(RECIST) criteria (2). In many of the clinical studies, the tumors failed to regress 
despite robust antigen-specific immune responses as measured by ex vivo 
laboratory techniques. These findings have led to two main questions. First, why is 
there little correlation between antigen-specific immune response and outcome 
among clinical studies? Second, how can we improve immunotherapeutic strategies 
to optimize therapeutic efficacy? 
Main characters of the immune system 
The first line of defense against tumor cells is mediated by the innate immune 
system. This response is quick, non-specific, short-lived and mediated by 
neutrophils (including granulocytes and eosinophils), macrophages, natural killer 
(NK) cells, y8 T cells, monocytes and dendritic cells. During its mode of action, the 
innate immune system also activates the adaptive immune system. This second line 
of defense is slow, specific, long-lasting and generally mediated by T and B cells. 
Innate immune system 
NK cells 
NK cells are thought to be the most important cells of the innate immune system 
that play a role in antitumor immunity. They were identified more than 30 years 
ago as a population of lymphokine activated killer cells that showed the ability to 
kill tumor cells in vitro in the absence of prior immune sensitization of the host (3-
6). Their biologic activity is controlled by a complex repertoire of surface receptors 
which, upon engagement by ligands on a target cell, signal either an inhibitory or 
activating (cytotoxic) response (7). The major inhibitory and activating receptors 
are products of germ line genes encoding killer cell immunoglobin-like receptors 
(KIRs) and in an autologous environment, inhibition of NK cell cytotoxic activity 
is dominant and governed by epitopes on self HLA class I alleles. This functional 
competency is also known as licensing (8). In general, cytotoxic activity is 
triggered when the target cell lacks expression of some or all HLA class I 
molecules; the basis for the "missing self' hypothesis (9). Importantly, NK cells 
express Fe-receptors, which enable them to mediate tumor cell killing through a 
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mechanism known as antibody-dependent cellular cytotoxicity (ADCC) (10,11). In 
addition, NK cells may amplify the adaptive immune response through the 
production of cytokines ( e.g. Interferon-y and Interleukin-2) which directly 
enhances the antigen presentation function of dendritic cells (12). 
Dendritic cells 
Dendritic cells (DC) possess an unique antigen presenting capacity since they are 
able to take up and process tumor-derived antigens (13). After processing, the 
tumor-derived antigens are presented in the context of HLA class I and II 
molecules expressed on the DC to T cells (14). In addition, DC provide co­
stimulatory signals necessary to induce tumor-specific T cell expansion (15). 
Importantly, only fully mature DC are able to boost tumor-specific immunity, since 
lack of DC maturation is associated with T cell tolerance (16). 
Adaptive immune system 
Tcells 
T cells are generally separated into CD8+ cytotoxic T cells (CTL) and CD4+ T 
helper cells. CTL recognize tumor-specific peptides presented in the context of 
HLA class I molecules expressed on most nucleated cells in the body, whereas T 
helper cells mainly recognize tumor-specific peptides presented in the context of 
HLA class II molecules expressed on DC. CTL are able to directly mediate 
antitumor directed immune responses. In contrast, the direct interaction of T helper 
cells with dendritic cells results in the activation and maturation of these cells and 
facilitates the effective presentation of tumor-specific antigens to CTL (17-19). 
Furthermore, tumor-specific T helper cells are required for the generation of tumor­
specific memory T cell responses (20,21). Various subsets of CD4+ T helper cells 
have been identified including (i) T helper 1 {Th-1) cells, (ii) T helper 2 {Th-2) 
cells and (iii) IL-17 producing T helper (Th-17) cells. The secretion of Th-1 
specific cytokines (e.g. IFN-y, IL-2) by Th-1 cells further supports induction of T 
cell mediated antitumor immunity. For example, the release of IFN-y by activated 
Th-1 cells activates antigen-presenting cells to up-regulate HLA class I and co­
stimulatory molecules which augment overall antigen presentation to CTL (22). In 
addition, the production of IL-2 directly stimulates CTL growth and proliferation 
(23) and it is recently reported that Th-1 cells rescue CTL from activation-induced­
cell-death (AICD) upon antigen encounter (24). Importantly, Th-1 cells not only 
provide help to CTL, they also demonstrate direct cytotoxic activity against tumor 
cells in several studies (25-29). There is evidence that some tumors ( e.g. 
melanoma, lung cancer, breast cancer and osteosarcomas) express HLA class II 
which facilitates recognition and direct killing by Th-1 cells (30). Th-2 specific 
12 
Chapter 1 Introduction 
cytokines (e.g. IL-4, IL-5, ILlO and IL-13) secreted by Th-2 cells establish 
delayed-type-hypersensitivity reactions in the tumor microenvironment, thereby 
recruiting tumoricidal macrophages and degranulating eosinophils to the tumor 
area (31), whereas Thl 7 cells are thought to play an important role in inflammation 
(32). Finally, regulatory T cells (Treg) are described. Treg are known to suppress 
CD8+ and CD4+ T cells and are critical for the maintenance of self tolerance (33). 
B cells 
Upon T cell mediated activation, B cells start producing antigen-specific antibodies 
which are able to directly recognize and destroy tumor cells (34,34,35). 
Furthermore, like DC, B cells are able to capture, process and present tumor­
specific antigens in the context of HLA class II molecules (36), which further 
enhances antitumor immunity. Moreover, B cells regulate immunosuppression 
through the secretion of Interleukin-(IL)lO (37), the expression of death-inducing 
ligands (e.g. Fas ligand (FasL) and tumor necrosis factor-related apoptosis­
inducing ligand (TRAIL)) (38,39), the expression of costimulatory molecules with 
inhibitory properties (e.g. PD-Ll and PD-L2) (40,41) and the secretion of 
regulatory antibodies ( 42). 
Co-stimulation 
Long-lasting antitumor immune responses require T cell activation. In tum, 
effective T cell activation depends on two subsequent signals. First, T cell receptor 
(TCR) ligation with antigen presented by HLA molecules expressed on DC 
followed by so called "co-stimulation" mediated through defined co-stimulatory 
receptor-ligand interactions (43). Co-stimulation results in T cell proliferation, 
differentiation and survival, while lack of co-stimulation induces T cell anergy, T 
cell deletion and immune tolerance ( 44). The most studied co-stimulatory 
molecules belong to the B7 family (45) or the TNF family (46) and depending on 
receptor-ligand interaction, may signal either activation, inhibition or both (tables 1 
and 2). The ability of co-stimulating molecules to modulate T and B cell function 
and thus antitumor immune responses, has stimulated significant interest in 
manipulating these pathways with therapeutic intent. As a result, several 
humanized antibodies targeting various co-stimulatory pathways are currently 
under clinical evaluation. 
13 
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B7 family 
CD28 
The CD28 receptor is expressed on T cells and recognizes the ligands CD80 and 
CD86 (also called B7- 1 and B7-2) expressed on DC. Ligation promotes T cell 
proliferation and T cell survival ( 4 7) as well as the production of cytokines 
required for B cell activation (48). Anti-CD28 targeting initially held great 
promise, although this enthusiasm was dramatically tempered after administration 
of an anti-CD28 super agonistic antibody to healthy volunteers in 2006. Its infusion 
resulted in a massive release of pro-inflammatory cytokines inducing multi-organ 
failure ( 49) and to date, no further clinical testing has been approved. 
CTLA-4 (CD152) 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is expressed on activated T cells and, 
like CD28, interacts with CD80 and CD86 expressed on DC. However, binding 
triggers an inhibitory signal resulting in T cell inhibition. Based on binding affinity, 
CTLA-4 competes favourably with CD80 and CD86 and therefore regulates 
ongoing antitumor immune responses. Recently, a fully humanized anti-CTLA-4 
antibody (ipilimumab, Yervoy®) has been approved for the treatment of 
unresectable or metastatic melanoma. 

























































Ref indicates reference; DC, dendritic cell; CTLA-4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death 
1; NKT, natural killer-like T; PD-L 1, programmed death ligand 1; PD-L2, programmed death ligand 2; ICOS, 
inducible T cell co-stimulator; L-ICOS, inducible T cell co-stimulator ligand 
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Ipilimumab enhances pre-existing immune responses, including antitumor immune 
responses which results in prolonged median survival and the induction of 
objective clinical responses in 10-15% of treated patients (50). However, its mode 
of action is also likely to break tolerance (51) and immune-mediated adverse 
reactions (irEAs) are observed in up to 60% of treated patients (50). 
(PD-1) CD279 
The ligands for programmed death 1 (PD-1) are the B7 family members PD-Ll 
(B7-Hl) and PD-L2 (B7-DC) (45). While PD-Ll is expressed on various cell types 
(52-55), including immune cells and tumor cells, PD-L2 is mainly found on 
activated macrophages and DC (56). PD-1 is expressed on activated T cells, B 
cells, DC, activated natural killer-like T (NKT) cells and monocytes ( 40,57). PD-1-
PD-Ll/PD-L2 interactions induce T and B cell inhibition (58). In addition, PD-1-
PD-Ll/PD-L2 interactions may also directly mediate an inhibitory signal into PD­
Ll/PD-L2 expressing DC or tumor cells (reverse signaling), which may render the 
latter resistant to T cell-mediated cytotoxicity (59). First in-human clinical studies 
demonstrated evidence of antitumor activity and limited toxicity of a fully human 
IgG4 anti-PD-I (60,61) and a fully human IgG4 anti-PD-LI blocking antibody (62) 
in select refractory or relapsed solid tumor patients and additional testing in Phase I 
and II clinical studies is ongoing (www.clinicaltrials.gov). 
TNF family 
CD27 
CD27 is exclusively expressed by activated T cells, B cells and NK cells. Its 
ligand, CD70, is transiently up-regulated on T cells and B cells after antigen 
receptor stimulation and has also been found on thymic DC (63). CD27-CD70 
ligation promotes TCR-induced expansion of CTL and T helper cells as well as 
plasma cell differentiation and antibody production in B cells (64,65). In addition, 
it is thought to protect against activation-induced cell death (AICD) (66). CD27-
and CD70-specific antibodies are currently under clinical evaluation for the 
treatment of CD27+ and CD70+ tumors, respectively (www.clinicaltrials.gov). 
Furthermore, pre-clinical models are evaluating the generation of genetically 
modified tumor antigen-specific T cells (CARs). These CARs directly link the 
CD27 domain intracellularly which enables CD27-mediated co-stimulation (67). 
CD30 
CD30 was initially described as an antigen expressed on Hodgkin lymphoma cells 
(68). More recent studies reported CD30 expression in a small subset of activated T 
cells, B cells and eosinophils (69). CD30 promotes T cell proliferation in the 
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presence of TCR stimulation (70) and stimulates T cell-mediated production of IL-
2, TNFa, IFNy and IL-5 (71,72). In B cells, CD30 stimulates proliferation and 
antibody production (73,74). Its restricted expression on normal cells and high 
expression on lymphoma cells makes the CD30 receptor an ideal candidate for 
immunotherapy. Clinical evaluation of a CD30-specific antibody in patients with 
relapsed or refractory CD30+ hematological malignancies showed an overall 
response rate of 50% and a complete response rate of 34% at a 3-week treatment 
interval (75). 
OX40 (CDI 34) 
OX40 is predominantly expressed on activated CTL and T helper cells, including 
Treg (76,77), while OX40 Ligand (OX40L) can be induced on activated B cells 
(78), DC (79), Langerhans cells (80), macrophages (81 ), NK cells (82), mast cells 
(83), vascular endothelial cells (84) and smooth muscle cells (85). OX40 promotes 
T cell division and survival (86) and protects against apoptosis (87). In addition, 
OX40 is shown to stimulate effector T cells to produce IL-2 (77) and to block the 
up-regulation of CTLA-4 (88), Foxp3 (89) and IL-10 (90) which augments ongoing 
immune responses. OX40-mediated immunotherapy is geared towards its immune­
stimulatory properties and is postulated to enhance induced antitumor immune 
responses. Therefore, OX40-based immunotherapeutics will likely be employed as 
adjuvants and find a role in the combined use of various immunotherapeutic 
strategies. Patients suffering from metastatic prostate cancer are currently treated 
with an anti-OX40 antibody in a phase I clinical study which evaluates the 
combined use of anti-OX40, cyclophosphamide and radiation 
(www.clinicaltrials.gov). 
4-JBB (CDI 37) 
4-1 BB (hereafter called CD 13 7) is recognized as an important target for the 
treatment of both cancer and autoimmunity (91-95). Its expression is induced on 
both activated human T cells, NK cells and B cells (96-98), while the ligand 
(CD137L) is expressed on monocytes, DC, B cells and NKT cells (99-101). 
CD137-CD137L ligation results in T cell proliferation and increased cell survival 
(102) as well as NK-dependent antitumor immunity (92,94,100). Furthermore, 
unlike other co-stimulatory-based immunotherapies ( e.g. CTLA-4 blockade), 
CD 13 7 ligation does not result in self reactivity, but rather has therapeutic benefit 
in several murine models of autoimmune disease such as inflammatory bowel 
disease, rheumatoid arthritis and systemic lupus erythematosus ( 103-105). 
Although the mechanisms of CD137-mediated antitumor immunity and reduction 
of autoimmunity appear distinct, manipulation of this pathway is attractive for the 
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treatment of disease. First in-human studies of an agonistic fully humanized IgG4 
monoclonal anti-CD137 antibody demonstrated promising clinical efficacy ( 1 06) 
and several clinical phase I and II studies in patients with various solid 
malignancies are ongoing. However, in some patients anti-CD137 antibody 
treatment was associated with severe liver toxicity. This side effect was seemingly 
dose-dependent and self-limiting in most cases, yet remains a major concern ( 107). 
CD40 
CD40 is constitutively expressed on B cells, macrophages, DC and platelets and 
can be inducibly expressed by endothelial cells ( I  08). Binding to its ligand, CD40 
Ligand (CD40L), which is primarily expressed on T cells ( 1 09), induces B cell 
proliferation and antibody production ( 1 1 0) as well as the activation and 
maturation of DC ( 19). CD40-mediated co-stimulation augments T cell-dependent 
antitumor immunity ( 17, 19) while blocking the CD40 pathway is shown to prevent 
graft-versus-host disease ( 1 1 1 ). However, clinical trials testing anti-CD40 blocking 
antibodies were cancelled due to thromboembolic complications ( 1 12). In contrast, 
clinical testing of an agonistic anti-CD40 antibody in patients with advanced solid 
tumors was well tolerated and associated with objective tumor responses (36). 
Table 2 Receptors and ligands belonging to the TNF family 
receptor expression ligand expression signal ref 
CD27 T cells, B cells; CD70 T cells; B cells; DC activation 57 
NK cells 
CD30 T cells; B cells; CD153 T cells; B cells activation; 1 63 
eosinophils inhibition 
OX40 T cells OX40L B cells; NK cells; activation 1 64 
(CD1 34) (CD134L) DC; macrophages; 
Langerhans cells; 
mast cells; smooth 
muscle cells 
4- IBB T cells; B cells; CD137L B cells; NKT cells; activation; 93, 
(CD137) NK cells (4- IBBL) DC; monocytes inhibition 96 
CD40 B cells; DC; CD40L T cells activation 1 65 
macrophages; (CD1 54) 
platelets; 
endothelial cells 
GITR T cells; B cells; GITRL B cells; DC; activation 166 
NK cells; DC; macrophages 
macrophages HVEM T cells; APC LIGHT T cells; tumor cells activation 1 67, 
1 68 
Ref indicates reference; DC, dendritic cell; NK cell, natural killer cell; NKT cell; natural killer-like T cell; GITR, 
glucocorticoid-induced TNF receptor; GITL, glucocorticoid-induced TNF receptor ligand; HVEM, herpesvirus­
entry mediator; APC, antigen-presenting cell 
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Moreover, treatment of patients with surgically incurable pancreatic cancer with 
agonistic anti-CD40 antibody in combination with gemcitabine chemotherapy 
induced tumor regression in a subset of patients (113). Additional animal studies 
revealed that this tumor regression required macrophages, which facilitated the 
depletion of the tumor stroma. Further clinical testing of agonistic anti-CD40 
antibodies is ongoing (www.clinicaltrials.gov) and additional treatment strategies 
in which tumor cells are modified to express CD40L are explored (114). 
GJTR 
GITR is expressed on T cells, including Treg, activated B cells, macrophages, DC 
and NK cells (115,116). In contrast, GITR Ligand (GITRL) is expressed on DC, 
macrophages and B cells (117,118). Receptor-ligand interaction enhances T cell 
proliferation and the production of cytokines in an antigen-dependent manner. In 
addition, murine models provided evidence that GITR-expressing Treg lose their 
immunosuppressive function after GITR stimulation (119), although these findings 
seemed not reproducible in human in vitro models (120). 
Current concepts in cancer immunotherapy 
Immunothei::apeutic strategies are divided into two major groups: (i) passive 
immunotherapeutic strategies directly targeting tumor cells or host-defending 
immune cells including monoclonal antibodies and (ii) active immunotherapeutic 
strategies inducing tumor-specific T cells and long-lasting antitumor immune 
responses including cytokine treatment, the adoptive transfer of T cells, NK cells or 
DC and vaccination with tumor-specific peptides, tumor-specific proteins, 
irradiated tumor cells, tumor-cell lysates or DC. To date, a total of eight 
immunotherapeutics have been approved for the treatment of solid tumors which 
are summarized in table 3. 
Monoclonal antibodies 
Monoclonal antibodies have been approved for the treatment of solid malignancies 
since 1998 (121). Their antitumor effect is partially dictated by the amount of 
antibody-specific antigen expressed on the target cell (122) and relies on (i) the 
direct delivery of apoptotic signals to the target cell, (ii) the direct inhibition of 
cancer-promoting signaling pathways, (iii) ADCC, (iv) complement-dependent 
cytotoxicity (CDC) and (v) the induction of antagonistic effects and agonistic 
effects on inhibitory and activating receptors, respectively. Currently, five 
monoclonal antibodies (Herceptin®, Erbitux®, Avastin®, Vectibix® and 
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Yervoy®) are approved for the treatment of solid malignancies and several others 
are under clinical evaluation (www.clinicaltrials.gov). 
Cytokines 
Cytokines are immunomodulating molecules which are critically important in the 
development of robust self-limiting immune responses including antitumor 
responses. Their secretion by various cells, including immune cells, facilitates 
immune signaling without the need of direct cell-to-cell interactions (123). In 
general, cytokines act as a growth factor and induce immune cell activation and 
proliferation, although they can also stimulate immune inhibition. In addition, they 
may enhance or suppress the production of other cytokines or exhibit antagonistic, 
additive or synergistic effects on overall immunity. To date, Interleukin-2 {IL-2) is 
approved for the treatment of metastatic renal carcinoma and melanoma, whereas 
Interferon-alpha {IFN-a) is approved for the adjuvant treatment of stage III 
melanoma and the combined use with Bevacizumab (Avastin®) in renal 
carcinoma. In addition, various cytokines are currently under clinical evaluation 
including IL-7, IL-12, IL-15 and IL-21 (www.clinicaltrials.gov). 
Cytokines are highly pleiotropic in nature and thus, drive multiple immune-specific 
interactions (124). This is reflected by regularly observed, sometimes severe, side­
effects in association with IL-2 or IFN-a therapy. Specifically, over 80% of treated 
cancer patients experience immune-related side effects including fever, fatigue, 
headache, gastrointestinal symptoms, myalgias, thrombocytopenia, leucopenia, 
neutropenia and increased hepatic enzymes under IFN-a therapy (125). 
Furthermore, depression (45%), confusion (10%), mania (<1 %) and suicides 
(rarely) are reported (126,127). IL-2 therapy is associated with fever, chills, 
fatigue, gastrointestinal symptoms, transaminase elevation and cholestasis. In 
addition, IL-2 therapy may induce a capillary leak syndrome illustrated by 
hypotension, tachycardia, peripheral edema, cardiac arrhythmias and death ( 128-
130). However, IL-2 therapy induces objective antitumor responses in 15% of 
patients with long-lasting antitumor responses in 5% of treated patients (128). 
Cancer vaccines 
Effective cancer immunotherapy is the net result of circulating tumor-specific T 
and B cells. Therefore, cancer vaccine strategies aim at the direct presentation of 
tumor-specific antigens to T and B cells. Initial cancer vaccine approaches 
facilitated tumor-antigen presentation by direct injection of tumor-specific peptides 
(131), tumor-specific proteins, tumor-specific long peptides (including Trojan 
peptide-based vaccines) (132,133), irradiated tumor cells or tumor-cell lysates. 
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Table 3 Approved immunotherapies for the treatment of solid tumors 
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SCCHN indicates squamous cell carcinoma of the head and neck; NSCLC, non-small cell lung cancer; IL, 
Interleukin; IFN, Interferon; HER2/neu, human epidermal growth factor receptor 2; EGFR, epidermal growth 
factor receptor; VEGR, vascular endothelial growth factor; CTLA-4, cytotoxic T-lymphocyte antigen 4 
"only in combination with Interferon-alpha 
To enhance antigen-presentation and co-stimulation, cancer vaccine approaches 
were extended towards cellular vaccination with a primary focus on DC loaded or 
transfected with tumor-specific antigens. In this case tumor-specific antigens are 
presented in context of HLA class I and II molecules in the presence of co­
stimulatory molecules expressed on the DC surface which have the potential to 
regulate the antitumor immune responses (134,135). Importantly, based on this 
premise, Sipuleucel-T (Provenge®) was shown to prolong overall survival with 4.1 
months in a phase III trial conducted in patients with metastatic prostate carcinoma 
and resulted in the FDA approval of Provenge® as first cell-based 
immunotherapeutic strategy for the treatment of solid malignancies (136). 
Adoptive cellular therapy 
Adoptive cellular therapy (ACT) is a form of immunotherapy that is based on the 
ex vivo selection, activation, expansion and subsequent reinfusion of tumor-specific 
T cells into patients (137). To improve clinical responses, patients may be depleted 
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of immunosuppressive cell subsets prior to infusion. Objective tumor responses 
were observed in 56% of patients who received ex vivo expanded tumor-specific T 
cells along with IL-2 following a lymphodepletion protocol. In addition, 19  out of 
20 patients experienced long-lasting and complete tumor regression with ongoing 
remissions beyond 3 years ( 138). Unfortunately, in some of the patients, tumor 
resection for isolation of tumor-specific T cells is not feasible. Furthermore, tumor­
specific T cells fail to expand ex vivo in half of the cases assessed ( 13 7). Therefore, 
the genetic modification of autologous T cells with genes encoding for tumor­
specific T cell receptors is explored. Early clinical results demonstrated complete 
tumor regression in two out of 1 7  metastatic melanoma patients ( 139) and further 
clinical testing is ongoing (www.clinicaltrials.gov). 
Some studies focused on the ex vivo expansion and subsequent adoptive transfer of 
NK cells in patients with solid malignancies ( 140, 14 1 ), since NK cells were shown 
to mediate direct tumor cell killing ( 142). In addition, NK cells are thought to 
induce DC maturation and to facilitate cross-presentation of tumor-specific 
antigens derived from killed tumor cells ( 143). Some clinical benefit has been 
reported in patients with advanced non-small cell lung cancer (NSCLC) ( 144) and 
additional studies are ongoing 
Obstacles to successful application of immunotherapeutic 
strategies 
Successful cancer immunotherapy does not solely depend on the effective 
generation of high numbers of tumor-specific immune cells. These cells must 
localize the tumor and infiltrate the tumor microenvironment in order to clear 
primary or metastatic disease. Unfortunately, tumor cells can escape from 
antitumor immunity through a variety of mechanisms. In addition, successful 
cancer immunotherapy is further affected by the wide diversity of immune 
deficiencies found in individual cancer patients. Mechanisms associated with 
impaired antitumor immunity include (i) tolerance of T cells to tumor-specific 
antigens, (ii) active suppression of tumor-specific T cells, (iii) defects in 
professional antigen-presenting cells (APC), (iv) malfunctioning T cells as a 
consequence of alterations in their TCR and (v) loss of HLA class I antigens. 
Immune tolerance 
Immune tolerance is mediated, in part, by both the induction of T cell anergy and 
deletion of antigen-specific T cells from the peripheral circulation. As described 
previously, T cell anergy occurs when TCRs recognize antigen in the absence of 
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proper co-stimulation (145), which results in the failure of antigen-specific T cells 
to produce IL-2 and clonally expand upon antigen exposure (146). In addition, 
tumor antigen-specific T cells may directly be deleted from the peripheral 
circulation through AICD which is characterized by apoptosis of activated T cells 
upon antigen encounter (147). Fas and FasLigand (FasL) mediated mechanisms 
also play a role in the deletion of T cells. FasL is expressed in various types of 
human malignancies (148) and it has been shown that T cell apoptosis is abrogated 
by anti-FasL antibodies or Fas fusion protein (149). This form of T cell deletion is, 
in general, tumor-antigen independent. 
Immunosuppresion within the tumor microenvironment 
In the tumor microenvironment, suppression of T cells is mediated in various ways, 
including the expression of PD-L 1 and galectine-1 on the tumor cell surface. As 
described previously, blocking of PD-1/PD-Ll interactions results in improved 
antitumor T cell functions both in vitro and in vivo (150,151). In addition, the 
expression of tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) 
(152) and the secretion of soluble factors like TGF-� (153) and IL-10 (154) lead to 
T cell dysfunction and apoptosis. Furthermore, several tumor infiltrating cell 
subsets actively suppress antitumor T cells. Among these tumor infiltrating cell 
subsets are Treg (155), which suppress both T cell proliferation and NK cell 
mediated cytotoxicity (155,156) and myeloid derived suppressor cells (MDSC). 
The latter cell population strongly inhibits T cell function through the expression of 
arginase and inducible oxide synthase (iNOS) (157). In addition, in the presence of 
tumor, T cells have shown to develop a senescent-like phenotype characterized by 
the loss of CD28 and CD27. These tumor-induced senescent T cells mediate T cell 
suppression through direct cell-to-cell interactions (158). 
Deficiencies in APC and TCR abnormalities 
Deficiencies in APC include (i) decreased numbers of mature DC in the tumor 
micro-environment, draining lymph node and peripheral circulation, (ii) phenotypic 
alterations as demonstrated by low HLA class II and co-stimulatory molecule 
expression and (iii) a decreased ability to present soluble antigen to autologous T 
cells (159-161). In patients with advanced cancer stages, abnormalities of the 
CD3/TCR complex (TCRs) and signal transduction pathways cause T cell 
dysfunction through impaired tyrosine phosphorylation of the CD3/TCR complex 
(162). 
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Downregulation of HLA class I molecules 
It is extensively documented that solid tumors are able to evade the immune system 
through down-regulation or loss of HLA class I molecules (163) and abnormalities 
in class I molecules play a negative role in the clinical manifestation of cancer. 
Likewise, it is reported that the expression level of tumor associated peptide/HLA 
class I complexes is associated with recognition of tumor by CTL (164). For both 
cases it is shown that the addition of IFNy restores and/or enhances the expression 
of HLA surface molecules as well as tumor associated peptide/HLA class I 
complexes in vitro ( 165) but this is yet to be demonstrated in vivo in humans. 
Tumor-antigen selection 
The ideal tumor-antigen is highly expressed on the cell surface of cancer cells and 
has a high binding affinity for HLA class I and/or class II molecules. Preferably, it 
is expressed by most cells within a particular tumor, and required to maintain the 
tumor phenotype. It should not be expressed in the thymus or during fetal 
development to minimize tolerance. 
To date, no tumor-antigen naturally satisfies all the criteria to be classified as 
"ideal" cancer immunotherapeutic candidate. Most antigens ( e.g. epitopes) are 
identified by mass spectrometry (166), which can help identify tumor-antigens but 
does not provide any information on the immunologic potential of these antigens. 
Selection is further hindered by that fact that many antigens undergo post­
translational modifications (PTMs ). These modifications directly affect the stability 
and function of proteins and naturally processed antigen epitopes ( 167) and thus, 
affect the ability of antigen specific T-cells to recognize the modified epitope. The 
screening of PTMs in naturally processed peptides is technically challenging and 
therefore has major clinical implications. 
In summary, it is clear that individual cancer patients exhibit a variety of 
mechanisms which compromise effective antitumor immunity. Cancer patients 
likely possess several alterations in their antitumor immunity and therefore require 
immunotherapeutic strategies which are able to induce antitumor immunity and at 
the same time target these immune deficiencies. Cancer patients are likely to 
require individually chosen immunotherapeutic strategies or a combination of 
various treatment modalities, rather than a single treatment modality at a time. 
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Outline of the thesis 
Increasing clinical data suggest that eradication of human cancer may best be 
accomplished by concurrent activation of the various components of the immune 
system. This may be achieved by combining cancer treatment modalities which are 
able to enhance antitumor immune responses within the innate or adaptive immune 
system, by combing cancer treatment modalities, which simultaneously activate 
both innate and adaptive immunity or by combining treatment modalities, which 
stimulate tumor-specific immunity and target co-stimulatory pathways. At first, 
most treatment strategies prioritized the stimulation of CTL responses based on 
their ability to directly and specifically kill tumor cells. Currently, most 
immunotherapeutic strategies in patients with solid tumors are geared towards 
direct elimination of tumor cells or direct activation of the adaptive immune 
system, whereas relatively few are intended to stimulate co-signaling pathways or 
the innate immune system. For that reason, this thesis focuses on CD137-mediated 
co-stimulation (part A) and NK cell-based immunotherapy (part B) and their 
therapeutic potential in the treatment of solid malignancies. In addition, results of a 
clinical pilot study testing a MAGE and HPV peptide-based vaccine, which was 
shown to stimulate both CTL and T helper cell responses in murine models are 
presented and discussed (part C). 
Specifically, preclinical studies of a glycosylated and an aglycosylated anti-CD137 
antibody are reported since stimulation of CD 13 7, through its natural ligand or 
agonistic antibody, has been shown to induce antitumor immunity in murine 
models. Based on the crucial role of murine NK cells in CD 13 7-mediated 
antitumor immunity, comprehensive in vitro studies of the direct effect of the 
glycosylated and aglycosylated chimeric CD137 antibodies on human NK cells 
were performed. In addition, considering the role of B cells in antitumor immune 
regulation, the co-stimulatory function of CD 13 7 on human B cells was elucidated. 
These studies are reported in chapter 2 and 3, respectively. In addition, to 
facilitate clinical translation of the CD137 mAbs, in vitro non-human primate 
studies were conducted to ascertain feasibility and relevance of preclinical animal 
testing. These findings, reported in chapter 4, underscore the fundamental 
importance of preclinical in vitro animal model evaluation for in vivo relevance, 
since humanized anti-CD137 did not bind CD137-expressing macaque or baboon 
peripheral blood mononuclear cells (PBMC). This was directed by a three amino 
acid difference within the extracellular domain of human CD 13 7 between macaque 
and baboon CD 13 7. 
24 
Chapter 1 Outline of the thesis 
Based on (i) the pivotal role of NK cells in CD137-mediated antitumor immunity, 
(ii) the reported success of NK cell-based immunotherapy in patients affected with 
hematological malignancies and (iii) the importance of CD137-CD137L ligation in 
ex-vivo NK cell expansion additional studies focused on NK cell-mediated 
antitumor cytotoxicity as a means to potentially boost innate immunity. In chapter 
5, the successful ex-vivo expansion of GMP-compliant NK cells from patients with 
solid malignancies is reported. Expansion turned the NK receptor balance towards 
activation and resulted in cytotoxicity against autologous gastric tumor cells. In 
addition, cytotoxic activity could be enhanced by ADCC. Furthermore, in chapter 
6, an in vitro head and neck cancer model provides first preclinical evidence of the 
importance of FcyRIII polymorphisms in NK cell-mediated ADCC in solid 
malignancies. 
Finally, in the clinical study described in chapter 7, we were able to cross the line 
between scientific possibility and clinical reality. This chapter reports first in­
human data of the clinical evaluation of two peptide-based vaccines in patients 
suffering from head and neck carcinoma. It describes the successful in vivo 
induction of vaccine-specific T cell responses and in addition, comments on 
unexpected difficulties and how they were resolved. In chapter 8, all results and 
conclusions are summarized and discussed. 
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PART A 
CD137 mediated co-stimulation, i ts therapeutic 




CD 1 3  7 ( 4- 1 BB) i s  a co-stimulatory molecule which can be manipulated for 
the treatment of cancer and autoimmune disease. While agonistic antibodies 
(mAbs) against CD 1 3 7 enhance the rejection of murine tumors in a natural 
killer (NK) and T cell dependent fashion, the mechanism for NK dependence 
is poorly understood. 
In this study, we evaluated the abi lity of two different glycoforms of a chime­
rized anti-human CD 1 3  7 mAb, an aglycosylated (GA) and a low fucose form 
(GG), to react with human NK cells . Both mAbs bound similarly to CD 1 3 7,  
were competitively inhibited by the parental mAb and partial ly blocked the 
interaction between CD 1 3  7 and CD 1 3  7Ligand.  However, unlike GA mAb, 
immobilized GG mAb activated NK cells and enhanced CD 1 3  7 expression . 
These effects were seemingly dependent on Fe interaction with putative Fe­
receptors on the NK cell surface, as only the immobi lized F c-fragment of GG 
was required for CD 1 3  7 expression. Furthermore, CD 1 3  7 expression could 
be enhanced with antibodies directed against non-CD 1 3  7 epitopes, and the 
expression levels directly correlated with patterns of Fc-glycosylation recog­
nized to improve Fe interaction with Fey- receptors . 
Our data suggest that CD 1 3  7 can be enhanced on NK cells in an F c depen­
dent fashion and that expression correlates with phenotypic and functional 
parameters of activation . 
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Introduction 
CD137 (4-l BB), a member of the TNF receptor superfamily, is increasingly 
recognized as an important target for the treatment of both cancer and 
autoimmunity (1-5). Specifically, in murine models, it is clear that ligation of 
CD137 on the surface of activated T cells, through either CD137 ligand (CD137L) 
or agonistic monoclonal antibodies (mAbs), potentiates the immune response to 
weakly immunogenic tumors in a NK dependent fashion (3-6). Unlike other co­
stimulatory based antitumor immunotherapies (e.g. CTLA-4 blockade), CD137 
ligation does not induce self reactivity, but rather has therapeutic benefit in 
multiple murine models of autoimmune disease such as rheumatoid arthritis (7), 
systemic lupus erythematosus (8), and inflammatory bowel disease (9). In many 
studies, functional conclusions regarding CD 13 7 have been based on mAb or 
fusion protein manipulation of receptor/ligand pathways, with the assumption 
being that observed effects were secondary to Fab region or ligand interaction with 
CD137. Importantly, little attention has been paid to the potential link between the 
Fe region of these molecules and alternate pathways of CD137 regulation through 
F c receptors (F cy Rs). 
It is now evident that Fe cross-linking of FcyRIII (CD16) on human NK cells 
induces cellular activation defined by both phenotypic change and release of pro­
inflammatory cytokines (10). The affinity and functional consequences of the 
interaction between Fe and FcyRIII is dependent on the presence of 
oligosaccharides (N-glycan) covalently attached at asparagine (Asn)-297 of the Fe 
heavy chain (11). For example, Fe fragments with low fucose content at Asn-297 
have enhanced binding affinity for FcyRIII (12-14). Additionally, aglycosylated Fe 
fragments are unable to efficiently bind the FcyRIII (15,16). The interaction 
between Fc-FcyRs also has clinical implications, as it is now evident that 
polymorphisms within the FcyRIII, e.g. V/F at amino-acid position 158, which 
impact Fc-FcyRIII interactions, can be used to define the therapeutic efficacy of 
targeted anti-cancer therapeutics such as Rituxan® (17, 18). 
Based on the therapeutic potential of anti-CD137 mAbs and the recognized 
importance of Fc-FcyR interactions on mAb function, in collaboration with GTC 
Biotherapeutics, two chimeric anti-CD137 mAbs were developed. The first, a 
glycosylated form (GG) is likely to crosslink the FcyR and the second, an 
aglycosylated form (GA), is unlikely to efficiently crosslink the FcyR. Because of 
the recognized role of NK cells in the anti tumor function of anti-CD 13 7 mAbs in 
murine models, we initially hypothesized that IL-2 stimulated human NK cells 
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would express CD137 and that ligation with chimeric anti-CD137 mAb would 
result in cytokine release and degranulation. 
Surprisingly, we observed that, following IL-2 stimulation and subsequent culture, 
human NK cells do not express high levels of CD137. However, CD137 is 
enhanced on IL-2 stimulated human NK cells following culture in the presence of 
immobilized glycosylated mAbs or papain cleaved Fe fragments. The ability to 
enhance CD137 expression is independent of the antigen specificity of the Fab 
region and the magnitude of CD 13 7 expression is associated with patterns of 
glycosylation known to enhance the interaction between Fe and FcyRs. These data 
suggest that "agonistic effects" of select antibodies on co-stimulatory molecules, 
may be in part secondary to Fc-FcyR interactions and provide important insight 
into the design of antibodies intended to manipulate co-stimulatory pathways for 
clinical benefit. 
Materials and Methods 
Chimeric monoclonal antibodies 
Mouse anti-human CD137 mAb (G6) was generated in the laboratory of Dr. L. 
Chen. A glycosylated chimeric version of G6, hereafter called GG, was developed 
by replacing the mouse lgG2a Fe region with a human IgG 1 Fe region. Likewise, 
an aglycosylated (GA) chimeric anti-CD137 mAb was created by mutating Asn to 
glutamine (Gin) at amino-acid position 297 in the Fe region. Both GA and GG 
mAbs were produced in the milk of transgenic goats. Erbitux® ( cetuximab, 
hereafter called CTM) was obtained through the Greenebaum Cancer Center 
(University of Maryland Medical System, Baltimore, MD). For flow cytometry 
experiments, all chimeric mAbs were directly labeled to Allophycocyanin (APC) 
through the custom conjugation service of Invitrogen (Molecular Probes 
Invitrogen, Eugene, OR). 
Cells and transfectants 
Human blood samples were purchased (Biological Specialty Corporation, Colmar, 
PA) and whole peripheral blood mononuclear cells (PBMC) were isolated using 
density-gradient centrifugation. Fresh purified resting NK cells (CD3-CD56+CD16+ 
as defined by flow cytometry) were obtained by negative magnetic cell sorting 
using NK cell isolation beads (Miltenyi Biotec, Auburn, CA) according to the 
manufacturer's  instructions. Chinese hamster ovary (CHO) cells stably transfected 
with human CD 13 7 receptor and non-transfected wild type controls were 
established in the laboratory of Dr. L. Chen. CHO cells were maintained in DMEM 
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supplemented with 10% fetal bovine serum (FBS) (Atlanta Biological, 
Lawrenceville, GA), 1 % penicillin/streptomycin (P/S), 1 % Glutamax-1 (both 
Invitrogen, Grand Island, NY) and 1 % HEPES (Mediatech, Herndon, VA). K562 
cells were cultured in RPMI 1640 supplemented with 10% FBS, 1 % P/S and 1 % 
Glutamax-1. 
In vitro NK experiments 
Fresh purified resting NK cells (CD3-CD56+CD16+ as defined by flow cytometry; 
>90% purity) were stimulated for 72 hours in RPMI 1640 supplemented with 10% 
FBS, 1 % P/S, 1 % HEPES, 1 % Glutamax-1 and 200IU/ml recombinant human IL-2 
(rhIL-2, Proleukin®, Chiron Corporation, Emeryville, CA). After 72 hours, NK 
cells were washed three times with PBS and resuspended in RPMI 1640 
supplemented with all of the above except rhIL-2. IL-2 stimulated NK cells were 
plated at a concentration of 2xl05 cells/well in a 96-well flat bottom plate in the 
presence of either pre-coated (immobilized) or soluble chimeric mAb or polyclonal 
human IgG 1 (huigG 1) (Sigma-Aldrich, St. Louis, MO) at a concentration of 
20µg/ml. Control wells were pre-coated overnight with RPMI 1640 supplemented 
with 10% FBS to minimize cross-linking of soluble positively charged 
immunoglobulins present in the culture media. At the indicated time-points, NK 
cells and cell-free supernatants were harvested and analyzed for cell surface 
expression of defined proteins and secreted cytokines. 
Flow Cytometry 
NK cell phenotype was determined by staining with directly conjugated mouse 
anti-human mAbs against CD3, CD56, CD16, CD69, CD54, and CD137 (BD 
Biosciences, San Diego, CA). Unless indicated otherwise, CD137 expression was 
measured using commercial mouse anti-human CD137 mAb (clone 4B4-1). In 
some experiments, NK cells were stained with Annexin V/7-AAD (Annexin V 
apoptosis detection kit I, BD Biosiences) to distinguish live cells from apoptotic 
and/or necrotic cells. The number of degranulating NK cells was determined by 
staining with CD107a mAb (BD Biosciences). In brief, NK cell cultures were 
incubated for one hour at 37°C in 5% CO2 after which brefeldin A and monensin 
(both BD Biosiences) were added. NK cells were cultured for an additional five 
hours and subsequently stained for CD56 and CD 16. Directly conjugated mouse 
IgGs were used as isotype controls. A minimum of 10000 events were acquired 
using a BD™ LSR II flow cytometer and analyzed with BD™ F ACS DIV A 
Software. 
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Analysis of collected cell-free supernatants 
Cell-free culture supematants were collected at indicated time-points during 
incubation. Concentrations of IFN-y and TNF-a were determined by ELISA 
according to the manufacturer's  instructions (BD Biosciences). 
Flow Cytometry based competitive binding assays 
CD137 expressing CHO cells were incubated with different concentrations 
(0.8µg/ml-100µg/ml) of G6, GA and GG mAb at 4°C for 1hr. Purified mouse 
IgG2a (mulgG2a) and hulgGl (BD Biosciences) were used as control antibodies at 
a concentration of 100 µg/ml. Next, cells were incubated with 5ug/ml of human 
CD137L-muCD8 (Ancell, Bayport, MN) for 45 minutes at 4°C. Cells were further 
stained with PE conjugated anti-muCD8 mAb (BD Biosiences) and acquired using 
a BD™ LSR II flow cytometer. 
Generation of Fab fragments and Fe fragments 
Fab and Fe fragments from GG, CTM and hulgGl were generated by papain 
digestion followed by protein A and protein L chromatography using an 
ImmunoPure Fab Preparation kit (PIERCE, Rockford, IL) according to the 
manufacturer's instructions. Briefly, all mAbs were digested into Fe and Fab 
fragments using papain. The digests were dialyzed against protein A or protein L 
binding solutions, subsequently passed through protein A or protein L columns and 
the flow through, containing Fab or the Fe fragments respectively, were collected. 
Purity, determined by both immunoblotting and ELISA, was greater than 7 5% and 
95% for the Fe and Fab fractions respectively. 
Compositional monosaccharide analysis of lgG 1-Fc 
Purified Fe fragments (100-200µg) were diluted to 200µ1 using deionized water 
and mixed with an equal volume of 4N TF A (trifluoroacetic acid, Sigma Aldrich, 
St.Louis, MO). Samples were hydrolyzed at 100°C for 5h. After lyophilization, the 
residues were reconstituted with water prior to HP AEC analysis. The 
chromatography was performed on a Dionex DX600 chromatography system 
(Dionex Corporation, Sunnyvale, CA) equipped with an electrochemical detector 
(ED50). Monosaccharides were separated on a CarboPac PAlO column (4X250 
mm) with an isocratic 18 mM NaOH as the eluent. Monosaccharides were detected 
by the pulsed amperometric electrochemical detector with the following 
waveforms (potentials and durations): E l = +0.05 V (Tl = 0 to 04 s), E2 = +0.75 V 
(T2 = 0.41 to 0.6 s), and E3 = -0.15 V (T3 = 0.61 to 1 s). Typically, 10µ1 of sample 
containing 0.1-l nmole of monosaccharides was injected. For quantification, the 
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peaks corresponding to the monosaccharides were integrated and peak areas were 
normalized to molar quantity by comparison with standard solution of 
monosaccharide standards. 
Cytotoxicity assays 
NK cytotoxicity was measured by 4 hour chromium 5 1  (5 1Cr)-release assays. K562 
tumor targets were labeled with 1 50 µCi 5 1Cr (Na/ 1CrO4, Perkin Elmer, Shelton, 
CT) for one hour at 37°C in 5% CO2 • After incubation, cells were washed two 
times and incubated for an additional 30 minutes in order to reduce spontaneous 
release. Finally, tumor targets were plated at 5000 targets/well in triplicate wells in 
a 96-well V-bottom plate. Effector cells consisted of CD3-CD56+ NK cells which 
were IL-2 stimulated for 72 hours and subsequently cultured for 24 hours in the 
presence of immobilized GA or GG mAb. One hundred micro liter of NK effectors 
were added at indicated effector:target ratio to give a final volume of 200µ1 per 
well. After 4 hours of incubation, 1 00µ1 of supernatant was harvested and mixed 
with 1 00µ1 of scintillation cocktail (Perkin Elmer) in a 96-well sample plate 
(Perkin Elmer). Its radioactive content was measured using a gamma-counter and 
the percentage of specific lysis was calculated using the formula: 1 00 X 
( experimental release - spontaneous release )/(maximum release - spontaneous 
release). 
Statistical analysis 
A Q-Q plot was used to assess if normality could be assumed for the flow 
cytometric parameters. Statistical significance, as measured by a two-sided paired 
Student's t test (or the non-parametric sign test if the normality was not plausible) 
was calculated using Excel v2003 and Splus, based on the number of experiments 
as indicated in the figure legends. NK cell cultures with immobilized GA mAb 
were used as control cultures to calculate statistical differences. Differences were 
considered to be significant at P< 0.05. 
Results 
Immobilized glycosylated mAbs enhance CD137 expression on human NK 
cells 
Several groups, including ours, have demonstrated in murine models that the 
antitumor activity of anti-CD137 agonistic mAbs is NK dependent (2,3,6). Based 
on the crucial role of NK cells in antitumor activity and the recognized expression 
of CD137 on IL-2 stimulated murine NK cells, we initially hypothesized that 
human NK cells cultured in IL-2 would express high levels of CD 13  7 and that 
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chimeric anti-CD137 mAbs would react with CD137 expressed on IL-2 stimulated 
human NK cells, inducing degranulation and cytokine release. 
Interestingly, we found that following IL-2 stimulation and subsequent culture in 
RPMI 1640 supplemented with FBS, human NK cells, did not demonstrate high 
levels of CD 13 7 expression ( data not shown). In contrast, IL-2 stimulated NK cells 
cultured in the presence of immobilized glycosylated mAbs showed high levels of 
CD137 expression (Figure 1). Expression of CD137 was transient and was not 
observed to a measurable extent after 72 hours of culture ( data not shown). Of note, 
NK cells from one individual evidenced relatively high levels of CD137 after IL-2 
stimulation. This exception may reflect ongoing infection/inflammation in this 
donor or individual variation in susceptibility for IL-2. 
CD137 was only enhanced on IL-2 stimulated NK cells in cultures with 
immobilized GG (range 22%-61 %; P=0.0071) and not with GA (range 1 %-14%). 
Cultures of IL-2 stimulated NK cells in the presence of non-immobilized (soluble) 
mAbs failed to induce CD137 expression. CD137 was also up-regulated on IL-2 
stimulated NK cells cultured with immobilized polyclonal hulgG 1 (range 3%-73%; 
P=0.0232) and, to a lesser extent with immobilized anti-EGFR mAb CTM (range 
3%-10%). The Fab region of GA and GG did not appear to augment CD137 
expression, as the levels of CD 13 7 in cultures with immobilized hulgG 1 + 
immobilized GA (range 14%-25%) were lower than in cultures with immobilized 
hulgGl or immobilized GA alone (range 3%-73% and 1%-14% respectively). 
Additionally, CD 13 7 expression was inversely associated with the presence of 
FcyRIII. NK cell cultures with high levels of CD137 showed low levels of FcyRIII 
as indicated by CD 16 in figure 1. Likewise, cultures with low levels of CD 13 7 
were associated with high levels of FcyRIII. To avoid possible interference of 
purified chimeric anti-CD137 mAbs in flow cytometry analysis, CD137 expression 
levels were determined using commercial mouse anti-human CD137 mAb (clone 
4B4-1), whose binding to CD137 was not blocked by ten fold differences in 
concentration of GA or GG mAb (range 0.02µg/ml to 20µg/ml) as determined by 
flow cytometry based competition-inhibition studies ( data not shown). 
In order to exclude other possible sources of NK cell activation, we indirectly 
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Figure 1. Immobilized glycosylated mAbs stimulate CD137 expression on human NK cells. IL-2 stimulated 
NK cells were cultured for 24 hours in the presence of immobilized or soluble chimeric mAbs as indicated. CD1 37 
expression was measured by flow cytometry. Gates were set around CD56+ (NK) cells and numbers in the dot 
plots indicate percentage of CD56+ (NK) cells expressing CD137. Immobilized mAb culture conditions and 
soluble mAb culture conditions are indicated with i- and s- respectively. The data shown is representative of one 
of six individual experiments. Statistical analysis is based on six experiments; CD1 37 expression levels are 
significantly increased in NK cell cultures with i-hulgGI or i-GG (P=0.0232 and P=0.007 1 ,  respectively) as 
compared with i-GA cultures. HulgG I indicates polyclonal human IgG I ;  GA, aglycosylated chimeric anti-CD 1 3  7 
mAb; GG, glycosylated chimeric anti-CD137  mAb; CTM, cetuximab. 
The up-regulation of CD 13  7 on the NK cell surface was likely not induced by LPS 
contamination, since boiling the GG mAb preparation eliminated its ability to up­
regulate CD137 (data not shown). Furthermore, observed differences in CD137  
expression were also not likely to be secondary to variable levels of immobilized 
immunoglobulins since similar levels of immobilized GG, GA and hulgG I were 
present on the surface of pre-coated wells ( data not shown). In addition, I O  fold 
increases in GG concentration did not further enhance CD1 37 expression on IL-2 
stimulated NK cells. However, CD137  expression levels were slightly enhanced 
with a ten fold increase in immobilized CTM concentration ( l Oµg/ml to IOOµg/ml) 
and CD 1 3  7 started to reach expression levels as observed in cultures with I Oµg/ml 
GG ( data not shown). These experiments support the conclusion that CD 1 3  7 
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expression on NK cells is Fe dependent and that different Fe regions have variable 
ability to induce CD 13  7 on human NK cells. 
CD137 expression on NK cells is induced in an Fe dependent fashion 
The fact that immobilized glycosylated mAbs, but not soluble glycosylated mAbs 
or aglycoslyated mAb, induce high levels of CD137 expression on IL-2 stimulated 
NK cells strongly supports the idea that CD 13 7 expression on the NK cell surface 
is mediated through Fc-FcyR interactions. In order to exclude the potential 
influence of a CD137 specific Fab region in non-Fe mediated CD137 expression, 
purified Fab and Fe fragments of GG mAb were employed in IL-2 stimulated NK 
cell experiments. 
As expected, NK cells cultured with immobilized GG/Fc fragments induced 
CD 13 7 expression at levels similar to those observed with immobilized GG mAb 
(range 27%-61 % and 22%-61 %, respectively). In contrast, NK cells cultured with 
immobilized GA mAb or GG/Fab fragments only induced small amounts of 
CD137 expression (range 1 %- 14% and 6%-13%, respectively) as shown in Figure 
2A-i and this difference was determined to be statistically significant (P=0.0002). 
Interestingly, the total number of live NK cells (gated as 7-AAff/AnnexinV- cells) 
decreased in the culture with immobilized GG mAb versus the culture with purified 
GG/Fc fragments as indicated by the increased ratio of total number of live cells 
versus total number of acquired cells, 1 /6.7 and 1 /3.7 respectively (Figure 2A-ii). 
CD137 was not only detected by commercial mouse anti-CD137 mAb but also by 
both chimeric anti-CD 13  7 mAbs, demonstrating that GG and GA cross-react with 
CD137 induced on IL-2 stimulated NK cells. These data have importance for 
future clinical translational studies (Figure 2B). Importantly, the purity of the Fab 
fragments was 95% and of the Fe fragments 75%. However, given that the Fab 
fragments did not induce high levels of CD 13 7, it is unlikely that our results are 
secondary to contamination. Therefore, these data provide convincing evidence 
that CD137 is induced on IL-2 stimulated NK cells in an Fe dependent fashion. 
Chimeric GA and GG mAb have similar Fab regions despite differences in Fe 
In order to further evaluate the potential role of the Fab fragments of GA and GG 
in inducing CD 13  7 on the NK cell surface, we compared their ability to bind 4-
1 BB transfected CHO cells and to block natural 4- lBB-4- lBBL interactions. Both 
mAbs showed similar binding to CHO/CD137 cells and failed to bind wild type 
(CHO/WT) controls (Figure 3A). To determine if the parent mAb (mouse anti-
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human CD 13 7) G6 and both chimeric mAbs GA and GG recognized the same 
CD137 epitope, CHO/CD137 cells were incubated with increasing concentrations 
of purified G6, GA or GG mAb respectively (Figure 3B). All mAbs partially 
blocked binding of G6-APC in a dose-dependent fashion, suggesting that 
chimerization did not alter epitope affinity. 
A 
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Figure 2. CD137 expression on NK cells is induced in an Fe dependent fashion. GG mAb was digested into 
separate Fab and Fe fragments using papain. Digests were passed over Protein L or Protein A columns and single 
Fab fragments or Fe fragments were collected respectively. IL-2 stimulated NK cells were cultured in the presence 
of immobilized chimeric mAb or immobilized fragments as indicated in the figure. (A) After 24 hours, CD137 
expression was determined by flow cytometry. Gates were set around 7-AAD"/AnnexinY- cells. Numbers in the 
dot plots indicate the percentage of CD56• (NK) cells expressing CD137 (i). Ratios represent the number of live 
NK cells and are calculated based upon the total number of 7-AAD"/AnnexinY- cells within the total number of 
acquired cells (ii). (B) CD137 expressed on NK cells is not only recognized by commercial available mouse-anti­
CD137  mAb but also by both chimeric anti-CD137 mAbs, GA and GG. Experiment shown represents one of three 
individual experiments. Statistical analysis is based on six (i-GG and i-GA) and three (i-GG/Fc and i-GG/Fab) 
experiments; CD137 expression levels are significantly increased in NK cell cultures with i-GG and i-GG/Fc as 
compared with i-GA and i-GG/Fab (P=0.0002). HulgG 1 indicates polyclonal human IgG 1; GA, aglycosylated 
chimeric anti-CD137 mAb; GG, glycosylated chimeric anti-CD137 mAb. 
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Figure 3 Chimeric GA 
and GG mAb have 
similar Fab regions 
despite differences in 
Fe. (A) G6, GA and GG 
mAbs bind similar to 
CD137 expressing CHO 
cells and fail to bind 
CHO/WT controls. (B) 
CD137 expressing CHO 
cells were incubated with 
different concentrations 
of purified G6, GA or 
GG mAb. Cells were 
subsequently stained 
with G6-APC mAb. 
Increasing concentrations 
of purified G6, GA or 
GG mAb blocked 
binding of G6-APC as 
indicated by MFI in a 
dose-dependent fashion. 
(C) CD137 expressing 
CHO cells were first 
incubated with 
increasing concentrations 
of G6, GA or GG and 
subsequently incubated 
with human CD137L­
muCD8 fusion protein. 
Cells were then stained 
with PE conjugated anti­
muCD8. As indicated by 
MFI, G6, GA and GG 
blocked CD137/CD137L 
interaction in a dose­
dependent fashion. Filled 
histograms represent 
CHO/WT cells (A) or 
isotype control mAb 
(B+C). Open histograms 
represent staining with 
the indicated antibody. 
GA indicates 
aglycosylated chimeric 
anti-CD137 mAb; GG, 
glycosylated chimeric 
anti-CD137 mAb; G6, 
mouse anti-human 
CD137 mAb; MFI, mean 
fluorescence intensity. 
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Finally, to further define the functional characteristics of these mAbs, the ability of 
G6, GA and GG to block the interaction of the CD 13 7 receptor with its natural 
ligand, CD137L was determined. CHO/CD137 cells, incubated with increasing 
concentrations of purified G6, GA or GG, blocked the binding of human 
CD 13 7L/mouse CD8 fusion protein in a dose-dependent fashion (Figure 3C). 
These data indicate that both chimeric mAbs bind similarly to CD 13 7 and partially 
block CD137 receptor-ligand interactions in a dose-dependent fashion suggesting 
equal specificity of their Fab region for the CD 13 7 receptor. Thus, the fundamental 
difference between GA and GG mAb is the status of N glycosylation of the mAb 
Fe region. The fact that the Fab fragments of these antibodies are identical suggests 
that differences in CD137 expression levels in NK cell cultures with immobilized 
GG and GA mAb are secondary to the variable ability of the Fe regions of GG and 
GA to interact with putative FcyRs expressed on human NK cells. 
CD137 expression levels on NK cells are associated with defined patterns of Fe 
glycosylation 
Human IgGl mAbs carry a conserved N-glycan at Asn-297 of the Fe region. Fc­
FcyR interactions are dependent on the extent of core fucosylation of the Fe N­
glycan, with lower fucosylated IgG 1 having significantly enhanced affinity for the 
FcyIII receptor in comparison to those with high fucose content. The level of 
fucosylation has functional implications as lower fucosylated mAbs induce more 
potent antibody-dependent cellular cytotoxicity (ADCC) at lower antigen densities 
(13). Based on our observations that mAbs from different sources stimulated 
variable levels of CD 13 7 on the NK cell surface, we sought to investigate if the 
difference in fucose composition of N-glycans was associated with CD 13 7 
expression. In order to quantitate the monosaccharide composition, we performed 
HP AEC profile analysis of hydrolysates of the different mAbs studied. To exclude 
the interference of potential glycosylation at other sites, we purified respective 
IgG 1-F c fragments from all mAbs and analyzed the monosaccharide composition 
of the Fe N-glycan. Treatment of the mAb Fe fragments with trifluoroacetic acid 
resulted in complete hydrolysis of N-glycan into the compositional 
monosaccharides, where N-acetylglucosamine (GlcNAc) was released as 
glucosamine (GlcN). The HPAEC profiles of the hydrolysates of all IgGl -Fc are 
demonstrated in Figure 4. As expected, the hydrolysis of GA did not release typical 
monosaccharides, e.g . .  Mannose (Man), GlcN, and Galactose (Gal) of the N­
glycan, confirming that no N-glycan was attached to this antibody. In contrast, GG, 
CTM and hulgG 1 revealed typical monosaccharide patterns as compared with a 
standard monosaccharide profile. 
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Figure 4 HP AEC profile analysis 
of lgGl-Fc. Trifluoroacetic (TFA) 
hydrolysis resulted in complete 
degradation of the N-glycan within 
the separate Fe fragments to 
compositional monosaccharides 
where N-acetylglucosamine 
(GlcNac) was released as 
glucosamine. Compositional 
monosaccharide patterns were 
compared with a standard 
monosaccharide profile composed 
of fucose, glucosamine, galactose, 
glucose and mannose, respectively. 
Fuc indicates fucose; GlcN, 
glucosamine; Gal, galactose; Glc, 
glucose; Man, mannose; GP-2, 
standard glycopeptide; GA, 
aglycosylated chimeric anti-CD137 
mAb; GG, glycosylated chimeric 
anti-CD137 mAb; CTM, 
cetuximab; HulgG I ,  polyclonal 
human IgG I . 
Table 1 Compositional monosaccharide quantification of lgGl-Fc 
IgGl-Fc MONOSACCHARIDE MOLAR RATIOS 
DETERMINED BY HPAEC-PAD ANALYSISa 
FUC GlcN GAL MANb 
Bi-antennary GPc na 3.86 2.08 3.00 
HulgGl 0.95 3.50 0.80 3.00 
GG 0.56 3.60 1.40 3.00 
GA na na na na 
CTM 1 .10 5.20 1.90 3.00 
Fuc indicates fucose; GlcN, glucosamine; Gal, galactose; Man, mannose; na, not applicable; HulgG I ,  polyclonal 
human IgGI ;  GG, glycosylated chimeric anti-CDI37 mAb; GA, aglycosylated chimeric anti-CDl37 mAb; CTM, 
cetuximab. 
3fc fragments were hydrolyzed in 2M trifluoroacetic acid (TF A) at I 00°C for 4 hours. The hydrolysates were 
lyophilized and subject to Dionex HPAEC-PAD analysis. 
bFor quantification, the peaks corresponding to the different monosaccharides were integrated and peak areas were 
normalized to molar quantity by comparison with bi-antennary GP. The molar ratios were normalized by setting 
mannose as 3 .  
cBi-antennary GP represents a standard glycopeptide isolated from hen's egg yolk that contains a full-size bi­
antennary complex type N-glycan with the following molar ratios of monosaccharides: Man:Gal:GlcN = 3 :2:4. 
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Based on these calculations, the molar ratios of the monosaccharide composition of 
all IgGl-Fc are summarized in Table I .  GG showed much less fucosylated N 
glycan than CTM and huigGI. Interestingly, CTM showed a higher content of 
GlcNAc (Man:GlcN = 3:5) than GG and huigGl (Man:GlcN = 3:4), suggesting 
that this mAb may have an additional bisecting GlcNAc. These observations 
suggest that the low fucose content on GG might contribute to its enhanced ability 
to induce CD 13 7 on human NK cells. 
CD137 expression on human NK cells is associated with phenotypic markers 
of activation and the release of pro-inflammatory cytokines 
In order to begin to understand the function of CD 13 7 on human NK cells, we 
sought to associate CD 13 7 expression with cellular activation, as characterized by 
NK cell surface expression of CD69 and CD54 and pro-inflammatory cytokine 
secretion. CD 13 7 expressing NK cell cultures were associated with increased 
levels of CD69 and CD54 bright expression with the highest levels of CD69 
expression in cultures with huigG 1 and GG mAb (range 32%-62% and 36%-86% 
respectively; P=0.0361 for GG). CD54bright expression varied from 4%-17% 
expression in cultures with huigG 1 (P=0.0 186) to 10%-24% expression in cultures 
with GG mAb (P=0.004) as indicated in Figure 5A-B. 
Because activated human NK cells are known to secrete pro-inflammatory 
cytokines, we evaluated the supematants of NK cell cultures for IFN-y and TNF-a. 
Levels of TNF-a and IFN-y in cultures containing immobilized GG, were 
significantly increased (P=0.0468 and P=0.0477, respectively) in comparison to 
cultures with immobilized huigG 1, CTM or soluble mAb (Figure 5C-D). The 
levels of IFN-y and TNF-a declined over time; only remaining detectable in wells 
with immobilized GG after 72 hours (data not shown). In conclusion, these data 
suggest that Fe dependent CD137 expression is associated with phenotypic markers 
of activation and pro-inflammatory cytokine release. 
Degranulation precedes CD137 expression on human NK cells and results in 
less efficient lysis of NK sensitive tumor targets by CD137 expressing human 
NK cells 
While Fc-FcyRIII interactions induce NK cell activation resulting in the up­
regulation of phenotypic markers of activation and the release of pro- inflammatory 
cytokines, they do not reveal the capability of these NK cells to lyse targets cells. 
5 1Cr release assays were used to determine the lytic capacity of CD137 expressing 
and non-CD137 expressing NK cells. 
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Figure 5. CD137 expression on human NK cells associates with phenotypic markers of activation and pro­
inflammatory cytokine secretion. Gates were set around CD56+ (NK) cells and numbers in the dot plots indicate 
the percentage of NK cells expressing indicated surface marker. CD137 expression on IL-2 stimulated NK cells 
associates with increased levels of CD69 (A) and CD54 bnght (B) expression in cultures with immobilized hulgG 1 
and GG mAb. Pro-inflammatory cytokines were determined by ELISA in supematants after 24 hours of cultures. 
(C) TNF-a levels were significantly (*P=0.0468) increased in cultures with immobilized GG mAb. (D) IFN-y 
levels were significantly (*P=0.0477) increased in cultures with immobilized GG mAb. Immobilized mAb culture 
conditions and soluble mAb culture conditions are indicated with i- and s- respectively. Experiment shown 
represents one of six individual experiments. Statistical analysis is based on six experiments; CD69 expression 
levels are significantly increased in NK cell cultures with i-GG (P=0.0361) and co54bright expression levels are 
significantly increased in NK cell cultures with i-hulgG 1 (P=0.0 186) and i-GG (P=0.004) as compared with i-GA. 
HulgG I indicates polyclonal human IgG 1; GA, aglycosylated chimeric anti-CD 13 7 mAb; GG, glycosylated 
chimeric anti-CD 13 7 mAb; CTM, cetuximab. 
Surprisingly, the lytic capacity of CD137 expressing NK cells was significantly 
diminished (P=0.0054) in comparison to non-CD137 expressing NK cells (Figure 
6A). Importantly, influence on lytic capacity mediated through CD137-CD137L 
interactions is unlikely given the fact that K562 tumor targets did not express 
CD137L as determined by flow cytometry (data not shown). In order to understand 
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this observation, the temporal relationship between CD 1 3  7 expression and NK cell 
degranulation, as measured by CD107a expression ( 1 9) was determined. We 
observed that in the presence of immobilized GG mAb, IL-2 stimulated NK cells 
express high levels of the cytolytic surface marker CD107a (range 1 7%-43%; 
P=0.0 109 compared to immobilized GA) after 6 hours of culture (Figure 6B) while 
CD137 cell surface expression peaks between 12-24 hours of culture. These data 
suggest that de granulation and CD 1 3  7 expression on human NK cells are 
discordant which is reflected in the lytic activity against K562 tumor targets. 
Discussion 
The critical findings of these studies are that (i) immobilized Fe enhances the 
expression of CD 1 3  7 on IL-2 stimulated NK cells, (ii) the levels of CD 13  7 
expression are dependent on patterns of Fe glycosylation known to impact Fe 
interactions with FcyRIII, and (iii) the ability to induce CD1 37 expression is 
independent of the antigen specificity of the Fab region. Importantly, our 
experiments do not specifically address the therapeutic utility of targeting the 
CD 13  7 pathway on CD 1 3  7 expressing NK cells, which is perhaps best studied 
using CD 13 7L. Our findings shed new light onto a secondary function of mAbs 
against co-stimulatory molecules and demand caution when describing mAbs as 
being "agonistic" if their function in in vivo and in vitro studies is assessed with 
intact Fe regions. 
Knowledge of the functional import of CD1 37 on human NK cells is primarily 
derived from murine studies. It is now clear that IL-2 stimulated murine NK cells 
express CD 13 7 in vivo and that, in some but not all cases, these cells are required 
for the antitumor effects of agonistic mAbs against CD1 37 (2,3 ,6). The function of 
CD 1 3  7 /CD 1 3  7L interactions on murine NK cells is not completely understood, yet 
it appears that CD 1 3  7 ligation enhances NK cell proliferation, cytokine secretion 
and may provide a helper function in the induction of cytotoxic T lymphocytes 
(CTL); thereby bridging the innate and adaptive immune system in mice (20,2 1). 
Correlate studies suggest that human NK cells play a pivotal role in the regulation 
of both innate and adaptive immune responses, yet limited information is available 
regarding CD137 expression and its role in modulating these interactions (22). For 
example, it has been demonstrated that low levels of CD137 (-2.02%) can be 
induced on NKB 1 + cells when PBMC are exposed to Doxorubicin, Bleomycin or 
Mitomycin, although it remains uncertain if the small NKB 1+CD137+ cell 
population depicted in this study, represents T cells, NK cells, NKT cells or y8T 
cells (23). Similarly, from a functional perspective, human NK cells transfected 
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with a construct containing the intracellular domain of CD 13  7 directly linked to an 
anti- CD3/CD 19 chimeric receptor are more effective than NK cells transfected 
with anti-CD3-CD19 chimeric receptor alone, in both killing leukemic cells and 
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Figure 6. CD137 expressing human NK cells lyse NK sensitive tumor targets less efficient than non-CD137 
expressing human NK cells. (A) IL-2 stimulated NK cells were cultured for 24 hours in the presence of 
immobilized GG rnAb (•) or immobilized GA rnAb (•) and subsequently used in a 4 hour 5 1Cr release assay to 
determine Iytic activity against K562 target cells. Non-CD137 expressing NK cells (•) and CD137 expressing NK 
cells (•) were added at the indicated effector-to-target ratio's (E/T). Data represents mean and standard deviation 
of two independent experiments. Lytic activity of CD137 expressing NK cells (i-GG cultured) was significantly 
diminished as compared with non-CD137 expressing NK cells (i-GA cultured) with *P=0.0054. (B) Expression of 
degranulation marker CD107a on IL-2 stimulated NK cells after 6 hours of culture with i-GG. Gates were set 
around live cells based on forward- and site scatter plots and numbers in the dot plots indicate the percentage of 
NK cells expressing CD107a. Experiment shown represents one of four individual experiments. Statistical analysis 
is based on four experiments performed with P=0.0109 for i-GG compared to i-GA. Immobilized rnAb culture 
conditions are indicated with i-. GG indicates glycosylated chimeric anti-CD137 rnAb; GA, aglycosylated 
chimeric anti-CD137 rnAb. 
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Our experiments using various chimeric lgG 1 antibodies with different Fe regions, 
support the novel concept that interactions between F c and putative F cy Rs on the 
surface of human NK cells directly modulate the CD 13 7 co-stimulatory pathway 
independent of mAb antigen specificity. Because NK cells express CD16 and 
CD32 exclusively, it is likely that the observed effects are secondary to ligation of 
these receptors (25). Importantly, it is unlikely that the ability of GG and GA mAb 
to block CD137-CD137L interactions influenced our results as CD137L is only 
reported to be expressed on activated macrophages, dendritic cells and B cells and 
not on human NK cells (3,26). In addition, similar CD137 expression levels were 
observed in NK cell cultures in which the CD137 specific Fab fragment was absent 
(NK cell cultures with GG/Fc). While the up-regulation of CD137 did not appear to 
be augmented by cross-reactivity of anti-CD 13 7 specific Fab regions, these 
differences are difficult to ascertain in vitro. Our findings offer new insight into the 
role of antibody Fe fragments in mediating CD137 based NK cell responses. 
Consistent with the idea that Fc-FcyR interactions play an important role m 
regulating CD 13 7 expression on human NK cells, we found that for GG and CTM, 
the levels of CD 13 7 expression were inversely associated with fucose content 
within the N-glycan of the Fe region. Furthermore, while CD137 expression levels 
were enhanced in the presence of 10 fold increases in CTM concentration, CD 13 7 
expression levels did not increase in the presence of immobilized GG at 
concentrations over 1 0ug/ml. These data are consistent with previous observations 
that low-fucose IgG 1 mAbs enhance NK cell activation at lower mAb density (13). 
Interestingly, we did not observe an inverse correlation between CD137 expression 
levels and fucosylated N-glycan in cultures with hulgG 1. This observation may 
reflect the fact that the hulgG 1 used in our experiments is polyclonal, resulting in 
potential enhancement of CD137 expression levels through Fab binding. The 
higher GlcNAc contents in CTM (Man:GlcN = 3:5) in comparison to GG and 
hulgGl (Man:GlcN = 3:4) implicates the presence of a bisecting GlcNAc in the N­
glycan of this mAb. It is reported that the addition of bisecting GlcNAc enhances 
ADCC much less efficiently than the presence or absence of fucose (27). Our 
observation that, regardless the higher GlcNAc content, CTM is less efficient in 
inducing CD 13 7, phenotypic markers of activation and pro-inflammatory cytokines 
is in agreement with these previously published reports. Previous studies have 
demonstrated that Fc-FcyRIII cross-linking induces NK cell activation resulting in 
the loss of Fey RIii receptor expression and cytokine release (10) ( e.g. IFN-y and 
TNF-a). We found a direct association between GG cross-linking and acquisition 
of an activated NK cell phenotype characterized by CD69 and CD54bright 
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expression. This pattern of activation was inversely associated with FcyRIII 
expression. However, our studies did not rule out that possible FcyRIII loss could 
have been artifactual, secondary to the interference of lgG 1 with F cy RIII binding. 
Interestingly, the number of live NK cells was substantially decreased in cultures 
with GG. This observation is likely secondary to the specificity of GG for CD137 
and two potential mechanisms may be involved. First, GG interaction with CD 13 7 
may induce ADCC among CD137 expressing NK cells and/or second, GG 
interactions may either block or deliver a signal through CD 13 7. These 
mechanisms are not mutually exclusive, and both could potentially play a role. In 
addition to displaying phenotypic markers characteristic of NK activation, cultures 
with high levels of CD137 expression demonstrated the pro-inflammatory 
cytokines IFN-y and TNF-a. Furthermore, GG stimulated NK cells were 
functionally capable of degranulation as evidenced by high levels of CD 107 a 
expression (28). As degranulation precedes CD 13 7 expression, reflected by 
diminished lytic capacity against NK sensitive tumor targets, this may suggest that 
CD 13 7 expressing human NK cells play a role in immunomodulation rather than 
exhibiting direct lytic functions. Importantly, because there is a substantial time­
interval between the intracellular expression of CD107a and cytokines (maximum 
at 6 hours) and the surface expression of CD137 (maximum at >12 hours) we 
cannot ascertain whether CD 13 7 expressing cells are directly responsible for the 
observed differences. 
In summary, our findings that immobilized Fe induces CD137 expression on IL-2 
stimulated NK cells are pivotal to the interpretation of studies using anti-CD137 
mAbs with an Fe region capable of binding FcyRs. Specifically, under these 
circumstances, effects previously attributed to CD137 interactions with the Fab 
region, must now be re-evaluated as potentially related to Fe induced expression of 
CD137 on NK cells with subsequent effects due to (i) direct interaction of CD137L 
with Fe induced CD137, (ii) direct stimulation of Fe induced CD137 by agonistic 
anti-CD137 mAbs or (iii) antibody blockade of interactions between Fe induced 
CD137 and CD137L. 
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Chapter 3 CDI 37  promotes B cell proliferation and survival 
Introduction 
CD137 (4-lBB/ILA) is a member of the TNF receptor superfamily and is 
predominantly found on activated T cells and NK cells ( 1 -3). CD137 ligand 
(CD137L) is present on APCs including dendritic cells, macrophages, monocytes 
and B cells (4, 5). Stimulation of CD137, through either its natural ligand or 
agonistic antibody, induces potent antitumor immunity (6-8), yet also effectively 
ameliorates disease severity in several mouse models of autoimmunity, including 
systemic lupus erythematosus (SLE) (9), chronic graft versus host disease ( I  0), 
collagen induced arthritis ( 1 1 ,  12), inflammatory bowel disease ( 13) and 
experimental autoimmune encephalitis (14). Thus, immunotherapeutics targeting 
CD 13 7 represent promising new approaches to a wide array of distinct immune 
disorders. 
The explanation for the apparent disparity between the ability to promote tumor 
rejection and treat autoimmune disease appears to be predicated on CD137-
mediated manipulation of T cell function. Specifically, in conceptually overlapping 
experimental models of autoimmunity, CD 13  7 ligation induces T cell deletion or 
hyporesponsiveness ( 10, 13), stimulation of CD4+CD25+ antigen-specific 
regulatory T cell subsets ( 1 5) or proliferation of antigen-specific CD8+ CD 1 1  c + T 
cells which suppress CD4+ T cell responses ( 1 1 ). This CD137-mediated immune 
modulation of T cells is postulated to be mechanistically responsible for observed 
changes in B cell function, including diminished isotype-specific antibody 
responses and changes in B cell survival. For example, in both murine and primate 
models, administration of agonistic antibodies against CD137, reduces T cell­
dependent antibody production, and CD 13 7 deficient mice demonstrate reduced 
IgG2a and IgG3 responses to keyhole limpet hemocyanin (KLH) ( 1 6- 18). 
Additionally, the importance of CD137-CD137L co-stimulation in B cell survival 
is evidenced in CD 13  7L transgenic mice, where B cells are noted to decline in 
absolute number with advancing age ( 19). Importantly, murine B cells do not 
express CD 13  7, while human B cells are reported to up-regulate CD 13  7 in 
response to anti-IgM stimulation ( 1 ,  20, 2 1 ). Therefore, it is uncertain whether 
murine-based animal models will accurately predict clinical response to CD 13 7 
manipulation. Considering the importance of B cells in antitumor immune 
regulation and autoimmunity (22, 23), it is striking that the function of CD137 on 
human B cells has not been elucidated. 
The goal of our study was first to evaluate which external signals regulate CD 13  7 
expression on human B cells and second to define the biological effect of CD 13  7-
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mediated co-stimulation on human B cells. We demonstrate that the expression of 
CD 13 7 on human B cells in vitro is initiated by BCR stimulation while CD40 
ligation and cytokines provide second tier regulation. Furthermore, we show that 
CD137 is naturally expressed on B cells in tonsillar tissue in vivo, and that this 
expression is temporally distinct from CD 13 7L in vitro. The presence of CD 13 7 on 
human B cells is functionally relevant since stimulation with human CD 13 7L 
transfected cell lines at the time of activation, induces proliferation, protects B cells 
from activation-induced cell death and promotes secretion of TNF-a and TNF-�. 
Thus, our findings demonstrate that CD 13 7 co-stimulation may play a role m 
defining the fate of antigen-stimulated human B cells. 
Materials and Methods 
Cells 
Buffy coats from healthy donors were purchased (Biological Specialty 
Corporation, Colmar, PA) and PBMC were prepared by density centrifugation 
(Ficoll-Paque, Amersham). B lymphocytes were purified from PBMC by negative 
selection using a B cell isolation kit II (Miltenyi Biotec, Auburn, CA) and T 
lymphocytes were purified by positive selection using CD3 microbeads (Miltenyi 
Biotec), according to the manufacturer's  instructions. Purity of cell separations 
were typically >98% for B and T lymphocytes with less than 0.2% contamination 
of CD3+ T cells in purified B cell populations (as assessed by flow cytometry). For 
the isolation of narve and memory B cell subsets, CD 19+ cells were positively 
selected using a CD 19 multisort kit (Miltenyi Biotec ), followed by separation of 
CD19+CD27+ (purity >80%) and CD19+CD2T (purity >90%) cell subsets using 
CD27 microbeads (Miltenyi Biotec), according to the manufacturer's instructions. 
Tonsils were obtained with informed consent from patients undergoing routine 
tonsillectomies at the University of Maryland Medical Center. Cells were 
mechanically homogenized in complete medium, and mashed through a 40-µm 
sieve to clear the cell solution from tissue fragments and cell clusters. The 
mononuclear cells were isolated by Ficoll-Paque density centrifugation. 
B cell activation experiments 
All in vitro cell cultures were performed in RPMI 1640 ( Cellgro) supplemented 
with 10% FCS (Atlanta biologicals), 1 % penicillin/streptomycin, 1 % HEPES and 
1 % Glutamax (all from Life Technologies). 
Stimulation of PBMC: 2x l 06 PBMC were stimulated with 2µg/ml of PWM 
(Sigma), 5µg/ml of PHA (Calbiochem), 25ng/ml of PMA/l µg/ml of Ionomycin 
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(Sigma), 2.5µg/ml of CpG (InvivoGen) or 5µg/ml of LPS (Sigma) in 24-well 
plates. After 72 hours, PBMC were harvested, washed and assessed for CD 13 7 
expression by flow cytometry. 
BIT cell co-culture experiments: Purified B cells (1 x 106) and T cells (2x 106) were 
co-cultured and stimulated with PWM under the conditions described above. Direct 
BIT cell interactions were inhibited by the addition of transwell membranes. In 
brief, 2x I 06 T cells were added to the upper chamber of a transwell plate (polyester 
membranes 6.5-mm, 0.4-µm, Coming Costar) and I xI06 B cells were added to the 
lower chamber. 
Anti-CD40 L blocking experiments: To block CD40-CD40 ligand (CD40L) 
interactions, various concentrations (1-20µg/ml) of purified mouse anti-human 
CD40L (BD Biosciences) mAb or isotype control mAb were added to PBMC and 
BIT cell co-cultures. 
B CR-mediated stimulation experiments: Purified B cells or B cell subsets were 
cultured at a concentration of I x  I 06 /ml in a 48-well or 96-well flat bottom plate. B 
cells were activated with IOµg/ml anti-Igs F( ab')2 fragments (goat anti-human 
IgA+IgG+IgM (H+L), Jackson ImmunoResearch Laboratories), with or without 
the addition of l µg/ml purified goat anti-human CD40 antibody (R&D Systems). 
The following human recombinant cytokines were used to evaluate their impact on 
B cell stimulation: I OOU/ml of interleukin-2 (IL-2) (Proleukin, Chiron Corporation, 
Emeryville, CA), 20ng/ml of IL-4 (R&D Systems), I ng/ml of IL-6 (BD 
Bioscience), 50ng/ml of IL-IO ( eBioscience ), 50ng/ml of IL-15 (R&D Systems), 
I OOng/ml of IL-21 (Biosource International Inc., Camarillo, CA), 500U/ml of IFN­
y (eBioscience) and 50ng/ml of TNF-a (BD Bioscience). 
Real-Time RT-PCR Analysis 
Total RNA was isolated using a SV Total RNA Isolation System (Promega) and 
cDNA was synthesized using a Transcriptor First Strand cDNA Synthesis Kit 
(Roche Applied Sciences). Real-time quantitative PCR (Q-PCR) was performed 
using a 7500-Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) 
with specific primers, probes and software (Applied Biosystems). The level of 
CD137 mRNA was quantified based on a titrated standard curve co-run in the same 
experiment and calibrated with the expression level of glyceraldehyde-3-phosphate 
dehydrogenase. All samples were done in triplicate. 
Western blot analysis 
Proteins were separated by 4%-20% SDS-P AGE gels and transferred to 
nitrocellulose membranes (Amersham). Membranes were blocked and incubated 
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overnight at 4°C with goat anti-human CD137 antibody (R&D Systems). Murine 
mAb against B-actin was used as an internal control. Membranes were then washed 
and subsequently incubated with horseradish peroxidase-conjugated secondary 
antibody. The protein bands were visualized by chemiluminescence (GE 
Healthcare). 
Flow Cytometry 
Peripheral blood and tonsillar B cells were stained with directly conjugated mouse 
anti-human mAbs against CD3, CD19, CD20, CD32, CD69, CD86, CD95, CD137, 
CD137L, IgD, IgM (all BD Bioscience), CDS, CD23, CD25, CD27, CD38 and 
CD71(all eBioscience). Directly conjugated mouse IgGs were used as isotype 
controls. Labeled cells were acquired on a LSRII flow cytometer and analyzed with 
F ACS Diva (BD Biosciences) and Winlist (Verity Software House) Software. 
To evaluate cell proliferation by flow cytometry, B cells and separated B cell 
subsets were labeled with CFSE (Alexis Biochemicals), according to the 
manufacturer's  instructions. CFSE labeled cells were cultured as described above 
and indicated in appropriate figure legends. At day 3 or day 4 of culture, cells were 
harvested, stained with indicated cell surface markers and analyzed by flow 
cytometry. The total number of mitoses per a total of 100 gated cells was 
calculated using the formula: no. of mitoses= I(Xn*100-Xn*100/2n) , where X is 
the percentage of cells that underwent n divisions (24). 
Cell cycle analysis was performed using a BrdU-FITC flow kit (BD Biosciences). 
In brief, activated purified B cells were pulsed with l0µM BrdU. After 4 hours, 
cells were harvested and cell surface stained with mAbs indicated in the figure 
legends, followed by intracellular staining with anti-BrdU mAb. 7-AAD was used 
to evaluate DNA content. B cell apoptosis was determined by staining with 
Annexin V/7-AAD (Annexin V-PE apoptosis detection kit I, BD Biosciences), 
according to the manufacturer's recommendations. Accucount particles 
(Spherotech) were added before analyzing samples to obtain accurate absolute cell 
numbers which were calculated by the manufacturer's instructions. 
Immunohistological Analysis. 
OCT-embedded sections (5µm) of tonsil were fixed for 15 minutes in 4% 
paraformaldehyde and washed with PBS for 15 minutes. After incubating with 
10% normal human serum, the sections were double-stained for 45 minutes with 
the following primary antibodies: goat anti-human CD137 (2µg/ml; R&D 
systems)/mouse anti-human CD20 (1:500; eBioscience) and goat anti-human 
CD137/FITC-mouse anti-human IgD (1:20; BD Biosciences). Tissue sections were 
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washed with PBS and blocked with 5% rabbit serum. Each section was then 
incubated with secondary antibody: Alexa Fluor 594 conjugated rabbit anti-goat 
IgG, F(ab')2 fragment (1:1000; Invitrogen)/Alexa Fluor 488 conjugated rabbit anti­
mouse IgG, F(ab')2 fragment (1: 1000; Invitrogen) for 30 minutes. Slides were 
then washed and counterstained with DAPI (KPL) for 10 minutes. To control for 
nonspecific binding, control stains with isotype-matched primary antibodies were 
included. Tissue sections were viewed with a Nikon Eclipse E6000 fluorescent 
microscopy and were photographed with a Retiga 4000 camera (Q-Imaging). 
Functional B cell studies 
Generation of CD137 L transfectants: Human CD137L cDNA was obtained by RT­
PCR from total RNA extracted from human PBMC and sub-cloned into a 
mammalian expression vector (pcDNA3.l , Invitrogen, Huntsville, AL). P815 cells 
were transfected with human CD 13 7L using Lipofectamine (Invitrogen). After 
selection with G418 (800µg/ml) for 1-2 weeks, drug-resistant cells were F ACS 
sorted for CD 13 7L expression. CD 13 7L positive cells were further cloned by 
limiting dilution. A clone with high levels of CD 13 7L expression (hereafter called 
P815-CD 13 7L) was selected and used in subsequent functional B cell experiments. 
P815 cells transfected with vector alone were used as a negative control (hereafter 
called P815-mock). 
CD137-CD137 L interaction experiments: gamma-irradiated (100 gy) P815-
CD137L cells or P815-mock cells were cultured with purified human B cells for 3-
7 days. All cytokines and stimuli were added at the initiation of culture and are 
indicated in the figure legends. 
3H-TdR incorporation assays: Purified B cells were seeded at 2x105/well in 
triplicate wells in a 96 well flat-bottom plate and stimulated as described under "B 
cell activation experiments" in the presence of irradiated P815-mock or P815-
CD137L cells. To block the interaction of CD137 with CD137 ligand, l 0µg/ml of 
soluble CD137 protein (Prospec, Rehovot Isreal) was added at the initiation of 
culture. 3H-TdR (37 Kbq/well) was added 16 hours before completion of the 
experiment and thymidine incorporation was measured using a liquid scintillation 
counter (Wallac). 
Induction of apoptosis: Activation-induced cell apoptosis was evaluated by 
culturing B cells with anti-lg alone, or in combination with IFN-y or anti-CD40 as 
described under "B cell activation experiments". 
Cytokine ELISA: Supematants were collected 24-48 h after cultures were initiated. 
The concentrations of IL-4, TNF-B ( eBioscience ), IL-6, IL-10 (BD Bioscience), 
65 
Chapter 3 CD] 37 promotes B cell proliferation and survival 
IFN-y and TNF-a (Diaclone) were measured by a standard ELISA following the 
manufacturer's protocol. 
Statistical analysis 
A repeated measures model was used to compare CD 13 7 expression under 
different conditions (reagents) to account for potential intra-donor correlation. The 
calculation for the repeated measure model was implemented in SAS PROC 
MIXED. Residual diagnosis such as Q-Q plots were used to check the normality 
and model goodness of fit. The model reduces to t-test and paired t-test when there 
was only one sample per donor in each group. 
Results 
CD137 is expressed on human B cells following activation and expression is 
regulated by interactions between CD40-CD40L and pro-inflammatory 
cytokines. 
We first characterized activating signals required to induce expression of CD 13 7 
on human B cells by stimulating whole PBMC with various mitogenic stimuli. 
Human B cells were found to up-regulate CD137 in the presence of PWM 
(12.05±9.76%, n=18, figure l A) while stimulation with PHA, LPS, 
PMA/Ionomycin or CpG were not effective ( data not shown). Because PWM is 
recognized to activate both T cells and B cells, we next sought to determine if 
CD137 expression on human B cells is T cell-dependent. We observed that purified 
B cells did not up-regulate CD137 in the presence of PWM (data not shown). 
However, PWM stimulation of cultures containing isolated T cells and B cells, 
induced B cell associated CD137 expression (19.78±10.52%, n=l 0). This 
expression of CD137 is cell-to-cell contact dependent since B cells separated from 
T cells by a transwell membrane, did not up-regulate CD137 (figure 1B). As the 
CD40-CD40L co-stimulatory pathway is integral to T cell-dependent B cell 
function, we defined the relative import of CD40-CD40L interactions in the up­
regulation of CD137 on B cells. The addition of escalating concentrations of 
CD40L mAb to both PWM stimulated PBMC and purified T/B cell co-cultures 
significantly reduced the percentage of CD137 expression (P<0.0001) in a dose­
dependent fashion (figure l C). To confirm the significance of CD40-CD40L 
interactions in the induction of CD137, purified B cells were stimulated with anti­
lg in the presence or absence of anti-CD40 stimulating antibody. Resting (non­
stimulated) B cells and B cells stimulated with anti-CD40 antibody alone did not 
up-regulate CD137. However, B cells stimulated with anti-lg up-regulated low 
levels of CD 13 7, while CD 13 7 expression was dramatically enhanced at both 
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mRNA and protein levels with concurrent CD40 ligation· (figure ID-F). These data 
demonstrate that CD 13 7 is induced on human B cells following BCR stimulation 
and that expression levels are enhanced by interactions between CD40 and CD40L. 
Importantly, CD 13 7 expression levels on B cells varied among different healthy 
individuals ranging from 3.2% to 30.7% (n=I0; median=13.9%) and from 10.7% to 
62.2% (n=14; median=43.1 %) upon stimulation with anti-lg or anti-Ig/anti-CD40, 
respectively. It is notable that the predominant CD137 band differed between anti­
CD3 stimulated T cells and anti-Ig/anti-CD40 stimulated B cells (figure IF). 
Specifically, activated B cells display a dominant band at approximately 28 kD, 
while activated T cells have a dominant band at a size of approximately 40 kD. 
Importantly, activated B cells also have an identical 40 kD subdominant band. 
These distinct protein sizes might reflect cell specific post-translational 
modifications of CD 13 7 or the presence of isoforms in different cell types. 
Because cytokines are recognized to influence human B cell function, we evaluated 
the impact of cytokine stimulation on CD 13 7 expression. Purified B cells were 
stimulated with anti-Ig/anti-CD40 antibodies in combination with defined 
cytokines recognized to mediate B cell function. IL-2, TNF-a, IL-6 and IL-15 did 
not directly affect CD137 expression on human B cells. However, co-culture of 
anti-Ig/anti-CD40 stimulated B cells with IFN-y dramatically enhanced (P<0.0001) 
the percentage of CD137 expressing cells while IL-4 (P<0.0001), IL-10 (P=0.0188) 
and IL-21 (P=0.0037) induced the opposite effect (figure 2A). Similar to the effects 
of CD40 ligation, the ability of IFN-y to enhance CD137 expression is dependent 
upon BCR signaling (figure 2B-C), since B cells stimulated with IFN-y alone or in 
combination with anti-CD40 did not up-regulate CD 13 7. These data suggest that 
exposure to antigen is required for CD 13 7 expression and that CD40 signaling and 
select cytokines provide a second level of regulatory control for CD 13 7 expression 
on human B cells. 
CD137 is preferentially expressed on activated B cells of naive origin 
As a first step in characterizing the function of CD 13 7 on human B cells, we 
compared the cell surface phenotype of CD137+ and CD I3T B cells. Anti-Ig/anti­
CD40 stimulated CD 13 7+ B cells demonstrated elevated levels of CD? 1, CD86, 
and CD95 but diminished expression of CD32 (figure 3A). Interestingly, while 
CD 13 T B cells expressed small amounts of CD2 7, this marker was virtually absent 
on CD137+ B cells. Since CD27 distinguishes naYve B cells (CD19+CD2T) from 
memory B cells (CD19+CD27+), we evaluated if CD137 was differentially up­
regulated on these distinct populations. NaYve and memory B cells were purified 
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based on their levels of CD27 expression, cultured in the presence of anti-Ig/anti­
CD40, and harvested at defined time intervals. In both cell populations, CD137 
expression was present on day one and reached a peak at day three. By day seven, 
the expression of CD137 returned to baseline. Overall, the percentage of CD137+ B 
cells was higher in cultures originating from CD2T versus CD27+ B cells at every 
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Figure 1. CD137 is induced on human B cells following activation and expression level is enhanced by 
interaction between CD40 and CD40 ligand. CD137 is up-regulated on B cells following PWM stimulation of 
PBMC from healthy individuals (n= l 8). A representative FACS analysis is shown as percentage of CD137 
expression on gated B (CD l 9+CD3-) cells in whole PBMC (A). B cells require T cell contact in order to up­
regulate CD137 during PWM stimulation. Isolated B cells and T cells from healthy individuals (n= I 0) were co­
cultured in the presence of PWM with or without transmembrane for 3 days (B). Histograms indicate percentage 
CD137 expression on gated B (CD19+ CD3-) cells from one donor. Anti-CD40L mAb blocks CD137 expression 
on PWM activated B cells in PBMC and BIT cell co-cultures in a dose-dependent fashion (C). Data are presented 
as mean ± SD and are representative of 5 individual experiments. CD 13 7 is induced on human B cells upon BCR 
stimulation with enhancement of cell surface expression level following CD40 ligation with agonistic anti-CD40 
antibody (D). Histograms indicate percentage of CD137 expression on B cells. The isotype control was used to 
define the gate in all FACS analyses. Expression of CD137  mRNA (E) and protein (F) in anti-Ig/anti-CD40 
activated B cells from two different donors was assessed by quantitative RT-PCR and Western blot. R indicated 
resting; A, activated; *P<0.05; **P<0.0001 median =13.9%) and from 10.7% to 62.2% (n= l4; median=43 . 1%) 
upon stimulation with anti-lg or anti-Ig/anti-CD40, respectively. 
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These data demonstrate that following anti-Ig/CD40 ligation, CD137 is 
preferentially, but not exclusively, found on activated naYve B cells. Because 
CD 13  7 was not found on non-stimulated peripheral blood B cells from healthy 
donors, we next �ought to determine the expression of CD 13  7 on B cells in 
secondary lymphoid organs. Ex vivo analysis of human tonsillar B cells revealed 
that 0.8±0.3% (n=6) of total B cells expressed CD1 37 (figure 4A). Consistent with 
the in vitro phenotype in peripheral blood B cells, these CD 13  7 expressing tonsillar 
B cells exhibit a phenotype associated with cell activation, e.g. elevated expression 
of CD23, CDS,  CD86, CD71 and CD95. Additionally, CD137+ tonsillar B cells are 
surface IgMh\ CD38+/- and surface IgD+/- (Figure 4B). The majority of CD137+ B 
cells are found in the germinal center and fewer cells are found in the follicular 
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Figure 2. Cytokines provide a second level of regulatory control for the expression of B cell associated 
CD137. Purified B (CD19+) cells were anti-lg/anti-CD40 stimulated in the presence of no cytokine, IL-2, IL-4, IL-
6, IL- 1 0, IL- 1 5, IL-2 1 ,  TNF-a or IFN-y. After 3 days of culture, B cells were harvested and assessed for CDl 3 7  
expression by flow cytometry (A). CD40 ligation and/or IFN-y enhance CDl37 expression levels on human B 
cells but primary B cell receptor stimulation is required (B). A representative F ACS analyses from one donor is 
shown as percentage of CD 137 expression on B cells (C). Data are representative of at least 10  individual 
experiments. The isotype control was used to define the gate in all F ACS analyses. 
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The differentiation of human B cells into effector immunoglobulin secreting cells 
requires cell division (25, 26). Therefore, we sought to determine if CD137 
expression on human B cells is associated with B cell division. Based on CFSE 
dilution, we observed that higher levels of CD137 are expressed on divided (figure 
5A) compared to non-divided B cells (figure 5B). Specifically, CD137 is 
predominantly expressed on divided memory B cells. In contrast, both divided and 
non-divided naYve B cells express high levels of CD 13 7 although higher CD 13 7 
expression levels are found on naYve B cells with low CFSE intensity. Importantly, 
the expression of CD 13 7 does not solely rely on B cell division since CD 13 7 is 
present on the B cell surface prior to cell division and blocking of B cell division 
with mitomycin C does not abrogate the ability of anti-Ig/anti-CD40 activated B 
cells to up-regulate CD137 (data not shown). Furthermore, cell cycle analysis 
confirmed that more CD 13 7+ B cells (3 0%) are present in the S phase than CD 13 T 
B cells (15%; figure SC). 
CD137 ligation enhances B cell proliferation 
To expand upon the observation that CD137 expression on B cells is associated 
with B cell activation and cell division, we evaluated whether CD 13 7 co­
stimulation of activated B cells induces proliferation. In order to study the effect of 
CD 13 7 co-stimulation on human B cells, P815 cell clones expressing human 
CD 13 7L were generated. The P815-CD 13 7L cells were recognized by both mouse 
anti-human CD137L mAb and human CD137 fusion protein, confirming cell 
surface expression of CD 13 7L and the ability to interact with the human CD 13 7 
receptor, respectively ( data not shown). Purified B cells were stimulated with anti­
lg, anti-Ig/IFN-y or anti-Ig/anti-CD40 in the presence of P815-CD137L or P815-
mock cells. In comparison to B cell cultures with P815-mock, the presence of 
P815-CD137L significantly enhanced 3H-TdR incorporation in all three culture 
conditions (figure 6A). As both IFN-y and anti-CD40 activate B cells, the baseline 
of 3H-TdR incorporation without P815 transfectants were significantly higher in 
the group with anti-lg/anti-CD40, followed with anti-Ig/IFN-y, in comparison with 
anti-lg only stimulation. The specificity of the observed effects was confirmed in 
CD 13 7-CD 13 7L blocking experiments, where the addition of soluble human 
CD137 protein to anti-lg stimulated B cell cultures completely abrogated the 
observed differences (figure 6B). These data suggest that the observed changes in 
thymidine incorporation are specifically mediated through CD 13 7-CD 13 7L 
interactions. Subsequent studies using CFSE dilution analysis confirmed that 
CD137 enhanced anti-lg activated B cell proliferation in all five donors tested 
(P=0.0076) (figure 6C). Specifically, anti-lg activated B cells only completed one 
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cell division in the presence of P815-mock whereas in the presence of CD 13 7 co­
stimulation (P815-CD137L), cells completed two or more divisions. Additionally, 
CD 13 7L stimulated B cells exhibited a greater percentage of cells in the S phase of 
the cell cycle compared to those cultured with P815-mock (figure 6D). When B 
cells were activated with anti-lg/anti-CD40, a significantly higher percent of cells 


























Figure 3. CD137 is preferentially expressed on activated B cells of naive origin. Purified human B cells were 
activated with anti-lg/anti-CD40. After 3 days, B cells were harvested and CD137 expressing B cells and non­
CD137 expressing B cells were assessed for cell surface phenotype by flow cytometry (A). Histograms show 
surface expression of indicated markers on CD137+ B cells and co1 37- B cells. Filled peaks represent isotype 
controls. Data are representative of 5 individual experiments. Purified human B cells were separated into naive 
(CDI 9+CD2T) and memory (CD1 9+CD27+) B cells and subsequently stimulated with anti-Ig/anti-CD40. CD137  
surface expression was determined at indicated time-points (B). Data shown are representative of  5 individual 
experiments. *P<0.05. 
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However, in this setting, CD137 stimulation does not further enhance the cell 
division and cell cycle progression ( data not shown). These data suggest that the 
initial B cell activation signal determines the net effect of CD137-mediated B cell 
proliferation. 
CD137 ligation promotes human B cell survival 
Based on our observation that CD137 ligation in B cell cultures exposed to anti­
Ig/anti-CD40 enhanced thymidine incorporation, yet failed to induce clear cell 
division and cell cycle progression, we postulated that CD 13 7 may provide a 
survival advantage for B cells. In order to test this hypothesis, purified B cells were 
stimulated with anti-lg, anti-Ig/IFN-y, or anti-lg/anti- CD40 in the presence of 
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Figure 4. Ex vivo expression of CD137 in tonsillar B cells. Tonsillar mononuclear cells were analyzed for 
CD137 expression on B cells by FACS. B cells (CD19+CD3") were gated and the percentage of CD137 expression 
on B cells is indicated in a dot plot (A). Data are representative of 6 individual experiments from different donors. 
The phenotype of CD 13 7+ B cells was analyzed in comparison to CD 13 T B  cells (B). Filled peaks indicate isotype 
controls. Data are representative of 5 individual experiments. Three-color immunohistochemistry of human tonsil 
sections was used to identify the localization of CD137 expressing B cells. The upper panel shows a tonsillar 
germinal center (original magnification x20; CD20, green; CD137, red; DAPI, blue) (C) and follicular mantle 
zone (IgD, green; CD137, red; DAPI, blue) B cells (D). The indicated area from germinal centers and follicular 
mantle zones were enlarged to identify the CD20+/CD137+ and IgD+/CD137+ cells (lower panel). 
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Cell survival was assessed at various time points by flow cytometric staining with 
Annexin-V and 7-AAD. In the presence of P815-CD137L, both the percentage and 
absolute number of survived B cells (as determined by Annexin-V-/7-AAD-) 
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Figure 5. CD137 expression is associated with enhanced B cell proliferation. High levels of CD1 37 are 
expressed on divided human B cells. Non-separated (bulk; CD1 9+), memory (CD 1 9+CD27+) and naYve 
(CD19+CD2T) B cells were CFSE labeled and stimulated with anti-Ig/anti-CD40. After 4 days, cells were 
harvested and analyzed for CFSE dilution and CD137  expression by flow cytometry. Based on CFSE dilution, 
divided and non-divided B cell subsets were gated and analyzed for CD137  surface expression. Histograms 
indicate percentage of CD 1 3  7 expression on indicated subset of divided (A) and non-divided (B) B cells. Data are 
representative of at least 5 individual experiments. CD 1 3  7 expression is associated with cell cycle progression in 
anti-Ig/anti-CD40 stimulated human B cells. Anti-Ig/anti-CD40 stimulated B cells were cultured for 3 days and 
pulsed with BrdU for 4 hours. Cell cycle status of CD 1 3  7 expressing (CD 1 9+CD 1 3  7+) and non-CD 1 3  7 expressing 
(CD19+CD1 3T) B cells was determined by flow cytometry using anti-BrdU and 7-AAD (C). Data are 
representative of 3 individual experiments. 
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Figure 6. CD137 ligation stimulates B cell proliferation. Purified B cells were stimulated with anti-lg, anti-lg/lFN-y or anti-lg/anti-CD40 in the presence of various 
numbers of irradiated P8 1 5-mock or P81 5-CD137L as indicated in the figure. Thymidine incorporation was measured after 3 days (anti-lg, anti-lg/lFN-y) or 4 days (anti­
lg/anti-CD40) of culture (A). Data are presented as mean ± SD of triplicate wells and are representative of 5 experiments. Without activation, the baseline thymidine 
incorporation (CCPM) of B cells ranges from 100 to 200. The addition of soluble CD137 (sCD 137) protein to cultures with anti-lg activated B cells abrogates the enhanced 
thymidine incorporation by P8 1 5-CD137L activated B cells. Bar graph shows thymidine incorporation in anti-lg stimulated B cell cultures with P8 1 5-mock or P8 1 5-CD 137L 
after the addition of sCD137 (B). Data are presented as mean ± SD of triplicate wells and are representative of 4 individual experiments. Anti-lg stimulated B cells exhibit 
enhanced cell proliferation in the presence of P8 1 5-CD 13 7L cells at day 4 as measured by CFSE dilution analysis. A representative F ACS analysis of a CFSE dilution assay 
(donor 3) is shown (C). Values indicate the percent of mitoses of gated B lymphocytes. Anti-lg stimulated B cells have more cells in the S phase of the cell cycle in the 
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Figure 7. CD137 ligation enhances B cell survival. Purified B cells were stimulated with anti-lg, anti-lg/IFN-y 
and anti-lg/anti-CD40 in the presence of P8 15-mock or P8 15-CD137L cells. The percentage (A) and absolute 
number (B) of B cell survival was assessed by flow cytometry at culture day 4 and day 6. B cells were identified 
from P815 cells according to FSC vs. SSC as well as CD19 staining. Annexin-V and 7-AAD staining was used to 
distinguish the survived cells (Annexin-V-/7-AAO-) from apoptotic and dead cells. Data are shown as mean ± SD 
of pooled data from 5 donors for anti-lg and anti-lg/IFN-y stimulation and 6 donors for anti-lg/anti-CD40 
stimulation. Bar graphs represent B cells survival in cultures with P8 15-mock or P8 15-CD137L cells. *P<0.05 
However, despite the significant higher CD137 expression level induced by anti­
Ig/anti-CD40 stimulation, the difference in the CD 1 3  7 mediated enhancement of 
survival in anti-Ig/anti-CD40 activated B cells appears less than the B cells 
activated by anti-lg alone, or anti-Ig/IFN-y. In fact, anti-Ig/anti-CD40 activated B 
cells exhibited a higher survival rate in comparison with anti-lg alone, or anti­
Ig/IFN-y in the absence of CD137 ligation, which is consistent with previous 
observations (27, 28), that CD40 provides a survival signal for B cells. 
CD137 ligation induces secretion of TNF-a and p 
It is known that B cells produce effector cytokines upon activation (29, 30). In 
order to further define the function of CD 1 3  7 stimulation on activated B cells, we 
stimulated B cells with anti-Ig/anti-CD40, in the presence of irradiated CD1 37L or 
mock transfected P8 1 5  cells and measured cytokine release by ELISA. No 
significant differences in the production of IL-4, IL-6, IL- 10  or IFN-y were 
detected between mock and CD 1 3  7L stimulated B cells. 
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Figure 8. CD137 ligation enhances TNF production by anti-Ig/anti-CD40 activated B cells. Purified B cells 
from 3 donors were activated with anti-Ig/anti-CD40 in the presence of irradiated CDl 37L or P8 15-mock cells. 
Cell supematants were collected at 24 and 48 hours and cytokine levels were detected by ELISA. 
However, B cells stimulated with CD137L demonstrated profound increases m 
both TNF-a and TNF-� secretion in each of the 3 donors tested (figure 8). These 
data are particularly interesting given the recognized role of TNF antagonists in the 
treatment of autoimmune diseases, such as rheumatoid arthritis and SLE, in which 
activated B cells are postulated to play an important role in disease pathogenesis. 
Discussion 
Here we demonstrate that despite the reported absence of CD 13 7 on murine B 
cells, CD 13 7 is expressed on human B cells. Our studies indicate that CD 13 7 is 
expressed on activated B cells following BCR stimulation. Cognate help from T 
cells through CD40-CD40L interaction and/or cytokines are important for 
regulation of CD 13 7 expression on human B cells. Among the cytokines tested, 
only the Thl cytokine IFN-y enhanced CD137 expression, while IL-4, IL-10 and 
IL-21 inhibited CD137 expression. Importantly, neither anti-CD40 stimulation nor 
cytokine alone were capable of inducing B cell expression of CD137 in the absence 
of BCR stimulation. In addition, polyclonal stimulation of human B cells with 
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CpG, which stimulates TLR9-mediated B cell proliferation and differentiation in 
the absence of antigen, fails to up-regulate CD137 (data not shown). These data 
suggest that (i) CD137 expression on human B cell is tightly controlled, (ii) strictly 
dependent upon antigen encounter and that (iii) the BCR serves as the initial 
"switch" which enables up-regulation of CD 13  7 on the B cell surface. 
Similar to T cell-associated CD137, B cells transiently up-regulate CD1 37 with 
detectable cell surface levels after 24 hours of activation, maximal expression 
levels by day three and a return to baseline levels by day seven. This study 
demonstrates that CD 13  7+ B cells are phenotypically associated with enhanced 
expression of CDS, CD23, CD71 ,  CD86 and CD95 while CD32 expression is 
decreased, which implies that CD 13  7+ B cells are highly activated. Furthermore, 
divided B cells express higher levels of CD 13 7 compared to non-divided B cells, 
although CD 13  7 expression is not dependent on B cell division. Interestingly, upon 
anti-Ig/anti-CD40 stimulation, naYve B cells are more prone to enhanced CD137 
expression than memory B cells. We postulate that CD 13  7 co-stimulation may be 
especially important for naYve B cell regulation, since naYve and memory B cells 
require different signals for cellular activation and differentiation (31 ,  32). 
The functional effects of CD137-mediated co-stimulation on T cell proliferation 
and survival are well documented (33-35). Here we demonstrate that CD137 on 
human B cells mediates analogous functional changes. 3H-thymidine incorporation 
by anti-lg, anti-Ig/IFN-y or anti-Ig/anti-CD40 stimulated B cells is significantly 
enhanced upon ligation with CD137. Interestingly, B cell division and cell cycle 
progression are differently affected depending on the initial B cell activation signal. 
For example, B cell division is enhanced through CD137 ligation on B cells which 
have been stimulated with anti-lg alone. In contrast, B cell division and cell cycle 
are not affected by CD 13  7 ligation among B cells which are stimulated with both 
anti-lg and anti-CD40, despite significantly higher CD137 expression levels. Since 
CD40 signaling is known to mediate B cell proliferation and survival (28), delicate 
CD 13  7-CD 13  7L mediated enhancements in cell division and cell cycle progression 
may be masked by the potent proliferative effects of the CD40 signal itself. Despite 
the fact that various B cell stimuli, e.g. anti-lg, anti-lg/lFN-y and anti-Ig/anti­
CD40, impact differently on CD 13  7-mediated B cell proliferation, B cell survival 
was improved by CD137 ligation in all culture conditions. Specifically, enhanced 
improvement in B cell survival was observed among B cells activated by anti-lg 
alone or in combination with IFN-y, compared to those activated by anti-Ig/anti­
CD40. Overall, our data indicate that CD137-mediated changes in B cell function 
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depend on initial B cell activation and are the net effect of both CD137-mediated B 
cell proliferation and B cell survival. 
Ex vivo histological analysis of human tonsil showed that the CD 13 7+ B cells 
mainly localize to the germinal center. Taken together with the observation that 
CD137 ligation promotes B cell proliferation and survival in vitro, we postulate 
that the interaction of CD 13 7 with CD 13 7L expressed on APC plays an important 
role during early B cell activation and expansion in the germinal center reaction. 
Because B cells are reported to express CD137L (36), we examined the 
relationship between CD 13 7L and CD 13 7 expression in vitro and ex vivo 
( supplemental figure 1 ). CD 13 7L is expressed during the early stage of B cell 
activation followed by the upregulation of CD 13 7. In our in vitro culture 
conditions, the majority of cells did not co-express CD137 and CD137L. 
However, activated B cells at different development stages circulate in vivo. We 
were able to detect both CD 13 7+ and CD 13 7L + B cells ex vivo from human tonsil, 
though the receptor and ligand are primarily expressed on distinct populations 
(supplemental figure 2). In this scenario, the interaction of CD137L+ B cells with 
CD137+ B cells might bi-directionally co-stimulate B cells and mediate cell 
functional changes, since CD 13 7L can also reverse signals in certain cell types (3 7-
39). 
In addition to antibody production and antigen presentation, activated B cells 
produce cytokines and thus, regulate immune responses (29, 30). Moreover, B cells 
play a key role in the pathogenesis of diseases such as rheumatoid arthritis 
demonstrated by the clinical efficacy of targeted B cell depletion ( 40). In response 
to CD137 stimulation, the production of TNF-a and TNF- O is greatly enhanced by 
anti-Ig/anti-CD40 activated B cells. Both cytokines independently or 
complementarily enhance immune responses and augment inflammation by 
targeting various immune cells. Specifically, (i) TNF-a has been established as a 
central player in the pathogenesis of rheumatoid arthritis (41), (ii) TNF-� is 
required for the formation of germinal center like structures within the inflamed 
synovium (42) and (iii) our unpublished studies suggest that the CD137 expression 
on peripheral B cells is elevated in autoimmunity ( e.g. rheumatoid arthritis). 
Therefore, our data suggest that CD 13 7 mediated B cell stimulation might be 
involved in the pathogenesis of rheumatoid arthritis. Further investigation on the 
function of B cell-associated CD137 in autoimmunity is underway. 
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To the best of our knowledge, the present study is the first to demonstrate that 
CD 13 7 promotes human B cell proliferation, B cell survival and cytokine 
production. The CD 13 7 receptor is distinct from other TNF receptor family 
members that regulate B cell proliferation and differentiation, such as CD40 and 
BAFF-Receptor (BAFF-R) (43-45). CD40 and BAFF-R are constitutively 
expressed on B cells whereas the upregulation of CD 13 7 is strictly dependent on 
the presence of anti-BCR stimulation. Similar to BAFF-R, CD137 co-stimulates 
the proliferation of B cells in the presence of anti-BCR. In contrast, CD40 
stimulates B cell proliferation and differentiation in the absence of anti-lg. 
Therefore, it is likely that CD40, CD 13 7 and BAFF-R fulfill distinct functions in 
vivo. However, comparison of the signaling cascade initiated through these 
receptors requires further investigation. 
Finally, our findings have important implications for the clinical translation of 
CD 13 7 based immunotherapeutic strategies. The disparity of CD 13 7 expression 
and function between human and murine B cells challenges the use of murine­
based disease models for the evaluation of CD137-mediated immune regulation. 
As a result, targeting the CD 13 7 pathway with therapeutic intent may have 
unanticipated consequences on human B cell function. In addition, the fact that the 
expression of B cell-associated CD137 is regulated by many of the factors involved 
in the pathogenesis of rheumatoid arthritis and SLE ( e.g. enhanced CD40 
expression and altered cytokine production) suggests that B cell-associated CD 13 7 
might be of functional import in these diseases ( 46, 4 7). 
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Abstract 
Antibody-based manipulation of the CD 1 37 (4- lBB) co-signaling pathway 
is an attractive option for the treatment of cancer and autoimmune disease. 
We developed a chimeric anti-human CD 1 3 7  monoclonal antibody (GG) and 
characterized its function. As a component of planned precl inical studies, we 
evaluated the binding of GG to activated PBMCs from cynomolgus macaque 
and baboon against human. Interestingly, GG only recognized human CD 1 3  7 ,  
while a commercial anti-CD 1 37 mAb (4B4- l ), recognized activated PBMCs 
from both human and non-human primates .  Subsequent analysis revealed 
that the amino acid sequence of CD 1 3  7 is largely conserved between primate 
species ( �95% identical) , with the extracellular domain differing by only 
9- 1 0  amino acids . Based on these data, we generated mutant constructs in the 
extracellular domain, replacing nonhuman primate with human CD 1 3  7 se­
quences ,  and identified 3 amino acids critical for GG binding. These residues 
are likely part of a conformational epitope, as a peptide spanning this region 
is unable to block mAb binding. These data demonstrate that subtle sequence 
variations of defined co-stimulatory molecules amongst primate species can 
be employed as a strategy for mapping residues necessary for antibody bin­
ding to conformational epitopes . 
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Introduction 
Recent events such as the TGN1412 trial in 2006, where healthy volunteers 
became critically ill following the administration of a super-agonistic anti-CD28 
mAb, underscore the importance of appropriate animal model choices in preclinical 
testing of therapeutic agents which alter the function of co-signaling pathways ( 1 -
4 ) .  The ability of  co-signaling molecules to modulate cell function has stimulated 
significant interest in manipulating these pathways with therapeutic intent. In order 
to maximize therapeutic benefits while reducing unanticipated side effects, both 
identification of co-signaling pathways with improved toxicity profiles and 
development of preclinical tests which more accurately predict potential toxic side 
effects in humans are mandated (3). 
Manipulation of the CD137 (4- lBB) co-signaling pathway can be used to provide a 
favorable toxicity profile, as shown in previous studies (5). While CD137  is 
induced on both activated human T cells and NK cells, the ligand, CD 1 3  7L, is 
expressed on monocytes, dendritic cells and B cells ( 6, 7). Binding of CD 1 3  7 to its 
ligand can result in T cell proliferation and increased cell survival (9). Other 
studies demonstrated antitumor immunity in mouse models in an NK-dependent 
fashion (5, 1 0). Unexpectedly, activation of CD137 also ameliorates autoimmune 
diseases in several murine models including, inflammatory bowel disease, 
rheumatoid arthritis and systemic lupus erythematosus ( 1 1 - 1 3). While the 
mechanism for CD 1 3  7 anti tumor immunity and reduction of autoimmune 
responses appear distinct, manipulation of this pathway is attractive for the 
treatment of disease. 
In collaboration with GTC Biotherapeutics Inc, we developed a chimeric mouse 
anti-human CD137 mAb with a human lgG 1 Fe, GG. Prior to clinical testing of 
this antibody, we planned to evaluate its safety in non-human primate (NHP) 
models. Interestingly, GG effectively bound to human CD 1 3  7, but failed to 
recognize either activated cynomolgus macaque (Macaca fascicularis) or olive 
baboon (Papio anubis) PBMC. In contrast, another anti-CD137 mAb (4B4- l), 
bound CD137 from both human and NHPs activated PBMCs. To map the binding 
site of GG, we first characterized the DNA sequences of CD137  from NHPs 
including cynomolgus macaques, olive baboons, and rhesus macaques (Macaca 
mulatta). The full-length CD137 from these NHP species demonstrated high 
homology, differing from human by only 9 amino acids (AA, cynomolgus) and 10  
AA (baboon) in the extracellular domain. Based on these data, we generated 
constructs of the external CD 13  7 domain, replacing individual NHP CD 1 3  7 
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sequences with the human equivalent, and identified three amino acids necessary 
for GG binding. These amino acids are likely to contribute to a conformational 
rather than a linear epitope, as we were unable to inhibit binding with a synthetic 
20 amino acid long peptide that contained the human sequence for the region 
identified. These data demonstrate that sequence variations between human and 
NHPs can serve as an effective tool for mapping the binding sites of antibodies 
against co-stimulatory molecules and provide further insight into the sites of 
CD137-CD137L interactions. 
Materials and Methods 
All experimental work related to NHP material was approved by the University of 
Maryland's Institutional Animal Care and Use Committee (IACUC). 
Antibodies 
The methods of chimerization and purification of the GG monoclonal antibody was 
previously published (7). For flow cytometry, GG was directly conjugated with 
allophycocyanin (APC) by Invitrogen (Molecular Probes Invitrogen, Eugene, OR) 
and 4B4-1 mAb was purchased from BD (BD Biosciences, San Jose, CA). 
Cell culture 
Wild type and transfected Chinese hamster ovary (CHO) cell lines were maintained 
in Dulbecco's modified Eagle's medium (DMEM; Mediatech, Inc., Herndon, VA) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, 
GA) and 1 % of penicillin/streptomycin (lnvitrogen, Carlsbad, CA), Glutamax 
(lnvitrogen, Carlsbad, CA), and HEPES buffer (Mediatech Inc., Herndon, VA). 
The cells were grown at 3 7°C in 5% CO2 atmosphere. 
PHA activation 
Human, rhesus macaque and baboon PBMC were plated at 2xl06 cells/well in 24 
well plates, activated with 20µg/ml of PHA and incubated at 37°C, 5% CO2• After 
48 hours, cells were harvested, washed and subsequently stained with CD 13 7 
specific mAbs as indicated. In addition, non PHA activated cells were stained for 
F ACS and used as a baseline control. 
cDNA preparation 
RNA from human PBMC (Biological Specialty Corporation, Colmar, PA) was 
extracted using a Qiagen RNA kit (Qiagen, Valencia, CA) as per manufacturer's  
instructions. cDNA of all species was purified from the processed RNAs using 
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Bio-Rad cDNA synthesis kit (Bio-Rad, Hercules, CA) according to manufacturer' s  recommendations. 
Primers The primers for human and NHP used in our study are shown in Table 1 .  Human specific CD 1 37 primers were designed from the human CD137  sequence (NCBI accession number NM_00156 1 .4). Cynomolgus macaque (Macaca fascicularis) and olive baboon (Papio anubis) specific CD1 37 primers were designed based on the rhesus macaque (Macaca mulatta) CD 1 37 sequence (NCBI accession number XM_00 1096 1 66). 
PCR amplification cDNA encoding the extracellular CD 13  7 domain of human and NHP were amplified using polymerase chain reaction (PCR). Briefly, the PCR reaction was optimized using 2µL of cDNA, 0.5mM dNTPs, 1 unit GoTaq polymerase (Promega, WI) and corresponding IX  buffer containing 1 .5 mM Mg2+. The PCR conditions include an initial denaturation step at 95°C for 3 minutes, followed by 35 cycles at 94°C for 30 seconds, 50°C for 45 seconds, and a final extension at 72°C for 1 0  minutes. The PCR amplified products were run on a 2% agarose gel and visualized with ethidium bromide staining. Where extractions were required, PCR products were obtained using a Qiagen Gel extraction kit (Valencia, CA) according to manufacturer' s  recommendations. 
Subcloning of inserts All amplified CD1 37 DNA were cloned into a TOPO TA Cloning® vector (pCR®2. l -TOPO®) (Invitrogen, Carlsbad, CA) according to manufacturer' s  suggestions. Each insert was confirmed by sequencing at the Biopolymer/Genomics Core Facility, University of Maryland, Baltimore, USA. After characterization the inserts were subcloned into expression vector pcDNA 3 . 1  using either a PCR based sewing by overlap extension procedure ( 14) or using existing restriction sites resulting in full-length CD137  constructs. 
Transfection All plasmids used were transfected into a CHO cell line using FuGENE® 6 Transfection reagent (Roche, Indianapolis, IN) according to manufacturer' s  recommendation. For transient transfection, CHO cells were seeded in a 6 well plate the day before transfection at a density of -1 .5 x 1 05 cells per well in 2 mL DMEM complete media. 
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Table 1 Primer seguences used for PCR am:elification of human and NHP CD137 
Name Sequence" Orientation PCR specificity 
SES 49 5 '-CAGCCCTATTGACTTCCA-3 ' Reverse Human full-length 4-l BB 
SES 57 5 '-ACCTGTGCCAGA TTTCA T-3 ' Forward Human full-length 4-1 BB 
SES73 5 ' -GCGAAGCTTGCCA TGGG- Forward Cynob full-length 4-l BB 
AAACAGCTGTTACAACAT AG-3 ' 
SES74 5 '-TGCTCAGATTAATGGTGAT- Reverse Cyno full-length 4-l BB 
GGTGATGATGCAGTTCACATCC 
TCCTTCTTC-3 ' 
SES 84 5 '-GGAGGACAGGGACTGCAA- Reverse Mutate cyno K-50*, 1-66*, S-67*,  
ATTTGATTCCTGTTATTATCACA Y-69*and E-75* to R, T, P, F, G, 
GAATGTACC-3 ' respectively 
SES 85 5 '-GGT ACA TTCTGTGAT AA T- Forward Mutate cyno K-50*, 1-66*, S-67*, 
AACAGGAATCAAATTTGCAGTC Y-69*and E-75* to R, T, P, F, G, 
CCTGTCCTCC-3 ' respectively 
SES 120 5 ' - Forward Mutate cyno 1-66*, S-67* and Y-
AGTTGTACTGCACTCCAGGGTT 69* to T, P and F, respectively 
TCA-3 ' 
SES 121 5 '- Reverse Mutate cyno 1-66*,  S-67* and Y-
TGAAACCCTGGAGTGCAGTCAC 69* to T, P and F, respectively 
ACT-3' 
SES 178 5 ' - Forward Mutate human Tl-66*, P67* and 
ATTTCAGGGTATCACTGCCTGG F-69* to I, S and Y, respectively 
GGGCAGGA-3 ' 
SES 179 5 '- Reverse Mutate human TI-66*, P67* and 
ATACCCTGAAATGCAGTCACAC F-69* to I, S and Y, respectively 
TCTGCA TTGCT-3 ' 
"Human specific CD137 primers were designed based on NCBI accession number NM_00156 1.4. Cynomolgus 
macaque and baboon specific CD137 primers were designed based on the rhesus macaque (Macaca mulatta) 
CD 13 7 sequence (NCBI accession number XM_ 001096 I 66. 1 ). 
bCyno, cynomolgus macaque 
*Numbering begins at the first amino acid after the signal peptide sequence of the human 4-1 BB sequence (8). 
One µg of green fluorescent protein DNA was used as a control to determine 
transfection efficiency. After 48 hours of transfection, cells were either harvested 
for transient analysis or selected for resistance to G-418 at 1 mg/mL for 1 week. To 
obtain clones from the stable transfection, limiting dilution cloning of the 
transfected cells were maintained in the standard growth medium containing 
0.8mg/mL G-418. Stable clones were selected and screened for optimal expression 
of CD137 using flow cytometry with commercial anti-CD137 mAb (clone 4B4-1). 
Flow cytometry 
Expression of CD 13 7 was determined by direct staining with mouse anti-human 
CD137 (4B4-1) or chimeric GG mAb. Directly conjugated human IgGl and mouse 
lgG2a were used as isotype controls for the mAbs 4B4-1 and GG, respectively. 
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Cells were incubated with the antibodies at 4°C for 30 minutes and washed twice 
with F ACS buffer and acquired using a BD™ LSR II flow cytometer and analyzed 
with BD™ F ACS DIV A Software or WinList™ (Verity Software House, 
Topsham, ME). 
Peptide inhibition 
A peptide was synthesized identical to the human CD 13 7 protein (Thr58 -Ser59 -
Asn60-Ala6 1 -Glu62-Cys63-Asp64-Cys65-Thr66-Pro67-Gly68-Phe69-His 70-Cys7 1 -Leu72-
Gly73-Ala74-Gly75-Cys76-Ser77), and was used to block the recognition of the GG 
mAb to its natural antigen. The peptide, with a calculated molecular weight of 
1972.2 g/mol, was titrated from 156.25 µg/mL to 5000 µg/mL (0.08 mM - 2.54 
mM). This concentration range is sufficient to saturate the GG mAb at 3.5 µg/mL 
(0.08 mM). Briefly, various concentrations of peptide were added to 3.5 µg/mL of 
GG mAb and incubated at 4°C for 30 minutes. CHO transfected human CD137 
cells were added to the peptide-mAb mixture and incubated for another 30 minutes 
at 4°C. Cells were washed once and analyzed by flow cytometry. 
Results 
GG antibody does not recognize CD137 on activated baboon or rhesus PBMC 
To understand the value of NHP models for evaluating the toxicity of our anti­
CD 13 7 mAb, we first sought to determine if the antibody bound to activated NHP 
T-cells. We and others have previously observed that activated PBMC express 
CD137 (15). FACS analysis of activated PBMC stained with a commercially 
available anti-CD137 mAb, 4B4-1, or the chimerized anti-human CD137 mAb, 
GG, revealed that all mAbs equally bound to CD137 on activated human PBMC. 
However, CD137 expression was only detected on activated PBMC from NHPs by 
4B4-1 (Figure 1). Importantly, NHP cells were recognized by 4B4-1 after 
activation, demonstrating that activation of these cells was effective. These results 
suggest that sequence differences between human and NHP CD 13 7 molecules 
could be employed to map the epitope recognized by GG. 
Characterization of human, baboon, and rhesus macaque CD137 
As a first step towards epitope mapping, we cloned and sequenced CD137 full­
length cDNA from both human and NHP. To clone the NHPs, we engineered 
primers based on either the human (NM_OO1561.4), or rhesus macaque 
(XM _ 001096166) sequences. The forward primers were designed to identify 
sequences in the region of the putative signal peptide and reverse primers in the 
predicted C terminus of the protein. RNA from human, cynomolgus macaque and 
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baboon PBMC were purified, reverse transcribed, amplified using PCR, and the 
products were cloned and characterized. Amino acid sequences of our human, 
rhesus and cynomolgus macaque CD 13 7 clones were identical to the available 
NCBI published sequences (16, 17). The novel baboon (Papio Anubis) sequence 
was deposited in GenBank with accession number FJ348360 (Banklt accession 
number 1139275). At the amino acid level, the full-length CD137 sequence of 
cynomolgus macaque and baboon differed from human by 4.7% and 5.4%, 
respectively (Figure 2). 
Expression of human, cynomolgus macaque and baboon CD137 constructs in 
CHO cells 
In order to minimize the variability observed in mAb binding in activated PBMC, 
we established stable cell lines expressing either human or NHP full-length CD137 
proteins. This was achieved by transfecting the full-length human, cynomolgus 
macaque and baboon CD 13 7 cDNA into CHO cells. The stably transfected cell 
lines were stained with 4B4-1 and GG. Figure 3 shows FACS analysis of CHO 












Figure 1. Expression of CD137 on activated PBM from human and NHP. PBMC were activated with 
PMA/Ionomycin for 48 hours and stained with either isotype control antibodies (A) or with anti-human CD 137 
monoclonal antibodies (B). The vertical axis is represented by side scatter (SSC). The numbers represent the 
percentage of CD 1 3  7+ cells. Gates were set according to the isotype controls as indicated. 
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Clones demonstrating a high level of anti-CD137 expression using mAb 4B4- 1 
were selected and tested against GG. Although all transfected clones consistently 
expressed high levels of anti-CD137 when stained with 4B4- 1 ,  only cells 
transfected with the human CD137 were recognized by GG. Using the full length 
human and cynomolgus macaque constructs, we designed an approach to identify 
the epitope uniquely recognized by GG by engineering chimeric constructs (Figure 
4). 
Glycosylation is not responsible for observed binding differences for GG 
Glycosylation of proteins can affect ligand interaction or alter antibody 
recognition. In the sequence characterization of human CD 13  7, there were two 
sites (Asn 1 03 and Asn 1 15) in the extracellular portion of the protein that scored 











I MGNSCYNIVA TLLLVLNFER TRS, �QD!CSN CPAGTFCDNN R!!OICSPCPP NSFS SAGGQR 
MGNSCYNIVA TLLLVLNFER TRS LQDLCSN CPAGTFCDNN RSQICSPCPP NSFS SAGGQR 
MGNSCYNIVA TLLLVLNFGR TRB LQDLCSN CPAGTFCDNN RSQIC BPCPP NSFS SAGGQR 
TCD:ICRQCKG V�TRKECSS TSNAECDC!!_ G!:,HCL�CS MCEODCKOGC! ELTKKGCKDC 
TCD:ICRQCKG VFKTRKECSS TSNAECDC:IS G"i'HCLGAECS MCEODCKOGC! ELTKKGCKDC 
TCD:ICRQCKG VFMTRKECSS TSNAl!:CDCIS G"i'HCLGAECS MCEODCKQGQ ELTKKGCKDC 
CFGTFNDQKR G!CRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS 8!'.l'PPAPA!!;B 
CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS SATPPAPAKB 
CFGTFNDQKR GVCRl?WTNCS LDGRSVLVNG TKERDVVCGI? SPADL SPGAS SATl?PAJ?ARE 
•••••••  transmembrane region •••s•• 
l?GHSl?Qr:I!F FLALTST�L FLLFFL!,LRF SVVKR,!RRRL LYIFROJ?F!:!R J?VQ'l'TQEEDG 
l?GHSl?Qrr-F FLALTSTVVL FLLFFLVLRF SVVKR SRRRL LYIFRQJ?FMR J?VQ'l'TQEEDG 
l?GHSl?QrI-F FLALTSTVVL FLLFFLVLRF SVVKRSRKKL LYIFKQJ?FVR J?VQ'l'TQEEDG 
C SCRFl?EEEE GGCEL 
CSCRFl?EEEE GGCEL 
C SCRFPEEEE GGCEL 
Figure 2. Comparison of human and NHP CD137 sequences. Sequence comparison of full-length CD137 
between human and NHP indicate the protein is conserved throughout old world primates and apes. The human 
sequence is based on Pub Med NM_00156 1 .4 submission. The predicted signal sequence in human is identified in 
the box and the numbering of the human sequence is based on the mature protein (after removal of the predicted 
signal sequence (8)). The putative transmembrane region is noted and bounded by asterisk. Differences between 
human and NHP sequences are identified in bold and underlined. 
91 
Chapter 4 Epitope mapping of a chimeric CD 13 7 monoclonal antibody 
However, these residues were shared between the human and non-human primate 
species used in this study. Another site that had a significantly lower probability for 
glycosylation, Asn 1 9, was only present in the human sequence and differed in NHP 
(Figure 2). Based on these data, we mutated Ser 19 in the cynomolgus macaque to 
Asn 1 9, which is present in the human sequence. F ACS analysis demonstrated that 
the cynomolgus macaque mutated construct was not detected by GG, suggesting 
that Asn 1 9  and glycosylation are not important for anti-CD137 mAb binding 
(Figure 4, Construct 1 ). 
Binding of GG depends on the amino acid sequence between Arg37 and Ile109 
To further localize the epitope, we took advantage of the sequence similarity 
between human and NHP and created a chimeric construct using conserved 
restriction sites present in both human and cynomolgus macaque at the same 
position within the sequence. Restriction digestion of both human and cynomolgus 
macaque CD 13 7 constructs with restriction enzymes PpuMI and Sall permitted the 
creation of a new construct in which amino acids from Arg37 to Ile109 of 
cynomolgus macaque were replaced with those of the human equivalent (Figure 4, 
Construct 2). Stable clones of transfected construct 2 were stained with the anti­
CD 13 7 mAbs and significant binding of chimeric GG to this partially "humanized" 
cynomolgus construct was observed. These data localize the possible residues 
responsible for GG binding to the central part of the extracellular region of CD 13  7. 
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Figure 3. CD137 
expression of stably 
transfected CHO cells 
with human and NHP 
CD137 constructs. 
Stably transfected 
CHO cells expressing 
the human and NHP 
full-length CD137 
constructs were stained 
with either 4B4- 1 or 
GG mAb. The highest 
CD 13 7 clones 
( determined by 
staining with 4B4-1 
mAb) were used for 
studies. Filled 
histograms represent 
isotype control mAb; 
open histograms 
represent CD 13 7 mAb 
staining. 
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Binding of GG antibody is dependent upon amino acids Thr66, Pro67 and Phe69 
To further define the possible binding site(s) of GG, we mutated the three clustered 
amino acids at position Ile66, Ser67 and Tyr69 of the human equivalent (Thr66, Pro67 
and Phe69) in the cynomolgus construct using gene sewing. This resulting chimeric 
CD137 cynomolgus construct is recognized by both 4B4-1 and GG (Figure 4, 
Construct 3). To insure that these residues are responsible for binding, we made the 
reciprocal construct using human CD 13 7 as the backbone and replaced the three 
amino acids from cynomolgus macaque with the human equivalent using the same 
approach. As predicted, the full length human CD 13 7 construct with these three 
amino acid changes from cynomolgus macaque was not recognized by GG after 
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Figure 4 .  Constructs of  the extracellular region of  CD137 used in  GG mAb epitope mapping. "Chimeric 
constructs ( 1 -4) were engineered based on the amino acid (AA) sequence dissimilarities found between human and 
cynomolgus macaque using gene sewing PCR or sequence replacement by restriction enzyme digestions due to 
conserved restriction sites present in both species. Constructs 1 ,  2 and 3 made from the cynomolgus backbone, 
were replaced with equivalent regions of the human CD137. Construct 4 was engineered to contain cynomolgus 
CD137 AA on a human CD137 backbone as a control to determine if indeed, the indicated 3 AA residues 
contribute to GG binding. Filled histograms represent isotype control mAb; open histograms represent CD137 
mAb staining. 
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Epitope recognition by GG is not inhibited by a 20 AA peptide spanning 
residues 58-77 
To determine whether the structure of the binding site was a linear epitope, and 
whether a peptide could be employed for in vitro blocking of the antigen, we 
synthesized a 20 amino acid long peptide identical to the human sequence. This 
peptide contains the three unique amino acids (Thr66, Pro67 and Phe69) that 
contributed to mAb GG recognition to the CD 13 7 protein. When increasing 
concentrations of peptide were added to a constant amount of GG mAb, we 
observed no decrease in antibody binding (Figure 5). In addition, we used both 
W estem blotting with CD 13 7 fusion protein and immunoprecipitation from a 
CD137 transfected CHO cell lysate with biotinylated GG to detect a non-reduced 
CD137 (data now shown). However, we were not able to observe the same 
antibody recognition under reduced conditions. Additionally, incubation with the 
synthetic peptide had no effect in either reduced or non-reduced conditions, 
suggesting that GG may only recognize conformational characteristics that are not 
present in the soluble peptide or after alteration of protein structure. 
Discussion 
Safe and effective translation of antibodies designed to manipulate co-signaling 
pathways requires in depth preclinical assessment, which often includes studies in 
NHP. The relevance of such studies is largely dependent upon the ability of the 
target reagent to elicit functionally similar responses amongst primate species. In 
order to understand the potential utility of NHP studies for predicting the safety 
and toxicity of a novel chimeric anti-CD137 mAb, GG, we performed binding 
studies on activated T cells from humans, baboons and cynomolgus macaques. 
While the commercially available anti-CD137 (4B4-1) antibody bound all species 
comparably, GG bound only to human. In order to understand the differences in 
binding affinity between these mAbs, we sequenced the cDNA of CD137 from 
several NHP species and revealed that the CD137 proteins are - 95% identical 
when compared to human. Sequential replacement of cynomolgus macaque with 
human sequences identified at least three amino acids critical for GG binding. 
These residues are likely involved in a conformational rather than a linear epitope, 
as an overlapping peptide was unable to inhibit GG recognition, even at excess 
molar concentrations. To determine the relevance of planned preclinical NHP 
studies to evaluate the safety and toxicity profile of GG, we performed binding 
studies on activated PBMC from rhesus, cynomolgus macaque and baboons. Our 
initial binding data were difficult to interpret. Specifically, all 
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antibodies clearly bound activated human PBMC, and mAb 4B4-1 also recognized 
activated PBMC from NHP. However, GG binding to PBMC from NHP was 
equivocal. To clearly determine the ability of GG to recognize NHP CD137, we 
generated stable constructs expressing these molecules using the cynomolgus 
macaque species. While 4B4-1 recognized all NHP CD137 tested, GG failed to 
bind cells expressing these constructs. These data are particularly relevant to 
preclinical NHP studies using antibodies against inducible co-signaling molecules 
as they clearly demonstrate that binding studies must be interpreted with caution, 
particularly in the absence of true positive and negative controls .  
To date, only a limited amount of research has been carried out to investigate the 
cross-reactivity of CD137 mAbs with NHP species. A recent study using a novel 
humanized CD137 mAb (H4B4) not only demonstrated cross-reactivity to 
activated baboon CD3+ and CD4+ T cells, but also indicated that the immune 
unresponsiveness using the H4B4 mAb was antigen specific, and not by immune 
suppression (19). Another study using cynomolgus macaques as study model 
suggests a possible increase in cellular response based on subdominant epitopes of 
the mAb (20). These data, along with our amino acid sequences of both baboon and 
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cynomolgus macaque demonstrate that CD 13 7 is largely conserved throughout old 
world primates and apes. Furthermore, this sequence conservation and the presence 
of a mAb which recognized CD 13 7 from human but not NHP as well as another 
that recognized both provided an ideal opportunity for both epitope mapping and as 
a means to gain insight into potential residues involved in CD 13 7-CD 13 7L 
interactions. 
Our data indicate that residues 66, 67, and 69 in the extracellular domain of the 
human CD 13 7 are critical for GG binding. The necessity of these residues for 
antibody recognition was confirmed by mutating the NHP constructs at specific 
amino acid positions to human, which restored binding affinity. Similarly, 
analogous mutations in the human construct to cynomolgus macaque eliminated 
binding. Importantly, because the residues used for producing the mutants were 
from the human CD 13 7 sequence, it is unlikely that the failure of antibody 
recognition was secondary to significant structural changes in the protein. 
Furthermore, the fact that the mutant constructs retained their ability to be 
recognized by the mAb 4B4-1, suggests that the residues present in human CD137 
directly contribute to GG recognition. Using the NCBI database, we found that the 
only other animal that contains the three amino acids Thr66, Pro67 and Phe69 
responsible for GG recognition is the chimpanzee ( accession number 
XM_00l 157779). Unfortunately, research using chimpanzees has been severely 
restricted. Additionally, inherent polymorphisms for CD 13 7 within individuals of a 
species need to be considered before initiating further studies. 
In conclusion, we demonstrate an approach that can be applied to strategically 
define mAb epitope binding residues necessary for recognition by manipulation of 
NHP sequences. These findings are particularly relevant to preclinical NHP studies 
for two reasons. First, the fact that our initial binding studies from activated PBMC 
were equivocal, demonstrates that activation of native cells may be difficult to 
interpret. This was overcome in our studies by making stable transfections. Second, 
in some instances, the high degree of homology between NHP and human co­
stimulatory molecules can facilitate rapid identification of both linear and 
conformational epitopes potentially important for antibody binding. A recent 
published sequence for cynomolgus CD 13 7 agrees with our AA sequence in this 
study, with the exception of K156 in our sequence compared to R156 in that study 
(16). Optimistically, use of this comparative homology strategy for epitope 
identification, will ensure the relevance of NHP models for preclinical testing of 
mAbs, and enhance the safety of mAb based clinical trials. 
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NK cell-based immunotherapy and its therapeutic 




The possibility that autologous NK cells could serve as an effective treatment 
modality for solid tumors has long been considered. However, implementa­
tion is hampered by (i) the small number of NK cells in peripheral blood, (ii) 
the difficulties associated with large-scale production of GMP compliant cy­
tolytic NK cells, ( i i i )  the need to activate the NK cells in order to induce NK 
cell mediated killing and (iv) the constraints imposed by autologous inhibito­
ry receptor-ligand interactions. To address these issues, we determined (i) if 
large numbers ofNK cells could be expanded from PBMC and GMP compli­
ant cell fractions derived by elutriation, ( i i) their abil ity to kill allogeneic and 
autologous tumor targets by direct cytotoxicity and by antibody-mediated 
cellular cytotoxicity and (iii) defined NK cell specific receptor-l igand inter­
actions that mediate tumor target cell ki l l ing. Human NK cells were expan­
ded during 1 4  days . Expansion efficiency, NK receptor repertoire before and 
after expansion, expression of NK specific l igands, cytolytic activity against 
allogeneic and autologous tumor targets, with and without the addition of 
chimeric EGFR monoclonal antibody, were investigated. 
Cell expansion shifted the NK cell receptor repertoire towards activation 
and resulted in cytotoxicity against various allogeneic tumor cell lines and 
autologous gastric cancer cells, while sparing normal PBMC. B locking stu­
dies confirmed that autologous cytotoxicity is establ ished through multiple 
activating receptor-ligand interactions . Importantly, expanded NK cells also 
mediated ADCC in an autologous and allogeneic setting by antibodies that 
are currently being used to treat patients with select solid tumors . 
These data demonstrate that large numbers of cytolytic NK cells can be 
generated from PBMC and lymphocyte-enriched fractions obtained by GMP 
compliant counter current elutriation from PBMC, establishing the pre­
clinical evidence necessary to support clinical trials uti l izing autologous 
expanded NK cells, both directly and in combination with monoclonal anti­
bodies in future cell-based immunotherapy in select solid tumors . 
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Introduction 
Natural killer cells (NK) were identified more than 30 years ago as a population of 
lymphokine activated killer cells that showed the ability to kill tumor cells in vitro 
in the absence of prior immune sensitization of the host (1,4). Over the ensuing 
years, much has been learned about regulation of their biologic activity and, in 
particular, their potential use as an immunotherapeutic modality in cancer (5). It 
has become clear that the biologic activity of NK cells is controlled by a complex 
repertoire of surface receptors which, upon engagement by ligands on a target cell, 
signal either an inhibitory or activating response (6). The major inhibitory and 
activating receptors are products of germ line genes encoding killer cell 
immunoglobulin-like receptors (KIRs) and in an autologous environment, 
inhibition of NK cell cytotoxic activity is dominant and governed by epitopes on 
self HLA class I alleles. In general, cytotoxic activity of NK cells is triggered when 
the target cell lacks expression of some or all HLA class I molecules; the basis for 
the "missing self' hypothesis (7). Recognizing the possibility that NK cells have 
the ability to kill tumors that lack expression of the inhibitory HLA class I alleles, 
investigators have reported significant antitumor responses in clinical settings of 
allogeneic stem cell transplantation. Importantly, clinical effects are demonstrated 
when inhibitory effects are bypassed by utilizing haplo-identical NK cells and best 
results are achieved when, in addition, KIR-ligand mismatched NK cells are 
selected (8,9). In tum, this approach requires extensive donor screening and careful 
depletion of allogeneic T cells from the NK cell product before administration to 
the host in order to avoid the risk of graft-versus-host disease (GvHD) (10). 
The possibility that infusion of autologous NK cells could serve as an effective 
treatment modality for solid tumors has long been considered (11). However, 
implementation is hampered by (i) the small number of NK cells in peripheral 
blood that could be isolated relative to the number of cells that would be required 
to be effective and the difficulties associated with large-scale production of 
cytolytic NK cells in compliance with Good Manufacturing Practices (GMP), (ii) 
the need to activate the NK cells in order to induce NK cell mediated killing of a 
resident tumor and (iii) the constraints imposed by autologous inhibitory receptor­
ligand interactions. The first issue has been addressed in a number of reports that 
demonstrate that large numbers of NK cells could be expanded from CD56+ cells 
isolated from peripheral blood mononuclear cells (PBMC) obtained from healthy 
individuals and patients with hematological malignancies and solid tumors. 
Expansion was achieved by short term culture with cytokines alone, by cytokines 
and co-culture with irradiated feeder cells consisting of EBV transformed 
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lymphoblastoid cell lines or cytokines and co-culture with K562 cells that had been 
transfected with and express cell membrane-bound IL-15 and 4-l BBL (12-16). In 
most instances, these expanded cells were generated from NK cells (CD56+CD3-) 
isolated from peripheral blood using magnetic beads. The expanded NK cells were 
highly cytotoxic when tested against variety of target cells that consisted primarily 
of allogeneic cancer cell lines established from hematologic malignancies (12,17). 
In addition, a GMP compliant and closed system has successfully been established 
for the enrichment of monocytes from PBMC using counter current elutriation 
(18). Besides a highly enriched population of monocytes, lymphocyte-enriched 
fractions are also obtained. Currently, clinical studies are ongoing utilizing 
elutriation derived monocytes for large-scale generation of dendritic cells in order 
to treat a variety of metastatic cancers. 
The objectives of this study were to evaluate if the aforementioned strategies could 
be combined in order to expand large numbers of NK cells from PBMC from 
normal individuals and patients with various solid tumors. Furthermore, the 
possibility to expand NK cells from lymphocyte-enriched cell fractions derived 
from PBMC by elutriation rather than utilizing isolated CD56+ cells as the starting 
cell population was determined. In addition, cytolytic allogeneic and autologous 
activity by direct cytotoxicity as well as antibody-mediated cellular cytotoxicity 
and NK specific receptor-ligand interactions that mediate target cell killing were 
defined. 
We confirmed that large quantities of cytotoxic NK cells can be expanded from 
PBMC in the presence of K562 cells expressing membrane-bound IL-15 and 4-
l BBLigand from normal individuals and patients with various solid tumors. Ex 
vivo expansion tended to alter the balance of NK cell receptor expression towards 
those that activate and mediate cytotoxicity. This activity resulted in cytotoxicity 
against various allogeneic tumor targets and more importantly, against autologous­
derived gastric tumor targets. Blocking studies identified multiple activating 
receptor-ligand interactions that would be predicted to mediate NK cell 
cytotoxicity. Moreover, these activating receptor-ligand interactions were operative 
in antibody-dependent cellular cytotoxicity (ADCC) in an allogeneic and 
autologous setting. Importantly, as a mean for future clinical translation, GMP 
compliant cytolytic NK cells could efficiently be expanded from lymphocyte­
enriched cell fractions obtained from PBMC by counter current elutriation. 
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Our studies demonstrate that human NK cells acquire cytolytic activity against 
autologous gastric tumor cells after ex vivo expansion and suggest a therapeutic 
potential for autologous expanded NK cells, both directly and in combination with 
monoclonal antibodies in future cell-based immunotherapy. 
Materials and methods 
Cells and Cell Fractions 
Human blood samples were purchased (BRT Laboratories, Baltimore, MD) and 
whole peripheral blood mononuclear cells (PBMC) were isolated using density­
gradient centrifugation. Using leukapheresis products purchased from the same 
source, the constitutive cell populations were fractionated by continuous­
counterflow elutriation following protocols established by the manufacturer of the 
Elutra cell separator (Elutra, Gambro BCT). This instrument uses continuous 
counter-flow elutriation technology to separate cells fractions based primarily by 
size and secondarily by specific gravity. In brief, the leukapheresis product was 
loaded via an inlet pump into a constantly rotating (2,400 rpm) elutriation chamber. 
Based on centrifuge speed and cell density, five elutriated cell fractions were 
collected. PBMC and various elutriated cell fractions were viably frozen in RPMI-
1640 (Invitrogen Corp., Grand Island, NY) supplemented with 20% human AB 
serum (Gemini Bio-Products, Woodland, CA) and 10% Dimethylsulfoxide (Sigma, 
St. Louis, MO) using an automated cell freezer (Gordinier Electronics, Roseville, 
MI) and stored in the vapor phase of liquid nitrogen until used. 
The myeloid cell line K562, prostate cancer cell lines LNCaP, PC-3 and DU-145 
and breast cancer cell line MCF-7 were available in our laboratory. The lung 
cancer cell line H358 was kindly provided by Dr. S. Ostrand-Rosenberg 
(Department of Biological Sciences, University of Maryland Baltimore County, 
Catonsville, MD, USA) and the Head and Neck cancer cell line TU-167 was kindly 
provided by Dr. S. Strome (Department of Otorhinolaryngology-Head and Neck 
Surgery, University of Maryland, Baltimore, MD, USA). 
With patient consent and under approval of the Institutional Review Board, 
peripheral blood mononuclear cells were obtained from two patients with gastric 
cancer undergoing treatment at the Tokyo Clinic and Research Institute, Tokyo, 
Japan. Cell lines (tumor I and tumor 2) were established from biopsies of 
metastatic gastric tumor lesions from the respective patients. All tumor cell lines 
were cultured in RPMI 1640 supplemented with 1 0% Fetal Bovine Serum, I %  PIS 
and I% Glutamax-1 (cRPMI). 
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Ex vivo NK cell expansion 
NK cells were expanded from PBMC as previously described with some minor 
modifications (12). In brief, PBMC (1.5 x 106) were incubated with irradiated 
(14,000 rad) K562-mbIL15-4-1BBL cells (106) in a 24-well tissue culture plate in 
the presence of 200 IU/ml human IL-2 (R&D Systems Inc) in cRPMI. Half of the 
culture medium was replaced every 2-3 days with fresh culture medium for the first 
6 days. After 6 days of expansion, cells were harvested, washed, counted and re­
cultured at a starting cell density of l x l 05-3xl05/ml in T-25 or T-75 culture flasks 
in cRPMI supplemented with IL-2. Cells were expanded for an additional 8 days. 
Additional cRPMI was added to the flasks if necessary based on cell density. 
Flow Cytometry 
Cell surface expression was determined before and after 14 days of cell expansion 
by staining with directly conjugated mouse anti-human antibodies (mAbs) against 
CD3, CD56, a�TCR, y8TCR, HLA class I, HLA-DR, Fas, Fas-ligand, KLRDl ,  
NKG2a, KIR3DL1, ILT2, CD62L, KIR3DL2/3, NKG2d, DNAM-1, NKp46, 
NKp44 and NKp30 (BD Biosciences). Gates were set around NK cells which were 
defined as CD3-CD56+ cells. Surface expression of NK cell ligands was 
determined on both autologous gastric tumor cell lines and included directly 
conjugated mouse anti-human nectin-2, PVR, MIC A/B, Fas, HLA class I, HLA 
class II, HLA-G and purified mouse anti-human HLA-E, ULPB-1, ULBP-2 and 
ULBP-3. For EGFR-mediated ADCC, gastric tumors were stained with mouse 
anti-human EGFR mAb. Mouse lgGs were used as isotype controls and purified 
mAbs were secondarily stained with FITC labeled goat anti-mouse mAb. A 
minimum of 10,000 events were acquired using a BD™ LSR II flow cytometer. 
Data was analyzed with BD™ F ACS DIV A Software. 
Cytotoxicity assays 
Cytolytic NK cell activity was measured by 4 hour chromium 51 (5 1Cr)-release 
assays as previously described (19). K562 cells were included in all cytotoxicity 
assays to assess overall cytotoxicity performance (data not shown). Expanded day 
14 cells were purified into separate populations of NK cells (CD3-CD56+) and 
NKT/T (CD3+CD56+/CD3+CD56-) cells using MACS human CD3 microbeads and 
non-expanded NK cells were purified from PBMC using a MACS human NK cell 
isolation kit. (Miltenyi Biotec Inc). Cell purity was determined to be >92% and 
95% respectively. To determine ADCC, 1 0µg/ml human IgG 1 (hulgG 1, Sigma­
Aldrich Corp, St. Louis, MO, USA) or Cetuximab (University of Maryland 
Marlene and Stewart Greenebaum Cancer Center Pharmacy) was added to defined 
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wells. Purified mouse IgG l ,  mouse anti-DNAM-1 ,  NK.p46, NK.p44, NK.p30 or all 
four together (all at l Oµg/ml) were added to defined wells during 4 hours of 
cytotoxicity in order to assess specific activating NK cell receptor-tumor ligand 
interactions. Reduction in cytotoxicity was calculated based on percentage 
cytotoxicity in the presence of indicated blocking mAb( s) versus percentage 
cytotoxicity in the presence of mouse control mAb. The % reduction in ADCC was 
calculated with percentage cytotoxicity in the presence of human IgG 1 set at 100%. 
To minimize changes that may occur when cell lines are established from primary 
tumors, the gastric cell lines used in these studies were cultured for less than 1 0  
passages after isolation from the primary tumor tissue. 
Statistics 
Paired two-tailed Student's t tests were used to calculate p values. P<0.05 was 
considered to be significant. 
Results 
Cytotoxic NK cells are efficiently expanded from PBMC from normal 
individuals and patients with various solid tumors without the need of 
primary enrichment protocols. 
To achieve large-scale expansion of human NK cells, PBMC were co-cultured in a 
1 to 1 .5 ratio with lethally irradiated K562 cells expressing membrane-bound IL- 1 5  
and 4- lBBLigand (K562-mbIL1 5-4- 1BBL) in culture media containing 200 units 
IL2 /ml. After 14  days of culture, NK cells (CD56+CD3- as defined by flow 
cytometry) expanded greater than 2 orders of magnitude from PBMC (mean 1 65 
fold; range 4-567 fold, n=6) and cell products became significantly enriched in NK 
cells (day 0 with mean 7%, range 3 .2%- 12.6% versus day 14  with mean 45 .6%, 
range 7.4%-76.4%; P=0.0140). At the same time, NKT cells (CD56+CD3+ as 
defined by flow cytometry) expanded at an average of 57 fold (range 7-234), 
although no significant enrichment (day 0 with mean 3.8%, range 0.8%-8 . 1  % 
versus day 14 with mean 1 1 .4%, range 2.3%- 1 7.9%; P=0. 1 907) was observed. In 
contrast, a significant decrease in T cells (CD3+ as defined by flow cytometry) was 
noted after 14 days of expansion (day 0 with mean 54.5%, range 39.9%-7 1 .2% 
versus day 14 with mean 30.0%, range 4.2%-58.4%; P=0.0436) with an absolute 
expansion of 7 fold (range 2- 19). The distribution of NK cells and NKT cells in 
PBMC after expansion is shown in Fig lA. Importantly, ex vivo expanded NK cells 
from healthy donor PBMC efficiently lysed allogeneic breast-and prostate-derived 
tumor targets but not allogeneic or autologous PBMC (Figure l B). We did observe 
that cytotoxicity was associated with overall expansion efficiency. Specifically, the 
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one donor whose cells expanded 4 fold after 14 days of culture demonstrated an 
average of 11. 7% cytotoxicity ( effector to target ratio 1: 10) against K562 cells, 
whereas donors who expanded an average of 202 fold (range 34-576; n=4) 
possessed an average of 59.8% cytotoxicity (range 56.0%-65.9%; n=4) against 
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Figure 1. Cytolytic NK cells are efficiently expanded from PBMC. In the presence of K562-IL l 5-4- I BBL (A) 
expanded cells become significantly enriched (P=0.0307) in NK cells (defined by CD56+CD3- cells) after 14 days 
of culture. Expanded cells were evaluated for cytolytic activity using 4 hour 5 1Cr release assays. Ex vivo expanded 
cells from PBMC (• donor 1 and I-,. donor 2), but not freshly purified non-expanded NK cells (0), efficiently lysed 
allogeneic tumor cell lines derived from breast (MCF-7) and prostate (LNCaP) cancers but not allogeneic or 
autologous PBMC derived from donor 1 (B). The mean percentage cytotoxicity is shown from triplicate wells. 
Error bars represent the SD. Lytic activity is likely mediated by NK cells in the expanded cell population (o) since 
separation in individual populations ofNK cells (0) and NKT/T cells (!-,.) resulted in allogeneic cytolytic activity of 
the expanded cell population and the purified NK cell population. Little lytic activity was observed in the presence 
of NKT/T cells alone (C). The mean percentage cytotoxicity is shown from triplicate wells from one 
representative experiment. Error bars represent the SD. Experiment shown represents one of three individual 
experiments with three different donors. 
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Based on CD3 and/or CD56 phenotype, the majority of cells in the expanded cell 
products represented NK cells while a much smaller proportion represented NKT 
and T cells (Table 1 ) .  To determine if both the NK cells and NKT/T cells mediated 
cytolytic activity, the two populations were isolated by immunomagnetic bead 
selection and killing assays against prostate-derived tumor cell targets were 
performed. Cytolytic activity was mediated by NK cells and not NKT cells (Fig. 
IC). Interestingly, little to no killing was observed with the NKT/T cell population 
even though a subpopulation of the T cells was confirmed to be yo-TCR + by flow 
cytometry (data not shown). Although y8-TCR+ T cells are reported to have lytic 
activity against allogeneic tumor cells, they first require in vitro activation with 
isopentenyl pyrophosphate (IPP) and IL-2 (20) . Studies are underway to determine 
if addition of IPP will expand a cytolytic yo-TCR + population. 
The capacity of K562-mb 1 5-4 l BBL to stimulate expansion of NK cells from 
peripheral blood of healthy individuals and children with leukemia in remission 
was previously demonstrated ( 12, 1 7). However, there is little information in 
reference to expand NK cells from PBMC derived from patients with solid tumors. 
With informed consent, NK cells were expanded from PBMC derived from 
patients with various solid tumors, including gastric cancer, lung cancer, colon 
cancer and hepatocellular cancer. After 14 days of culture, cell products became 
significantly enriched in NK cells ( day 0 with mean 23.5%; range 5%-46% versus 
day 14  with mean 80%; range 60%-95%, n=6, P=0.000 1 data not shown). 
Expansion efficiency was comparable between PBMC derived from solid tumor 
patients versus healthy donor PBMC (mean 3 1 6  fold; range 1 - 1 795 with n=6 
versus mean 165 fold; range 4-567 with n=6, P=0.6685). These data suggest that 
NK cells are efficiently expanded from PBMC from normal individuals and more 
importantly, from patients with various solid tumors without the need of primary 
enrichment protocols. 
NK cell expansion turns the receptor balance towards activation and results in 
autologous gastric tumor cell lysis. 
Human NK cells maintain self tolerance by the expression of at least one 
inhibitory receptor specific for autologous HLA class I which prevents cytotoxicity 
against autologous cells (2 1 ). To establish cytotoxicity against autologous target 
cells, inhibitory signals must be overcome, either by (i) down-regulation of 
inhibitory ligands on the tumor cell, (ii) enhanced expression of activating 
receptors on NK cells, (iii) expression of ligands on the tumor target that activate 
the NK cell or (iv) a combination of thereof. Since NK cell activation is affected 
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Table 1 Cell phenotype and fold expansion after 14 days of expansion CD3-CD56+ NK cells CD3+CD56+ NKT cells CD3+CD56- r cells Donor population expansion population expansion population expansion 
(%) (fold) (%) (fold) (%) (fold) 7.4 4 1 7.9 31 58 .4 4 2 6 1 .7 140 4.2 26 2 1 .2 9 3 68.5 6 1  3. 1 7 23. 1 4 4 76.5 1 83 2.3 12 4.2 2 5 35 .6 576 37.2 234 22. 1 1 9  6 23.9 34 3.8 33 5 1 .2 7 
mean: 45 .6 1 65 1 1 .4 57 30.0 7 range: 7.4-76.5 4-576 2.3- 1 7.9 7-234 4.2-58 .4 2- 19  
by cytokines such as IL-2 and IL-15 (22), we sought to  determine if  NK cells 
expanded from PBMC were phenotypically different from non-expanded NK cells 
(Table 2). In expanded NK cells from normal individuals, no significant change 
was observed in inhibitory receptors KIR3DL 1 (P=0.1526), KIR3DL2/3 
(P=0.7858) and the activating receptor NKG2D (P=0.1074). In contrast, activating 
receptors DNAM-1 (P=0.0061), NKp46 (P=0.0161), NKp44 (P=0.0039) and 
NKp30 (P=0.0 131) were significantly increased in expression after 14 days of 
expansion. Interestingly, KLRDl (P=0.0012) and NKG2A (P=0.0118), which both 
form a complex with the inhibitory non-classical HLA class I ligand HLA-E 
(23,24) were also significantly increased after expansion. Importantly, expression 
of the inhibitory receptor IL T2 (P=0.0 142) which recognizes multiple HLA class I 
alleles, including non-classical HLA class I, HLA-G (25), was significantly 
decreased after expansion. 
In order to define the ability of expanded NK cells derived from patients with solid 
tumors, to kill their autologous tumors, tumor cell lines were established from 
tumor biopsies from two metastatic gastric cancer patients undergoing 
immunotherapy at the Tokyo Clinic and Research Institute, Tokyo, Japan. Of note, 
the expression of inhibitory and activating receptors on expanded NK cells from 
the gastric cancer donors were generally not different from expression on 
expanded NK cells from normal donors (table 2). Since autologous NK cell 
cytotoxicity is the net result of engagement of activating NK cell receptors with 
activating target cell ligands, the two gastric tumor cell lines were first 
phenotypically characterized for expression of ligands (Table 3) that are known to 
engage the NK cell receptors identified in table 2. 
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Table 2 Phenotypic changes on human NK cells after 14 days of expansion 
healthy donor (n=6) patient 1 patient 2 
day 0 day 14 day day 
mean range mean range P-valuea,b 0 14 0 14 
(%) (%) (%) (%) (%) (%) (%) (%) 
activating receptors 
DNAM-1 83 72-90 94 89-97 0.0335 (1') 90 97 37 90 
NKG2D 83 51-98 96 93-99 0.1074 30 94 87 98 
NKp46 68 27-91 87 64-97 0.0161 (1') 52 95 19 70 
NK.p44 3 2-5 59 16-93 0.0039 (1') 0.3 29 0.4 15 
NK.p30 52 11-93 82 67-97 0.0131 (1') 7 63 15 70 
inhibitory receptors 
KLRDl 68 56-82 92 86-95 0.0012( 1') ND 98 49 95 
NKG2A 46 14-67 68 34-89 0.0118 (1') ND 84 7 8 
KIRDLl 22 10-37 29 17-38 0.1526 ND 21 5 3 
KIR3DL2/3 28 9-48 29 14-44 0.7858 ND 35 88 96 
LIRl 22 13-37 6 3-9 0.0142 ( "') ND 18 70 44 
"Significant differences (P<0.05) are indicated in bold 
bArrows indicate significant increase (j) or significant decrease (!) 
DNAM-1 indicates DNAX accessory molecule- I; NKG2D, natural killer group 2 member D; K.LRD I, killer cell 
lectin-like receptor subfamily D member I ;  NKG2A, natural killer group 2 member A; KIRDLI ,  killer cell 
inhibitory receptor DLI ;  KIR3DL2/3, killer cell inhibitory receptor 3 DL2/3; LIR I ,  leukocyte lg-like receptor I ;  
ND, not determined 
While the ligands for human NKp46, NKp44 and NKp30 are to be defined, both 
patient cell lines expressed high levels of the inhibitory ligands HLA class I (75% 
and 67%, respectively) and HLA-G (42% and 57%, respectively) and relatively 
small amounts of the activation ligands MHC class I chain-related (MIC) A/B (2% 
and I%, respectively), UL16 binding protein (ULBP)-1 (both 3%), ULBP-3 (both 
3%) and polio-virus receptor (PVR; 8% and 9%, respectively). Importantly, both 
cell lines expressed the activating ligand nectin-2 (both 92%; specific for DNAM-
1) which prompted us to evaluate both cell lines for their sensitivity against 
autologous NK cells. Subsequent 4 hour chromium-release (5 'Cr-release) assays 
confirmed that gastric tumor cells derived from both patients were killed by 
autologous expanded NK cells (Figure 2A) and not by resting (non-expanded) NK 
cells from patient 2. Unfortunately, insufficient numbers of PBMC from patient I 
were available to isolate and test resting NK cells. Since expanded NK cells 
significantly up- regulated DNAM-1, NKp46, NKp44 and NKp30, we performed 
blocking studies in order to evaluate the importance of these activating receptor­
ligand interactions in autologous tumor cell recognition (Figure 2B). 
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Figure 2. Ex vivo expanded NK cells recognize autologous gastric tumor cells through different activating 
receptor-ligand interactions. PBMC from two gastric cancer patients were ex vivo expanded for 14 days and then 
tested for cytolytic activity against autologous gastric tumor cells in 4 hour 5 1Cr release assays. (A) Ex vivo 
expanded cells from both patients (patient 1 and patient 2), but not freshly purified non-expanded NK cells from 
patient 2, efficiently lysed autologous gastric tumor cells ( effector to target ratio 20: 1 ). To evaluate the impact of 
activating receptor-ligand interactions on autologous tumor cell lysis indicated blocking antibodies (1 0µg/ml) were 
added during 4 hours of incubation. (B) Cytotoxicity was reduced in the presence of DNAM-1 (P=0.0309) and 
NKp30 (P=0.0056) for patient 1 and in the presence of NKp46 (P=0.0003) for patient 2. In both patients 
autologous cytolytic activity was abrogated in the presence of all four blocking antibodies with P=0.0111 and 
P=0.0001, respectively. Statistical analysis is based on triplicate wells of four (patient 1) and two (patient 2) 
experiments performed, respectively. Error bars represent the SD. * P<0.05. MolgGl indicates mouse IgGl ;  
DNAM-1, DNAX accessory molecule-1. 
As expected, autologous lytic activity was significantly reduced (P=0.0 111 for 
patient 1 and P=0.0001 for patient 2) when activating receptor-ligand interactions 
were interrupted by all four blocking mAbs. Specifically, lytic activity of 
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Figure 3. Cetuximab significantly enhances cytolytic activity and ADCC is negatively affected by inhibition 
of activating receptor-ligand interactions. Ex vivo expanded cells from cancer patient 1 were evaluated for their 
ability to mediate ADCC against autologous (patient 1 )  and allogeneic (TU-167 and H-358) EGFR expressing 
cancer cells. (A) Cytolytic activity of ex vivo expanded cells was enhanced in the presence of Cetuximab 
(1 0µg/ml, black bar) but not in the presence of control human IgG 1 (1 0µg/ml; dotted bar) or media alone (white 
bar). The mean percentage cytotoxicity is shown from triplicate wells from one representative experiment. Error 
bars represent the SD. Experiment shown represents one of two individual experiments. (B) The addition of 
blocking antibodies ( IOµg/ml) against DNAM- 1, NKp46, NKp44 and NKp30 (= all) significantly reduced 
(P=0.0176) Cetuximab-mediated ADCC. Statistical analysis is based on three experiments performed. Error bars 
represent the SD. * P<0.05. HulgG 1 indicates human IgG 1, Ctx; Cetuximab and molgG 1; mouse IgG 1. 
mAb against DNAM-1 (P=0.0309) or NKp30 (P=0.0056) while lytic activity of 
autologous NK cells from patient 2 was only affected in the presence of mAb 
against NKp46 (P=0.003). 
Ex vivo expanded NK cells are capable of autologous and allogeneic target cell 
lysis by antibody-mediated cellular cytotoxicity 
Over many years, it has been postulated that eradication of human tumors may best 
be accomplished by combining cancer treatment modalities (26,27). Monoclonal 
antibodies that react with cell surface structures expressed on cancer cells represent 
the most successful cancer immunotherapy to date. It is quite clear that their 
mechanism of action is, at least, partially due to NK cell-mediated ADCC (28). 
Since expanded NK cells expressed high levels of CD16 (data not shown), an Fe 
receptor that mediates ADCC, we sought to determine if lytic activity against the 
gastric tumor cells could be enhanced in the presence of Cetuximab (Erbitux®), a 
chimeric monoclonal antibody that reacts with the EGFR receptor and is used to 
treat patients with a variety of solid tumors (29). Both gastric tumor cell lines were 
screened for EGFR and only one of the two patient tumor cell lines (patient 1) 
expressed EGFR (table 3). 
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Subsequent 5 1Cr-release assays confirmed that allogeneic and autologous cytolytic 
activity is greatly enhanced in the presence of chimeric anti-EGFR mAb but not in 
the presence of human lgG 1 control antibody (Figure 3A). As expected, the 
enhancement in cytotoxicity was far more dramatic in the autologous setting if 
compared to the allogeneic setting since allogeneic tumor cells do not maintain self 
tolerance through specific inhibitory receptor-ligand interactions. 
Importantly, the expression of activating receptors on the ex vivo expanded NK 
cells positively affected overall cytotoxic activity (Figure 3B) since blocking all 
four activating receptors on the NK cell surface decreased autologous cytotoxicity 
if compared with control mAb (P=0.0176 and P=0.1019, respectively). These data 
suggest that the combined strategy of adoptively transferred ex vivo expanded 
autologous NK cells with infusion of a mAb that is used for cancer immunotherapy 
may provide clinical benefit for the treatment of select human solid malignancies. 
To extend these observations, we are attempting to establish cell lines from other 
solid tumors where PBMC would be available to test NK expansion, direct 
cytotoxicity and ADCC capability. 
Table 3 Characterization of NK cell ligands on gastric tumor cells 
patient 1 (N=2) patient 2 (N=3) 
mean (%) range mean (%) range 
inhibitory ligands 
HLA class I 75 71-80 67 30-97 
HLA-E 0-1 2 1-3 
HLA-G 42 28-56 57 30-82 
activating ligands 
PVR 8 3-14 9 3-18 
Nectin-2 92 87-98 92 87-97 
MIC A/B 2 1-2 1 0-1 
ULBP-1 3 2-4 3 2-4 
ULBP-2 62 60-65 67 51-76 
ULBP-3 3 3-4 3 2-4 
other 
Fas 36 21-50 95 88-99 
EGFR 95 93-98 18 7-29 
PVR indicates polio-virus receptor; MIC A/B, MHC class I chain-related A/B; ULBP, UL binding protein; EGFR, 
epidermal growth factor receptor. 
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NK cells are efficiently expanded from lymphocyte-enriched cell fractions 
obtained from PBMC by counter current elutriation 
A GMP compliant system has successfully been established for the enrichment of 
monocytes from PBMC using an Elutra cell separator. In this closed system, 
PBMC are fractionated by centrifugal elutriation and five cell fractions are 
obtained. In general, these fractions consist of platelets (fraction 1 ), erythrocytes 
mixed with lymphocytes (fraction 2), lymphocytes (fraction 3), lymphocytes mixed 
with monocytes (fraction 4) and mainly monocytes (fraction 5) as demonstrated in 
figure 4 (n= l 1) .  Current clinical cellular therapy protocols use monocytes obtained 
from elutriated fraction 5 to generate dendritic cells for cancer immunotherapy 
while the cells from fractions 2, 3 and 4 are usually "archived" in liquid nitrogen. 
As a means to facilitate clinical translation, we explored the possibility of these 
GMP compliant cell fractions to serve in future NK cell-based immunotherapy 
studies. PBMC and separate elutriated cell fractions were expanded with the 
aforementioned expansion strategy. After 14  days of culture in the presence of 
K562-mbIL1 5-41BBL cells and exogenous IL-2, NK cells expanded greater than 
A 
PBMC Fraction 2 Fraction 3 Fraction 4 Fraction 5 
. .  .. ..•.... , . . .. .. ..... . . . .. . 
6.9x109 5x109 1 .5x108 5 . 1x108 7x108 
B 
CD3+ 47+/-1 3 61 +/-20 55+/-21 24+/- 16  25+/-22 
CD4+ 1 7+/-14 39+/-9 36+/-13 47+/-23 32+/-28 
cos+ 1 1  +/-7 25+/-13 22+/- 12  7+/-7 3+/-4 
CD3+CD56+ 6+/-7 5+/-6 1 5+/-1 1 4+/-7 3+/-6 
CD3-CD56+ 4+/-4 4+/-4 8+/-7 6+/-6 2+/-3 
CD 1 4+ 5+/-6 0+/-0.4 9+/-6 56+/- 19  80+/-1 2 
CD19+ 5+/-4 9+/-5 3+/-2 3+/-2 2+/-3 
Figure 4. Distribution of lineage-specific phenotypic markers on PBMC and separate cell fractions obtained 
after counter current elutriation. PBMC and elutriated cell fractions were stained with various lineage-specific 
directly-conjugated antibodies and analyzed by flow cytometry. (A) Average number of cells and phenotypic 
distribution (%) expressing lineage-markers in elutriated cell fractions (n=l l )  (B). 
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Figure 5. Ex vivo expanded cells from elutriated cell fractions efficiently lyse allogeneic prostate cancer 
cells. PBMC and elutriated fractions 2, 3 and 4 from the same healthy individual were expanded ex vivo in the 
presence of K562-mb1Ll 5-4 IBBL and IL-2 for 14 days and then tested for in vitro cytolytic activity. Cytolytic 
activity was evaluated in 4 hour 5 1 Cr release assays against (A) prostate cancer (DU-145, PC-3 and LNCaP) cells. 
Ex vivo expanded cells from elutriated cell fractions 2 (0), 3 (L'.1) and 4 (o) lysed prostate cancer cells in a similar 
fashion as ex vivo expanded cells from PBMC ( o ). (B) Elutriated cell fractions become enriched in NK cells 
( defined by CD56+co3- cells) after 14 days of culture regardless the cellular content of these fractions. The mean 
percentage cytotoxicity is shown from triplicate wells from one representative experiment. Bars represent the SD. 
Experiment shown represents one of four individual experiments. 
two orders of magnitude from PBMC (mean 165 fold; range 4-567 fold with n=6, 
data not shown), elutriated cell fraction 2 (mean 209 fold; range 3-615 fold with 
n=3, data not shown), elutriated cell fraction 3 (mean 131 fold; range 4-339 fold 
with n=3, data not shown) and elutriated cell fraction 4 (mean 91 fold; range no 
expansion-358 fold with n=4, data not shown). Importantly, expanded cells from 
PBMC and separate elutriated cell fractions became significantly enriched in NK 
cells and lysed allogeneic prostate-derived tumor cell lines in a similar fashion 
(Figure 5A-B). Thus, these data show that large quantities of cytolytic NK cells can 
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be expanded from vanous elutriated cell fractions collected with the GMP 
compliant Elutra system. 
Discussion 
The use of NK cells as a cancer treatment modality in the absence of an allogeneic 
stem cell transplant requires that large quantities of NK cells are generated that kill 
the tumor cells directly or augment the cytotoxic effect of tumor directed 
monoclonal antibodies. The critical findings of the studies reported herein are that 
(i) the technology that was reported to successfully expand NK cells isolated from 
PBMC (12,17) was also effective in generating large numbers of NK cells from 
PBMC and various elutriated cell fractions without previous isolation of the CD56+ 
cells, (ii) activation receptors and other cell surface structures that mediate target 
cell killing are increasingly expressed on the expanded NK cells, (iii) NK cells 
expanded from PBMC from patients with solid tumors kill allogeneic and 
autologous cancer cell lines by direct cytotoxicity and, importantly, mediate ADCC 
to autologous tumor cell targets in the presence of chimeric mAb and (iv) the 
interactions of activating receptors DNAM-1, NKp30 and NK-p46 with cognate 
ligands on the tumor target appear to mediate direct and ADCC mediated 
autologous cytotoxicity in gastric carcinoma. 
For translation into the clinic it is important to observe that besides NK cells, 
relatively small numbers of NKT and T cells are expanded in this system. These 
cell populations may mediate GvHD when infused together with NK cells in 
adoptive allogeneic immunotherapy protocols. GvHD is a serious, potentially life­
threatening, condition resulting from transplanted or infused allogeneic donor cell 
recognition of the recipients' tissues as non-self, and is predominantly mediated by 
CD3+ T cells (30). These cells are often depleted to prevent GvHD, as could be 
accomplished with the cells expanded by the presented protocol. Depletion of T 
cells from the NK cell product before administration to the host is likely to be less 
critical in an autologous setting. 
An important observation in our studies was that the expanded NK cells did not kill 
autologous and allogeneic PBMC, an indication that despite the increase in surface 
expression of activating receptors on the NK cells, the inhibitory ligands expressed 
on normal PBMC were dominant and able to control cytolytic activity against non­
malignant cells. This is further illustrated by the fact that both gastric tumor cell 
lines were susceptible to autologous cytotoxicity despite the expression of high 
levels of inhibitory classical and non-classical HLA class I molecules. These data 
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suggest that, in certain circumstances, activating receptor-ligand recognition may 
override receptor-ligand interactions that inhibit NK activity. Emerging data 
indicates that important triggers in this interaction are surface structures (ligands) 
that are expressed on cells that have undergone malignant transformation. In 
addition, it is well recognized that HLA class I expression, the major NK cell 
inhibitory structure, is often down-regulated in many solid tumors. In the case of 
autologous NK cell cytotoxicity against PBMC, inhibitory signals still 
predominated over activating signals, since no cytotoxicity of NK cells against 
autologous or allogeneic PBMC was observed. Our results indicate that the NK 
cells expanded and activated by the methods described do not recognize and kill 
non-transformed cells. 
While significantly higher levels of the inhibitory CD94/NKG2A complex were 
expressed after ex vivo cell expansion, it did not affect the potential of autologous 
gastric tumor cell recognition. The CD94/NKG2A complex is reported to directly 
inhibit NK cell cytotoxicity through recognition of HLA-E (31). Although both 
autologous gastric tumor cell lines did not express HLA-E (Table 3), we cannot 
rule out that autologous tumor cell recognition will not be affected in HLA-E 
expressing tumors. 
The ligands for natural cytotoxicity receptors NKp30, NKp44 and NKp46 are 
currently unknown. However, we postulate that at least NKp46 and NKp30 may be 
involved in autologous gastric tumor cell recognition since lytic activity was 
abrogated in the presence of blocking antibody against these receptors. Since no 
significant change was observed in NKG2D expression on expanded NK cells, we 
did not directly test the involvement of this activating receptor in autologous 
gastric tumor cell cytotoxicity. The fact that autologous cytotoxicity was not 
completely inhibited by a combination of anti-DNAM-1, NKp46, NKp44 and 
NKp30 may indicate that NKG2D or other unidentified receptors may also be 
involved. Importantly, the interaction between NK cell receptors and their ligands 
has recently been shown to abrogate NK cell mediated cytotoxicity of human and 
mouse melanoma cell lines (32). 
Of note, both tumor cell lines also expressed high levels of Fas which is recognized 
to establish cell death upon interaction with its ligand, Fas-ligand (33). In order to 
test the possibility of target cell-induced killing of the expanded NK cells, all NK 
cells were evaluated for Fas and Fas-ligand expression before and after ex vivo 
118 
Chapter 5 Ex vivo expansion of human NK cells 
expansion. Although expanded NK cells up-regulated high levels of Fas, they did 
not express Fas-ligand (data not shown). 
It has been suggested that in order to overcome self tolerance, multiple activating 
receptor-ligand interactions should be engaged (31). Indeed, multiple activating 
interactions appear to be involved in autologous cytotoxicity of tumor cells derived 
from patient 1 when the inhibition of cytotoxicity, in the presence of all 4 
antibodies, is compared with DNAM-1 or NKp30 alone (P=0.0356 and P=0.0165, 
respectively). In contrast, no significant additional decline was observed in 
autologous cytotoxicity for patient 2 when cytolytic activity of all four activating 
receptors was compared to NKp46 alone (P=0.7359). We postulate that these data 
reflect variation in expression of receptor-ligand combinations in human that are 
known to be operative in the control of NK cell cytotoxic activity. These variations 
include HLA and KIR polymorphism as well as tumor type and tumor origin ( e.g. 
primary versus metastatic tumor cells). This is illustrated in a recent report on 
studies in patients with multiple myeloma (34) were the investigators demonstrated 
no specific association of autologous NK cell cytotoxicity with a single activating 
NK cell receptor. In fact, autologous cytotoxic effects were more likely mediated 
by several activating NK cell receptors which is also in agreement with a previous 
report (35) demonstrating that natural cytotoxicity of resting NK cells requires co­
activation by more than a single receptor. 
While currently elutriated cell fraction 5 is used for monocyte and dendritic cell­
based immunotherapy therapy protocols (36,3 7), we demonstrated that cytolytic 
NK cells can be expanded from elutriated cell fractions 2, 3 and 4 regardless of the 
cellular content of these fractions. However, since NK cell expansion from fraction 
4 failed in two out of four experiments, while expansion from PBMC and elutriated 
cell fractions 2 and 3 was highly successful, and considering the relative high 
amount of erythrocytes in fraction 2, it may be best to primarily utilize fraction 3 in 
NK cell expansion protocols. Of note, variability in expansion rates between 
donors is observed and requires further testing to determine the extent of this 
variation in the general population. Overall, these data provide a foundation for the 
large-scale generation of cytolytic NK cells from elutriated cell fractions, which 
could be employed alone or in combination with other cellular components such as 
dendritic cells for application in cellular therapy of cancer. 
In summary, the large numbers of cytotoxic NK cells generated by this ex vivo 
expansion protocol provides the numbers of NK cells that will probably be required 
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to be effective in the case of a large tumor burden. The ability of the expanded cells 
to mediate ADCC offers the possibility that their effect may be amplified if given 
in conjunction with a cancer cell directed mAb. An important issue to address is 
the ability of adoptively transferred NK cells to home and infiltrate into solid tumor 
tissue. Although the expanded NK cells only expressed small amounts of CD62L 
( data not shown) which is associated with homing into secondary tissue, we 
postulate that trafficking to the tumor micro-environment may be enhanced by 
opsonizing tumor cells with chimeric antibody. Clinical studies are needed to 
confirm this hypothesis, as well as to establish the therapeutic benefit of infusion of 
large number of ex vivo expanded autologous NK cells. 
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Abstract 
The interaction of Fe fragments of antibodies with the Fey receptors is  an es­
sential checkpoint in antibody-dependent cellular cytotoxicity (ADCC) . 
Specific polymorphisms at position 1 5 8 enhance FcyRIIIa affinity for IgG 1 
and are associated with improved clinical outcome in lymphoma patients 
treated with IgG 1 anti-CD20 antibody. The role of ADCC in the therapeutic 
effects of the a-epidermal growth factor receptor (EGFR) mAb, cetuximab , 
in patients with squamous cell carcinoma of the head and neck (SCCHN) is  
poorly defined.  We employed three SCCHN cel l  lines to test two hypothe­
ses: (i) SCCHN is susceptible to cetuximab-mediated ADCC and (ii) effi­
cacy of ADCC is associated with polymorphisms at position 1 5 8  of FcyRIIIa. 
FcyRIIIa- 1 5 8 polymorphisms were determined for healthy donors , and their 
purified NK cells were used as effector cel ls  against three SCCHN cell lines 
in ADCC assays . Cytotoxicity levels were compared for each polymorphism. 
Prol iferation and cell cycle assays were performed to examine the direct 
effects of cetuximab.  Our results indicate that SCCHN is susceptible to 
cetuximab-mediated ADCC in vitro. NK cytotoxic efficiency correlates with 
donor 1 5 8-polymorphisms in FcyRIIIa. Overall cytotoxicity was greatest for 
individuals having a single V allele when compared to homozygous FIF indi­
viduals; the cumulative percent cytotoxicity for each polymorphism among 
the cell l ines was 58 .2% for VIV, 50 .6% for V/F, and 26 . 1 % for F/F. Additi­
onally, the presence of a V allele correlated with superior natural cytotoxicity 
against NK sensitive targets . These data have both prognostic and therapeutic 
relevance and support the design of a prospective trial to determine the in­
fluence of FcyRIIIa polymorphisms on the clinical outcome of patients with 
SCCHN treated with a -EGFR mAbs. 
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Introduction 
Squamous cell carcinoma of the head and neck (SCCHN) affects nearly 40,000 
new patients in the United States annually and half a million worldwide, 
accounting for nearly 5% of all new solid tumors (18). Current SCCHN organ 
preservation options combine chemotherapy and radiation while newer approaches 
incorporate targeted therapeutics. Currently, the only approved targeted therapy for 
SCCHN is the epidermal growth factor receptor (EGFR) inhibitor, cetuximab 
(Erbitux®). Between 80-100% of SCCHNs over-express the EGF receptor, and the 
-levels of over-expression are critical to overall tumor survival and associated with 
decreased treatment responses (1, 15). Despite evidence that cetuximab in 
combination with radiotherapy improves outcome, its impact on both response rate 
and survival is incremental, with significant individual variability ( 4,6, 7, 11 ). One 
means to improve the therapeutic benefit of cetuximab is to define the population 
most likely to respond, through improved characterization of mode of action. 
It is postulated that cetuximab' s primary mechanism of action results from EGFR 
blockade. Cetuximab is an lgG 1 a-EGFR chimeric mAb that blocks the binding of 
natural receptor-ligand interactions, preventing ligand-dependent 
homodimerization, intracellular autophosphorylation, and activation of intracellular 
cascades that control cellular proliferation, adhesion, angiogenesis and apoptosis 
(9,10,14). Binding of cetuximab to the EGFR leads to internalization and 
degradation of the antibody-receptor complex and down-regulation of EGFR 
expression ( 6). Because of the high propensity for over-expression of EGFR on 
SCCHN, cetuximab's ability to block EFGR is especially advantageous in head 
and neck cancer. 
Another potential mechanism of action of cetuximab, which has remained largely 
unexplored to date, is antibody-dependent cellular cytotoxicity (ADCC). ADCC is 
increasingly recognized as an important component of the clinical efficacy seen in 
targeted antibody therapy for solid tumors (6,10,20). Growing experience with 
mAb targeted therapy in lymphoma patients demonstrates that select 
subpopulations experience superior clinical outcomes based upon FcyRIIla 
polymorphisms known to influence ADCC. The most relevant polymorphisms 
regulating Fc:FcR interactions are phenylalanine (F) or valine (V) expression at 
position 158 of the Fe fragment (12,19). Indeed, Weng et al demonstrated that the 
clinical response to rituximab in patients with non-Hodgkin's  lymphoma is 
predicted by the specific FcyRIIla (CD16) polymorphism that they possess (32). 
Similarly, in another study involving lymphoma patients treated with rituximab, 
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individuals possessing the FcyRIIIa 158 VIV genotype experienced a better tumor 
response and survival ( 5). It is postulated that the higher affinity binding of 
FcyRIIla containing a V allele enhances ADCC and improves clinical response. 
In this study we show for the first time that cetuximab can mediate ADCC in 
SCCHN, and more importantly, that these effects are more pronounced in 
individuals with a V at position 158 on FcyRIIIa. Unexpectedly, we also found that 
the presence of a V allele in donor NK cells is associated with enhanced 
tumoricidal activity against the NK sensitive K562 cell line, suggesting a broader 
enhanced cytotoxic phenotype associated with the V allele. Our results support the 
design and implementation of a clinical trial correlating FcyRIIIa polymorphisms 
with outcomes in SCCHN patients treated with cetuximab. 
Materials and methods 
NK cell separation 
Healthy human huffy coat in acid citrate dextrose anticoagulant was purchased 
from Biological Specialty Corporation (Colmar, PA). PBMC were isolated from 
the huffy coat using the Ficoll-Hypague centrifugation method. NK cells were then 
negatively selected using a MACS human NK cell isolation kit (Miltenyi Biotec, 
Auburn, CA). 
Cell culture 
SCCHN cell lines TU167 and TU159 were obtained from the MD Anderson 
Cancer Center, University of Texas, Houston, TX, USA. The cell line 012SCC was 
donated by Bert O'Malley from the University of Pennsylvania School of 
Medicine, Philadelphia, PA, USA. Cells were cultured in RPMI 1640 complete 
media containing 10% heat-inactivated fetal bovine serum (Atlanta Biologics, 
Lawrenceville, GA), 1 % L-glutamine (Gibco, Carlsbad, CA), 1 % Penicillin­
Streptomycin (Gibco, Carlsbad, CA), and 1 % HEPES buffer (Mediatech Inc., 
Herndon, VA). 
Flow cytometry 
SCCHN cell lines were stained with the FITC-conjugated rat a-human EGFR mAb 
(clone ICRl0, Chemicon, Temecula, CA) and APC-labeled cetuximab. Cetuximab 
was obtained from the Marlene and Stewart Greenebaum Cancer Center Pharmacy, 
University of Maryland School of Medicine, Baltimore, MD, USA and conjugated 
by Invitrogen (Thousand Oaks, CA) with APC-fluorochrome. All SCCHN cell 
lines were also stained for a-human CD 16 expression (BD Biosciences, San Jose, 
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CA). To evaluate NK purity after negative selection, isolated cells were stained 
with directly conjugated mouse a-human mAbs against CD56, CD 11 c, CD 16, 
CD14 and CD3 (BD Biosciences, San Jose, CA). A minimum of 10,000 events 
were acquired using a BD™ LSR II flow cytometer and analyzed with BD™ 
F ACS DIV A Software. 
Determination of FcyRIIIa polymorphisms 
Genomic DNA from human PBMC was obtained using the Qiagen DNA extraction 
kit (Qiagen, Valencia, CA) and stored at -20°C. The FcyRIIIa valine ( V)  or 
phenylalanine (F), at position 158 was determined by polymerase chain reaction 
(PCR), as described by Nieto et al, with modifications (26). Briefly, the PCR 
reaction was optimized using 250ng of DNA, 0.5mM dNTPs, 1 unit GoTaq 
polymerase (Promega, Madison, WI) and corresponding lX buffer containing 1.5 
mM MgSO4 to a final volume of 50µL. For PCR amplification, samples were 
subjected to an initial denaturation step at 94°C for 5 minutes, followed by 35 
cycles at 94°C for 40 seconds, 52°C for 1 minute, 72°C for 1 minute, and a final 
extension at 72°C for 5 minutes. Amplified PCR samples were cleaned using 
phenol extraction and ethanol precipitation prior to restriction digestion. Two 
digestions per sample were performed to distinguish the FcyRIIIa polymorphisms. 
First, l0µL of the PCR product was incubated at 37°C overnight with 10 units of 
RsaI with the appropriate lX buffer (Promega, Madison, WI) to a final volume of 
20µL. For the second digestion, l 0µL of the RsaI digested sample was 
subsequently incubated at 37°C overnight with 40 units of Eco130I with the 
appropriate lX buffer (Fermentas, Hanover, MD) to a final volume of 30 µL. Both 
RsaI and RsaI/Eco130I digested products were separated on a 3% agarose gel with 
ethidium bromide and visualized under UV light. 
Antibody dependent cellular mediated cytotoxicity 
ADCC assays were performed using SCCHN cells as targets, and purified NK cells 
as effectors. Target cells were incubated with 150 µCi of chromium-51 (5 1Cr) 
(Amersham, Piscataway, NJ) at 37°C for 1 hour, mixing thoroughly every 15 
minutes, and washed twice with media. Cells were subsequently incubated with 10 
µg/mL of cetuximab, 10 µg/mL of human IgG 1 isotype, or media alone for another 
30 minutes at 37°C, and washed twice with media to remove unbound antibody. 
Effector and target cells were plated at 50:1, 25:1, and 12.5:1 in 96 well plates and 
incubated overnight. Each assay was set up in triplicate wells. Cell lysis 
supernatant was collected and mixed with the Optiphase Supermix scintillation 
fluid (Perkin Elmer, Boston, MA) and counted in a MicroBeta 1450 scintillation 
127 
Chapter 6 Fe polymorphisms in cetuximab-induced cytotoxicity 
counter (Wallac, Turku, Finland). The NK sensitive K562 tumor cell line was used 
as a positive control for all ADCC experiments. Results were expressed as the 
percentage of specific lysis according to the following formula: (Experimental 
cpm-spontaneous cpm) x 100 / (maximum cpm-spontaneous cpm). 
Thymidine proliferation assay 
Growth inhibition of SCCHN in the presence of cetuximab was evaluated using 
thymidine assays. Each cell line was seeded at day 1 to a 96-well tissue culture 
plate at 0.lx l04 cells / well in l 00µL RPMI complete media. For dose-dependent 
inhibition assays, cetuximab or lgG 1 isotype controls were added to final 
concentrations of l 0µg/mL, 0.l µg/mL, 0.0l µg/mL, 0.00l µg/mL and 0.000l µg/mL 
to the appropriate wells. For media only controls, 100 µL of media was added to 
the appropriate wells. Plates were incubated at 37 °C in a 5% CO2 atmosphere for 
48 hours. Thymidine was added on day 3 to a concentration of 1 µCi /well, and 
plates were incubated for an additional 14-16 hours. Cells were embedded onto 
collection filters using the Packard Cell Harvester (Packard Biosciences, Shelton, 
CT). The filters were dried and counted in �-scintillation fluid using the MicroBeta 
1450 scintillation counter (Wallac, Turku, Finland). 
Cell cycle distribution 
A BrdU Flow Kit (BD Pharmingen, San Jose, CA) with 7-AAD was utilized to 
determine the effect of cetuximab on SCCHN cell cycle and DNA content. Tumor 
cells were seeded in 6 well plates at l .5x l05 cells / well. Cetuximab or isotype 
controls were introduced at 1 0µg/mL and incubated for 48 hours. Then the cells 
were pulsed with BrdU on day 3 for 4 hours at 37 °C, and stained according to 
manufacturer's protocol. 
Statistical methods 
Statistical analyses were performed using the SAS statistical software (SAS version 
9.1; SAS Institute, Cary, NC) and S-plus. Mean cytotoxicity was computed for 
each polymorphism according to the equation listed previously. Welch modified 
two-sample t-test (if the normality was not plausible), student t-test (a Q-Q plot 
was used to assess the correctness of normality assumption) and analysis of 
variance were used to determine statistically significant differences in mean 
cytotoxicity among cells bearing FcyRIIIa polymorphisms. Differences were 
considered to be significant at p below 0.05. 
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Results 
FcyRIIIa polymorphism distribution 
To establish the genotype of the FcyRIIIa for each donor, we modified an existing 
protocol to obtain a robust PCR amplification/restriction digest methodology that 
permitted the typing of each donor sample. We evaluated the frequency of 
polymorphisms at amino acid 1 5 8  from 45 samples, which included freshly 
obtained BOMC from 1 7  healthy donors that were used for ADCC studies and an 
additional 28 frozen donor PBMC samples. The frequency for F allele was 
calculated to be 0.70, and V allele to be 0.30. The combined distribution of 
polymorphic classes from our fresh and frozen donors was 5 1 . 1 % for FIF, 37 .8% 
for VIF, and 1 1 . 1  % for VIV. 
Cetuximab treatment of NK cells containing the FcyRIIIa V allele increases 
efficiency of ADCC against SCCHN 
In order to develop a model system to study ADCC for SCCHN, we first 
characterized the EGFR expression on our tumor targets. We confirmed the EGFR 
over-expression for the three different tumor cell lines (TU167, TU1 59 and 
0 12SCC) utilized in this study using both a monoclonal rat-derived a-human EGFR 
antibody and cetuximab (Figure 1 ). In order to rule out positive staining due to 
secondary Fe binding, each tumor cell line was stained for the expression of 
FcyRIIla (CD1 6) using commercially available a-CD 16  mAb. Our data indicate 
that none of the SCCHN cell lines expressed CD16  (data not shown). 
We first employed TUI 67 to determine whether cetuximab mediates ADCC, and to 
define the impact of FcyRIIla polymorphisms. In our initial study, we employed 
TU1 67 as target cells. We found that cetuximab-mediated ADCC is enhanced 
against this cell line in individuals possessing a V allele at all effector to target 
ratios (Figure 2). Combinatorial analysis of all ADCC experiments against TU1 67 
revealed that donors with either VIV (64.0%) or VIF (47.5%) had superior cytotoxic 
activity against TU1 67 when compared to NK cells from FIF (22.5%) individuals 
at a 50: 1 effector to target (E:T) ratio, (p= 0.04 and 0.004, respectively). This 
effect is not cell line specific as the advantage of having at least one V allele when 
compared to FIF was also seen for 0 12SCC, where individuals with at least one V 
allele ( VIV and VIF) had a combined mean percent cytotoxicity of 65 .0 % 
compared to 34.5% for those with FIF (p=0.00 1 9) at 50:  1 ratio. While we observed 
a similar trend in polymorphism-associated killing against TU1 59, differences were 
not statistically significant. 
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Figure 1. EGFR expression in SCCHN tumor cell lines. SCCHN cell lines TU167, TU59 and 012SCC were 
stained with a -EGFR mAb (clone ICR J O) with an IgG2a isotype control (A) and Cetuximab with human IgGI 
isotype control (B). Open histograms represent the isotype control. Filled histograms represent the mAb staining. 
All cell lines show a comparable shift for both a -EGFR and cetuximab mAb. EGFR indicates epidermal growth 
factor receptor, 
This lack of significance was most likely due to the small sample size. Using an 
analysis of variance, we determined that there was a significant difference among 
the cumulative mean percent cytotoxicity for each polymorphism against all three 
SCCHN cell lines at a 50:1 effector to target ratio (58.2% for VIV, 50.6% for V/F 
and 26.1 %for F/F; p<0.001 ). Cetuximab-treated SCCHN cell lines were subjected 
to higher levels of ADCC compared with cells treated with isotype controls or 
media alone. These data provide strong evidence for cetuximab-mediated ADCC in 
SCCHN, and demonstrate a direct correlation between cytotoxicity and the 
presence of a V allele at position 158 ofFcyRIIla (Table 1). 
The presence of a V allele is associated with enhanced NK killing of NK 
sensitive targets 
Our study and others have demonstrated that the presence of a V allele at position 
158 enhances ADCC in both SCCHN and lymphoma (16,32,33). However, it is 
uncertain whether the impact of such polymorphisms correlates with other 
important intrinsic differences in NK cytotoxic potential. 
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Figure 2. NK FcyRIIIa polymorphisms influencing cytotoxic activity on cetuximab-treated SCCHN TU167. 
NK cells purified from PBMC of healthy donors expressing either FIF, VIF or VIV alleles were tested for 
cytotoxicity against TUI 67 in a standard 5 1Cr-release assay (A). Before addition of effector cells, TUI 67 target 
cells were pretreated with media alone (closed diamonds), human IgGl isotype control at I Oµg/ml (closed 
squares) or cetuximab I Oµg/ml (closed triangles). Data are representative of independent experiments performed 
in triplicate wells. NK cells purified from PBMC of 17 individual donors FIF (open diamonds), VIF (open 
squares) and VIV ( open triangles) alleles were tested for cytotoxicity against the TU 167 SCCHN cell line using a 
standard 5 1 Cr-release assay (B). Before addition of effector cells, TUI 67 targets were pretreated with media alone, 
human IgG l isotype control at l Oµg/ml, or cetuximab at l Oµg/ml. Donors with either FcyRIIIa VIV or FcyRIIla 
VIF demonstrated significantly higher % cytotoxicity compared to FcyRIIIa FIF, when incubated with I O  µg/mL 
cetuximab (p= 0.04 and 0.004, respectively). 
In order to test the hypothesis that NK cells with a V allele are associated with an 
enhanced cytotoxic potential unrelated to ADCC, we evaluated the cytotoxic 
ability of NK cells Interestingly, we observed that the presence of a V allele in 
donor NK cells was associated with significantly enhanced cytotoxicity against the 
NK sensitive K562 target (Figure 3). Using the Welch modified two-sample t-test, 
we determined that donors possessing FcyRIIIa V/F and VIV at 50:1, 25:1 and 
12.5: 1 have significantly higher cytotoxic activity than that of FcyRIIIa FIF donors 
(p=0.17, 0.044 and 0.043 respectively, CI=90%). These data suggest, for the first 
time, that NK cells containing a single V allele provide better direct tumor killing 
in an antibody-independent manner. 
Cetuximab induces anti-proliferative effects 
In addition to studying cetuximab-mediated ADCC m SCCHN, we set out to 
evaluate the direct anti-proliferative effect of cetuximab on SCCHN, using 
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Figure 3 .  FcylllaR V polymorphism is associated with enhanced natural cytotoxicity against K562 tumor 
targets. Tumor cell line K562 was subjected to direct NK cytotoxicity in the absence of antibody. NK cells from 
healthy donors bearing FcyIIIaR FIF (open diamonds), V/F (open squares) and VIV (open triangles) alleles were 
tested for cytotoxicity against K562 using a standard 5 1 Cr-release assay. 
thymidine proliferation assays. A significant dose-dependent inhibition on cell 
growth was observed on TU159 in presence of cetuximab concentrations ranging 
between 1 Opg/ml and 1 Oµg/mL when compared to cells cultured with isotype 
control (Figure 4) . Interestingly, there was no dose-dependent inhibition observed 
with TU167 and 012SCC and the effect on proliferation of these two cell lines 
when co-incubated with cetuximab was less sensitive compared to TU159. Thus, 
among the three EGFR over-expressed (>90%) cell lines, inhibition by cetuximab 
did not correlate with EGFR expression. In order to understand how cetuximab 
influences tumor growth, we employed a BrdU/7-AAD staining strategy to 
determine the effects of cetuximab on the cell cycle. TU159 showed an 
approximate 2 fold increase in the G2 phase and M phase of the cell cycle, while 
no overt pro-apoptotic effect was induced by cetuximab (Figure 5). Consistent with 
our proliferation studies, 012SCC and TU167 did not demonstrate significant 
reductions in DNA synthesis. Distinct from its likely role in ADCC, cetuximab 
may demonstrate a specific anti-proliferative effect on SCCHN. This experiment 
supports the ability of cetuximab in directly inhibiting SCCHN growth, in some 
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Figure 4. Dose-dependent anti-proliferative activity of cetuximab measured by [3H] thymidine assays. 
TU1 59 cells were cultured in the presence of various concentrations of cetuximab for 72 h. Proliferation was 
measured by thymidine incorporation. Cetuximab significantly inhibited TUI 59 in a dose-dependent fashion. 
Discussion 
Targeted therapy with monoclonal antibodies, such as cetuximab, is an integral part 
of the management of a wide range of malignancies (2,8,20,25,32,35). In the 
present study, we demonstrate for the first time evidence for cetuximab-mediated 
ADCC in vitro among three different SCCHN cell lines. The effectiveness of 
ADCC is associated with FcyRIIIa donor polymorphisms recognized to enhance 
Fc-FcR interactions. Importantly, we also show that the presence of a V allele 
correlates with the ability of NK cells to kill sensitive targets in the absence of 
antibody. These data provide insight into the mechanism of action of cetuximab for 
SCCHN, and contribute to an increasing body of literature clarifying the role of 
FcyRIIla polymorphisms in ADCC. While the clinical relevance of ADCC is 
difficult to establish, we provide in vitro data that supports its presence in SCCHN. 
Several recent studies also provide strong evidence supporting the impact of 
ADCC in targeted therapies for lymphoma, esophageal, melanoma, and colon 
cancer (20,25,33,35). For example, Weng and Levy have demonstrated rituximab­
mediated cytotoxicity (ranging from 13.5%- 1 00%) for lymphoma cells from 43 
patients using effector cells from healthy donors (33). Recently, Kurai has provided 
evidence for cetuximab-mediated ADCC using low-expressing EGFR lung cancer 
cell lines as targets and healthy donor PMBC as effectors. In this study, Kurai 
demonstrated that NK cells were the effector cells responsible for ADCC and that 
their cytotoxicity was enhanced by IL-2 (20). Similarly, Naramura et al. 
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Table 1 Cetuximab-dependent ADCC against TU167, TU159 and 012SCC targets 
cell linea polymorphism 
FIF VIF VIV 
TU1 67 25% (range 2%-42% 48% (range 1 3%-93% 64% (range 49%-91% 
sample size n=7 n=7 n=3 
TU1 59 33% (range 6%-66%) 40% (38% and 42%) 4 1% 
sample size n=4 n=2 n=l 
012sec 35% ( 1 9% and 50%) 72% (62% and 82%) 58% 
sample size n=2 n=2 n=2 
"Data represent all ADCC experiments performed on three SCCHN cell lines with various FcyIIIa receptor 
polymorphism PBMC at an effector to target ratio of 50: 1 
demonstrated evidence for ADCC in a melanoma tumor model. These reports 
support our finding demonstrating that cetuximab mediates ADCC in SCCHN. 
Perhaps the most compelling support for the clinical contribution of ADCC relates 
to the observation that polymorphic variations of NK FcyRIIIa influence clinical 
response and survival (32,33). This observation, coupled with the fact that NK cells 
are the principle effector cells facilitating ADCC, lends support to the clinical 
relevance of ADCC as an important mechanism of action for cetuximab. The V 
allele not only confers more efficient ADCC in vitro, but is also associated with 
better clinical outcomes. In addition to providing evidence for ADCC, our data also 
convincingly show that donor NK cells that contain a FcyRIIIa V polymorphism at 
position 158 demonstrate more efficient cytotoxicity against SCCHN cell lines. 
This important finding was seen in all three SCCHN cell lines. However, given the 
infrequency of homozygous V donors and relatively small number of samples, we 
did not see a statistically significant higher cytotoxicity to determine superiority of 
VIV over V/F. Incidentally, the frequency of the V allele in our sample of donors 
was 0.3, which is in keeping with the frequency found by others (5,33,35). These 
findings are significant because they may have profound implications for the 
identification of SCCHN patients most likely to respond to cetuximab. 
Other investigators also provide support for an enhanced effect of the 15 8-V 
polymorphism. Hatijiharissi et al. demonstrated the superior effect of having a 
single V allele on ADCC against two CD20 expressing target cells lines using 
rituximab and NK cells from 52 healthy donors (16). Not only was rituximab­
mediated ADCC activity higher with the presence of at least one V compared to 
those homozygous for F, but there was also a higher absolute number of CD 16 
receptors per NK cell for donors who expressed at least one V allele. 
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Figure 5. Cell cycling and DNA synthesis activity of TU159 in the presence of lOµg/mL cetuximab. Panels A, 
B and C indicate representative experiments for TU 159 in media alone, 1 Oµg/mL isotype control or 10 µg/mL 
cetuximab respectively. With cetuximab incubation, an increase in G2 phase and M phase (PS quadrant) was 
observed compared to isotype control. S-phase (P6 quadrant) was decreased by at least 2 fold in panel C compared 
to panels A and B.  
It also has been well established that FcyRIIIa V binds to human IgG 1 better than 
the FcyRIIla F, and this increased affinity of the FcyRIIla V translates to an 
enhanced ADCC in the presence of NK cells (29 ,31 ). Optimizing the binding of 
FcyRIIla to the Fe portion of targeted mAbs may offer an effective mechanism to 
overcome individual variability in Fc-FcR interactions. Mechanistically, these data 
suggest that it is not only the higher affinity binding of the Fc-FcR for the V allele 
that confers ADCC benefits, but the higher absolute number of CD 16 receptors 
among individuals with the V allele may contribute to the superiority observed by 
many investigators. 
Additionally, there have been clinical studies reporting that individuals 
homozygous for the V allele have an advantage over those that are either 
heterozygous VIF or homozygous F. A retrospective clinical review of 136 
lymphoma patients demonstrated a clinical 5-year progression free survival (PFS) 
for VIV, VIF and FIF equaling 77%, 38%, and 48%, respectively (33). Another 
analysis of 87 lymphoma patients by Weng et al. confirmed the clinical benefits of 
homozygous V with a 2-year progression-free survival (PFS) for VIV, VIF and FIF 
that was 45%, 12%, and 16%, respectively (32). In contrast to the in vitro studies, 
these clinical findings suggest that lymphoma patients with the homozygous V 
allele may experience better clinical outcomes when treated with rituximab. While 
there is compelling support for the positive effect of a V allele on ADCC, there are 
studies that do not maintain this position. Zhang et al. recently suggested that VIV 
at amino acid position 158 was unfavorable among 35 patients with disseminated 
colon cancer (35). However, only 5 (14%) of the patients in this study were VIV 
and the benefit attributed to having an F was not statistically significant in this 
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small sample. No direct measure of ADCC was performed in this study to correlate 
with their observed clinical outcomes. Additionally, because many end-stage 
patients are relatively immunosuppressed and have significantly impaired NK 
function (20), the findings in this small, single institution study should be viewed 
in context. Other small studies were not able to provide evidence for or against the 
role of polymorphisms in outcomes using targeted antibody treatments, as well 
(13,22). While additional studies are necessary, our findings demonstrating the 
benefit of a V allele for cetuximab-mediated ADCC are supported by larger, 
reproducible clinical and in vitro ADCC studies described previously. 
One of the principle goals of this study was to evaluate cetuximab-medicated 
ADCC in SCCHN, however we acknowledge that there are additional proposed 
mechanisms for cetuximab's anti-tumor effect, such as complement dependent 
cytotoxicity (CDC), competitive inhibition, or possibly direct pro-apoptotic effects 
(21,28). Crystallography studies show that cetuximab interacts with the ligand 
binding domain of the receptor, resulting in steric hindrance of ligand binding and 
subsequent dimerization of the molecule, which prevents EGFR 
autophosphorylation and activation ( 17). Therefore, we also evaluated the direct 
inhibition of the EGF receptor via proliferation and cell cycle experiments. 
Our proliferation studies demonstrate significant inhibition only against TU159 in a 
dose dependent fashion, resulting in cell cycle arrest at the S-phase, with an 
increased shift at the G0/G 1 phase. We did not observe significant apoptosis in any 
of the three cell lines. Thus, it appears that this anti-proliferative property of 
cetuximab relates to direct inhibition of ligand binding. However, we did not 
observe significant levels of cetuximab inhibition with TU167 and 012SCC 
compared to TU159, despite similar EGFR expression among the three cell lines. 
Our findings demonstrate that inhibition did not correlate with EGFR expression. 
In fact, some EGFR over-expressed cancers demonstrate an ability to become less 
sensitive to cetuximab and proliferate in a manner that is less dependent on the 
EGFR/tyrosine kinase pathway (17,27,28,34). Interestingly, even though there is 
variation in cetuximab-mediated inhibition among the three tumor targets, all three 
cell lines show a strong susceptibility to cetuximab-mediated ADCC. 
In addition to ADCC, NK cells possess other important cytotoxic functions. Some 
of these include antibody-independent mechanisms of cytotoxicity, and their 
effectiveness in this capacity may also be associated with FcyRIIIa polymorphisms. 
Interestingly, we observed an unexpected, not previously described finding that 
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donor NK cells with a V allele were associated with superior cytotoxicity against 
K562 in an antibody-independent mechanism. This is the first report documenting 
an association with the FcyRIIIa polymorphisms in antibody-independent 
cytotoxicity with NK. Thus, in addition to demonstrating more efficient ADCC 
against SCCHN cells, NK cells with a V allele were also associated with a 
statistically significant higher cytotoxicity against NK susceptible K562 in the 
absence of antibody (Figure 6). The mechanism for the enhanced cytotoxic 
potential of NK cells bearing a V allele against NK sensitive targets is unknown. 
Sivori describes NK cells with phenotypically more proficient cytotoxic activity 
that have a higher surface density of NK.p46, an important NK natural cytotoxicity 
receptor (NCR) (30). Others have confirmed that individual donors have 
populations of NK with heterogeneous surface densities of NCR as well as other 
NK co-receptors that correlate with NK cytotoxic activity (3,23,24,30). Additional 
studies are necessary to determine if the same polymorphisms that are associated 
with enhanced ADCC in SCCHN may also correlate with a phenotype that confers 
superior cytotoxicity. 
The intent of our study was to determine if FcyRIIIa polymorphisms are important 
in predicting response to cetuximab in SCCHN tumor cells. We demonstrate, for 
the first time, that cetuximab can induce NK mediated ADCC in SCCHN in vitro. 
Furthermore, we show that CD 16 polymorphisms play a critical role in the 
efficiency of ADCC in SCCHN. Specifically the addition of a V allele provides 
enhanced ADCC. This observation may prove to be an important marker for 
identifying individuals who can derive the greatest benefit from cetuximab-based 
therapies. An additional finding is that the V allele may not only be associated with 
enhanced ADCC, but may also correlate with an enhanced antibody-independent 
cytotoxicity. Our observations provide insight into the mechanism by which 
cetuximab may mediate therapeutic effects in vivo and provide a rationale for 
developing clinical trials to determine the role of FcyRIII polymorphisms and 
response to cetuximab in patients with SCCHN. 
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Introduction 
The therapeutic options for patients with advanced squamous cell carcinoma of the 
head and neck (SCCHN), who fail surgical extirpation and/or treatment with 
chemoradiotherapy, are generally limited to observation or palliative chemotherapy 
( 1 ). In order to improve the outcomes for this patient population, investigators have 
explored the use of immunotherapy in the form of peptide vaccines in an attempt to 
stimulate therapeutic antitumor immune effector responses. Traditional peptide 
cancer vaccines have focused on priming HLA class I (HLA-I) restricted 
responses, adhering to the premise that efficient stimulation of antigen-specific 
CD8 T cells, is both necessary and sufficient for effective antitumor immunity (2). 
However, the limited clinical efficacy of HLA-I restricted vaccines in isolation (3), 
has increased attention on the potential utility of simultaneously stimulating HLA 
class II (HLA-II) mediated CD4 responses, which may be necessary for the 
development and/or maintenance of antitumor immunity ( 4, 5). A first step to 
capitalize on this strategy is to develop vaccines against well characterized antigens 
which employ both HLA-I and II peptide-specific sequences. 
In order to both generate HLA-I and II restricted T cell responses in humans and 
overcome historic problems associated with extracellular proteolysis of short HLA­
I peptides, we employed a "Trojan" peptide approach. Trojan peptide-based 
vaccines contain a "penetrin" peptide sequence derived from HIV-TAT 
(RKKRRQRRR) which allows the entire peptide to translocate through the cell 
membrane and penetrate directly into the Endoplasmic Reticulum (ER) and Golgi 
apparatus (Golgi) where they can form peptide-HLA complexes (6). In addition, 
this strategy utilizes furin-cleavable linkers to join multiple HLA-I and II peptide­
epitopes, enabling release of the individual peptide-epitopes in the Golgi, where 
furin endopeptidase resides (7). These Trojan peptide-based vaccines appear to be 
relatively resistant to proteolysis and do not require proteosomal processing and 
transport by TAP, since they penetrate directly to the ER and Golgi (6). Perhaps 
more importantly, these functional attributes are associated with improved 
outcomes in both prophylactic and therapeutic mouse tumor models (7). 
For purposes of this study we designed two separate Trojan constructs, using 
previously described HLA-I and II T cell epitopes of the human papilloma virus 
type 16 (HPV-16) and MAGE-A3 tumor associated antigens. MAGE is a cancer 
testis antigen originally found in melanomas but later identified in other epithelial 
cell malignancies (8), while HPV-16 is a papillomavirus which is associated with 
SCCHN of the oro- and hypopharynx (9, 10). The choice of HPV-16 was premised 
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on several considerations including its high prevalence in SCCHN, tumor 
specificity and the presence of well-defined peptide epitopes (9-13). Similarly, 
MAGE-A3 was selected based on its high levels of expression in SCCHN and the 
availability of well characterized HLA-1 and II immunostimulatory epitopes (14-
16). Prior to injection, the Trojan peptides were solubilized in Montanide ISA 51 
and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, 
Sargramostim), as a means to promote DC migration to the site of vaccination and 
to enhance antigen presentation (17). In the first group of patients both an HLA­
A *02 positive genotype and expression of HLA-A *02 on the tumor cell surface 
were mandated for study entry. This original study design was premised on the fact 
that the HLA-1 peptides in the vaccine are HLA-A *02 specific and could only 
target tumors expressing this HLA-1 allele (18). However, based on our interval 
findings that the peptides predominantly stimulated responses against the HLA-11 
epitopes, whose allele restrictions are recognized to be promiscuous, the inclusion 
criteria were modified to include all patients with either MAGE-A3 or HPV-16 
positive tumors. 
Thirty-one patients with recurrent or metastatic SCCHN were screened for this 
pilot study and five were enrolled. Three patients received the MAGE-A3 and two 
patients received the HPV-16 vaccine. Although one patient with a known stable 
brain metastases experienced a serious adverse event (SAE), the Trojan vaccines 
were well tolerated and toxicities in general did not require or prolong 
hospitalization. In four out of five immunized patients, durable IFNy responses 
were observed in response to both the intact Trojan peptide and the HLA -II 
specific peptide. In addition, Trojan peptide-specific IgG was detected in plasma 
from two patients. By Elispot, Trojan peptide-specific HLA-1 IFNy-producing cells 
were identified in the peripheral blood of one of the MAGE-A3 immunized 
patients. To the best of our knowledge, this study is the first to report the use of 
Trojan peptide vaccines in humans and suggests that this strategy might provide a 
useful platform for priming antigen specific T cell responses in patients with head 
and neck carcinoma. 
Materials and methods 
Patient population, study protocol and treatment schedule 
Between December 2005 and March 2007, 31 patients were screened for their 
eligibility to enroll in a phase I clinical study designed to evaluate toxicity and 
immunogenicity of two Trojan (HPV-16 and MAGE-A3) peptide-based vaccines. 
All experimental work related to human subjects in this study was approved by the 
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University of Maryland's Institutional Review Board. Written informed consent 
was provided according to the Declaration of Helsinki. Enrollment criteria included 
(i) patients with recurrent or metastatic SCCHN not amenable to treatment with 
standard therapy or patients who refused standard treatment, (ii) the presence of the 
HLA-A*02 genotype and (iii) either MAGE-A3 or HPV-16 expression in the 
tumor. Importantly, based on interim data analysis demonstrating that the immune 
responses were predominantly HLA-11 restricted, we eliminated the HLA-A *02 
restriction in the latter part of the study. 
The vaccine dose used in the trial was 300µg of Trojan peptide, with 1.2 milliliters 
(mL) of Montanide ISA 51 (Seppic, France) and 100µg/m2 of GM-CSF) (Berlex, 
Seattle, WA). This vaccine dose was chosen because it is well within the range of 
previous peptide vaccine trials for cancer and it was well tolerated by the majority 
of patients while providing evidence of immunological efficacy (2). Peptides were 
reconstituted with 0.5 mL of sterile water for injection and each vial was mixed 
with Montanide ISA 51 and GM-CSF in an empty vial. The total contents of the 
mixture were drawn up in a syringe and pushed back into the vial. This mixing step 
was repeated 25 times to make unified emulsions, and final emulsions were drawn 
up in multiple syringes for injection. All vaccinated patients were injected 
subcutaneously in the inguinal region with the appropriate Trojan peptide vaccine 
at 4-week intervals for up to four injections as indicated in figure 1. The primary 
indications for giving fewer than four injections were drug-related toxicity (patient 
1) or disease progression (patients 2 and 4). After the final injection, patients 
returned for follow-up visits every three months. 
Trojan-peptide based vaccines and individual peptides 
The MAGE-A3 Trojan peptide and the HPV-16 Trojan peptide were manufactured 
by Multiple Peptide Systems (San Diego, CA) and processed and vialed by Merck 
Biosciences AG (Laufelfingen, Switzerland). Patients were immunized with either 
the MAGE-A3- or the HPV-16-specific Trojan peptide vaccine. Specific sequences 
of the Trojan vaccines and individual antigens to determine vaccine-induced 
immune responses are listed in table 1. The peptides were studied under IND # 
10927 (NCI www.clinicaltrials.gov # NCT00257738). 
Isolation of PBMC and tissue/tumor infiltrating lymphocytes 
Whole blood samples were collected prior to the initiation of treatment, within 24 
hours before each vaccination and then at defined follow-up intervals. 
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Figure 1. Immunization schedule. All enrolled patients were immunized subcutaneously in the inguinal region at 
4-week intervals for up to four injections. After the final immunization, patients returned for follow-up visits every 
three months. 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll gradient 
centrifugation. Tissue/tumor infiltrating lymphocytes (TIL) were isolated as 
described by Whiteside et al. ( 19), cryopreserved in RPMI-1640 supplemented 
with 10% normal human AB serum (NHS) and 10% DMSO using an automated 
cell freezer ( Gordinier Electronics, Roseville, MI) and stored in the vapor phase of 
liquid nitrogen for later use. If possible, PBMC/TIL isolated from separate 
procurement dates were simultaneously thawed and assayed to assess in vitro 
function. All experiments were performed in RPMI-1640 supplemented with 10% 
NHS, 2% HEPES, 1 % P/S and 1 % L-Glutamate (hereafter indicated as cRPMI). 
HLA typing 
DNA was extracted from a portion of the PBMC using a QIAamp DNA mini kit 
(Qiagen) and the alleles of genes encoding HLA-ABDR were determined by the 
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Micro SSP™ HLA-ABDR DNA typing kit (One Lambda, Canoga Park, CA) as 
per manufacturer's instructions. All HLA-A *02 positive patients were further 
analyzed for the genes encoding HLA-A *02 by the Micro SSP™ HLA-A *02 DNA 
typing kit (One Lambda) as per the manufacturer's instructions. 
MAGE-A3 and HPV-16 PCR 
Total RNA was extracted from squamous cell tumor biopsies using a Qiagen 
RNeasy Mini kit as per manufacturer's instructions followed by cDNA synthesis 
using an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). The melanoma 
antigen gene family (MAGE) consists of twelve highly homologous genes encoded 
on human chromosome Xq28 (20). MAGE-A3 (NM_005362) is highly homologous 
to MAGE-Al,2,4,5, 6 and 12 in the region of the Trojan peptide. We observed that 
amplification and sequencing of MAGE-A3 from tumor samples using previously 
published primers for MAGE-3, was not specific for MAGE-A3 ( 1 5). Therefore, 
new PCR primers were designed. For specific amplification of MAGE-A3 from 
cDNA primers MA3_F4 AAC GAG CGA CGG CCT GAC G and MA3_R4 GTG 
GAA ACT AAG GGA TGC were designed, which yield a PCR product of 1221 
hp. For specific amplification of MAGE-A3 from genomic DNA primers MA3_Fl 
GTG GAA ACT AAG GGA TGC and MA3 _ R4 were designed, which yield a 
PCR product of 736 hp. Primer MA3_R4 is specific for MAGE-A3 and forms a 3' 
C:C mismatch with the sequences of MAGE-A2,4,5, 6 and 12, which is predicted to 
decrease PCR efficiency by greater than 99% (21 ). To confirm the specificity of 
the amplified products, total RNA and genomic DNA were extracted from three 
different SCCHN cell lines, TU1 59, 0 12SCC and HW12, which express multiple 
MAGE proteins. An EcoRI restriction enzyme recognition site is present in nucleic 
acid 1 0 1 7  of MAGE-A3 (NM_005362) but not in the potentially amplified 
sequence of any of the other MAGE genes. The specificity of the amplification was 
tested by restriction digestion of the PCR products with an EcoRI restriction 
enzyme followed by direct sequencing of PCR products (supplemental figure IA). 
Complete digestion of the PCR product indicated specific amplification in all 
samples tested, compared with non-specific amplification with previously 
published MAGE-3 primers (supplemental figure lB). Amplification of HPV16 
cDNA was performed using primers E7 _F GCT CAG AGG AGG AGG ATG AA 
and E7_R GCC CAT TAA CAG GTC TTC CA to amplify HPV16 E7 (255 hp 
product) ( 1 0). PCR products were then verified using direct sequencing 
(supplemental figure I C). All PCRs were performed using ABGENE 2X 
ThermoPrime Reddy Mix (Thermo Fischer Scientific, Rockford, IL) with l .5mM 
MgC12 and a PCR protocol that consisted of ten cycles that began with an 
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annealing temperature of 63 °C and decreased by 0.5 °C per cycle followed by 32 
cycles with an annealing temperature of 58 °C and a one minute elongation time. 
Immunohistochemistry 
For HLA-A *02 immunohistochemical detection, frozen sections were cut at five 
micron thickness from the patient and control tissues and mounted on charged 
slides. The slides were incubated in cold acetone for ten minutes prior to 
processing in a DAKO Autostainer with an anti-HLA-A *02 antibody (SB03-ll 1, 
kindly provided by Dr. S. Ferrone, University of Pittsburgh, PA, USA and AEC 
substrate as per manufacturer's instruction. Staining with lymphocyte markers 
CD3, CD8, and CD68 (all from Ventana, Tucson, Arizona) and CD4 (Biocare, 
Concord, CA) was performed on formalin fixed paraffin-embedded tissue. 
Deparaffinization, rehydration and epitope retrieval were performed following 
standard procedures. Staining was performed on a Ventana Benchmark-XT stainer 
using an AP detection system. 
Trojan-specific T cell response monitoring 
IFNy Recall Elispot assay 
96-well nitrocellulose-bottom (Elispot) plates (Millipore, Molsheim, France) were 
pre-coated with IFNy at a final concentration of 15µg/ml (Mabtech, Nacka, 
Sweden). Plates were then washed six times with sterile PBS and blocked with 
100µ1/well of RPMI 1640 supplemented with 10% NHS. After 60 minutes of 
incubation, the blocking media was discarded and 2 x 105 PBMC were plated in 
triplicate wells. Next, Trojan and individual peptides were added to appropriate 
wells at a final concentration of lOµg/ml and plates were incubated at 37 °C, 5% 
CO2 • After 48 hours of incubation, cell supematants were discarded and Elispot 
plates developed using a Mabtech development kit. In brief, plates were washed six 
times with IX PBS and subsequently incubated for two hours at room temperature 
with 100µ1/well of biotinylated anti-human IFNy (7-B6-l , Mabtech) antibody 
(mAb) at a final concentration of 1 µg/ml. After two hours, plates were washed six 
times with IX PBS and incubated for one hour with 100µ1/well of Streptavidin­
HRP (Mabtech) at room temperature. Finally, Elispot plates were washed six times 
with IX PBS and developed for 30 minutes with 100µ1/well of peroxidase substrate 
AEC kit (Vector Laboratories, Burlingame, CA), followed by rinsing under 
running tap water. Plates were stored over night in the dark at room temperature, 
and spots were counted using a VersaScan microplate reader (Velocity 11, Palo 
Alto, CA). 
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Table 1 Trojan-vaccines and individual peptides 
antigen amino acid sequencea. ,c HLA-restriction 
MAGE-Trojan KVAEL VHFURVKR/FLWGPRALV/RVKR/VIFSKASSSLQURKKRRQRR A2, DR4/DR 7 
MAGE-CTL1 KVAELVHFL A2 
MAGE-CTL2 FLWGPRALV A2 
MAGE-HTL VIFSKASSSLQL DR4/DR 7 
HPV-Trojan TLGIVZPI/RVKR/PAGQAEPDRAHYNIVTFZZKZD/RKKRRQRRR A2, DR1/DR4/DR13/DR 1 5  
HPV-CTL TLGIVZPI A2 
HPV-HTL PAGQAEPDRAHYNIVTFZZKZD DR1/DR4/DR1 3/DRl 5 
control YIGEVLVSV HA-2d 
aRVKR; furin-cleavable linkers are indicated in Bold 
bRKKRRQRRR; HIV-TAT translocating domain is indicated in Italic 
c Z = cyclophenyl alanine 
dHuman minor histocompatability antigen HA-2 
To assess pre-coating efficiency, cells were stimulated with Concanavalin A 
(CON-A, l µg/ml) and wells with cells alone and control peptide served as 
background control and negative controls, respectively. The mean total of IFNy 
spot-forming cells (SFC) in triplicate wells were determined based on the 
difference between the frequency of spots obtained with the vaccine-specific 
peptides and the control peptide and is expressed as number of SFC as indicated in 
the figure legends. Specific sequences of the Trojan vaccines, individual vaccine­
specific antigens and control antigen to determine vaccine-induced immune 
responses are listed in table 1 .  
IFNy re-stimulation Elispot assay 
To amplify T cell responses, PBMC were re-suspended at 2 x 1 06 cells/ml in 
cRPMI supplemented with GM-CSF (50 ng/ml) and IL-4 (25 ng/ml). Next, PBMC 
were plated at 2 x 1 06 per well in 24-well plates and half of the wells were re­
stimulated with the appropriate Trojan vaccine ( 10  µ1/ml) and incubated at 37° C, 
5% CO2. After 48 hours of incubation, cells were harvested, re-suspended at 1 x 
1 06 cells/ml in cRPMI supplemented with IL-7 and IL-15  (both at 5 ng/ml) and 
plated at a final concentration of 106 cells/well in a 24-well plate and incubated at 
37 °C, 5% CO2. After seven days, cells were harvested, washed and plated at 1 x 
1 05 cells/well in triplicate wells in 96-well IFNy pre-coated Elispot plates. Trojan­
vaccine and control peptides were added to the appropriate wells ( 1 0µg/ml) and the 
plates cultured for 24 hours at 37° C, 5% CO2. After 24 hours of incubation, 
Elispot plates were developed as described above. 
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MAGE-Trojan and HPV-Trojan IgG ELISA 
Plasma samples from the vaccinated patients were assayed for antibodies against 
either MAGE- or HPV-Trojan peptides by ELISA. In brief, ELISA plates (NUNC 
445101, Raskilde, Denmark) were coated overnight at 4 °C with 1 µg MAGE- or 
HPV-Trojan vaccine per well. Negative control wells included no vaccine, vaccine 
alone, secondary antibody alone and vaccine plus secondary antibody. After 
overnight incubation and subsequent washing, plasma samples were diluted in 
blocking buffer (as indicated in the figure legend) and 100µ1 of diluted plasma was 
added to triplicate wells. After one hour of incubation at room temperature, plates 
were washed five times with PBS supplemented with 0.05% Tween 20 (IX PBST) 
and incubated for another hour with 100 µl of peroxidase-conjugated goat anti­
human IgG (dilution 1:1000, Kirkegaard & Perry, Gaithersburg, MD). Finally, 100 
µl of 3,3' ,  5,5'-Tetramethylbenzidine (TMB, Kirkegaard & Perry, Gaithersburg, 
MD) substrate was added and plates were incubated for up to 30 minutes at room 
temperature. OD values were monitored at 650 nm to not exceed 1.3. Reactions 
were stopped with 100 µl IN HCl and OD values determined at 450nm. Baseline 
levels of samples tested with no vaccine were subtracted from those with vaccine. 
OD values at 450nm were graphed and reported. 
Tetramer Analysis 
PE-labeled tetramers were assembled by Beckman Coulter (Fullerton, CA). 
Tetramers specific for MAGE-A3 CTL 1 (KVAEL VHFL), MAGE-A3 CTL2 
(FLWGPRAL V), HPV-16 CTL (TLGIVZPI) and control HLA-A *02 restricted 
tetramer (YIGEVLVSV ) were used. For tetramer staining, 20µ1 aliquots of 
tetramer were directly added to 106 PBMC. Cells were incubated for 30 minutes at 
room temperature in the dark. Next, 5µ1 aliquots of CD3 and CD8 mAb were 
added for surface staining, and the cells were incubated for an additional 30 
minutes at 4 °C in the dark. After incubation, cells were washed twice with F ACS 
buffer, resuspended in 500µ1 of F ACS buffer and analyzed within two hours of 
staining. A minimum of 100,000 events were acquired using a BD LSR II flow 
cytometer and analyzed with BD FACS DIVA Software (BD Biosciences). 
Statistics 
The number of IFNy producing PBMC observed in separate Elispot wells were 
treated as events that occurred in a pseudo-time period. Poisson regression was 
therefore used to test if there were any significant differences in the mean events 
between pre-vaccine and post-vaccine time-points for various vaccine and epitope 
treatments in each patient. The analysis was implemented with the SAS 9 .2 (SAS 
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Institute Inc., Cary, NC) GENMOD procedure with Poisson distribution. Over­
dispersion (variance > mean) of the model was adjusted by using 'dscale' option in 
the model statement. The significance level was set at 5%. P <0.05 was considered 
to be significant. 
Results 
Patient characteristics, HLA results and MAGE-A3/HPV-16 expression 
A total of 31 patients were screened for enrollment in this pilot study and the 
demographic data on all screened study patients is provided in table 2. All screened 
patients had histologically proven SCCHN and had either failed therapy or refused 
standard therapy. HLA typing was performed on all potential study patients, 
followed by a tumor biopsy to determine MAGE-A3, HPV-16 and HLA-A*02 
expression within the tumor. Among the 31 patients who were HLA typed, 11 
patients were determined to be HLA-A *02 positive. Nine of the HLA-A *02 
positive patients and two of the HLA-A *02 negative patients were subjected to a 
tumor biopsy. Two HLA-A *02 positive patients were found to be negative for 
HLA-A *02 at the tumor level (supplemental figure 2). These findings are 
consistent with previous studies from others and us showing that loss of HLA-1 
expression is a relevant mechanism of immune escape in SCCHN (22). Of the 11 
patients biopsied, four were shown to express MAGE-A3 and two were proven to 
express HPV-16. One of these patients expressed both antigens. In contrast, four 
patients expressed neither of the required antigens. In summary, five SCCHN 
patients were enrolled (including one "single use exemption" secondary to a 
diagnosis of myelodysplastic syndrome) in this pilot study and treated with up to 
four immunizations with one of the Trojan vaccines (table 3). 
Clinical Outcomes and Toxicities 
None of the five patients immunized demonstrated a complete response (CR) or 
partial response (PR) by RECIST criteria. Patient 5 is alive at 31 months after trial 
entry. Patient 1 lived for 27 months while patients 3, 4 and 2 died at 24, 8 and 4 
months, respectively. Patient 1 received only one vaccine and was removed from 
study due to a serious adverse event. A follow up CT scan five months following 
vaccine administration showed stable disease. Patient 2 was removed from study 
following two vaccinations due to disease progression. Patients 3 and 4 showed 
disease progression by CT scan two months following trial entry. Patient 5 showed 
stable disease following two vaccinations and underwent tumor resection three 
months following the final vaccination. 
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Table 2 Demographics of screened study patients 
number of patients 
male 
female 
median age (years); Range (years) 
stage 











Tumor-antigen expressiona : MAGE-A3+ 
HPV-16+ 
MAGE-A3+/HPV-16+ 




















Importantly, our survival data must be taken in context with the fact that these 
patients received other surgical and/or chemotherapeutic regimens after 
vaccination. 
NIH Common Toxicity Criteria were employed to determine the clinical toxicities 
associated with the Trojan vaccines. Toxicities observed after the first 
immunization and worst toxicity observed after any immunization are summarized 
in table 4 and 5, respectively. One patient experienced a serious adverse event 
(SAE) which is particularly noteworthy. Specifically, this patient with a known 
stable brain metastases (figure 2A) developed right sided hemiplegia, right-sided 
facial weakness and speech impairment, 24 days after her first vaccination. T2-
weighted MRI revealed marked progression of increased signal surrounding the 
cerebral metastasis consistent with increased cerebral edema (figure 2B). In 
addition, there was a rim of decreased signal that developed along the periphery of 
the metastasis, which although nonspecific, is an imaging feature that could be 
consistent with the development of surrounding cellular/lymphocytic infiltration. 
With steroid treatment, these findings subsided and her neurological symptoms 
resolved (figure 2C). 
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Table 3 Demographics and HLA status of immunized patients 
patient age sex AJCC HLA ABDRa HLA A2 
(years) (tumor) 
50 F IV A1., A24, 877, 844, .QM, 60%-80% 
2 65 M IV A1., A66, 87, 871, ORIS, 60%-80% 
3 70 M IV A1., A-, 87, 8 13, ORIS, DR- 40%-60% 
4b 47 M IV A3, A33, 8-, 835, .Qfil_, n/a 
5 55 M IV A1., A3, 87, 835, DR12, 80%-1 00% 
3Trojan-vaccine specific HLA-I and II restrictions are underlined 
bsingle use exemption, due to a secondary diagnosis of myelodysplastic syndrome. 
n/a, not applicable 






In vitro Elispot interrogation of PBMC, demonstrated strong recognition of both 
the Trojan and HLA-11 restricted peptides post-immunization (figure 2D). We 
postulate that this cerebral edema is the result of a vaccine-induced inflammatory 
reaction, although direct biopsy evidence is lacking. 
Trojan peptide-based vaccines induce robust and long lasting systemic 
vaccine-specific HLA-11 T cell responses 
To evaluate the vaccine-specific T cells responses, PBMC obtained from patients at 
baseline, within 24 hours prior to each vaccination and at completion or 
discontinuation of study were evaluated both directly ex vivo and after in vitro 
sensitization using IFNy Elispot. In the absence of prior in vitro exposure (hereafter 
called "recall Elispot") Trojan-vaccine specific post immunization T cell responses 
were observed in PBMC from patient 3 (P=0.0045,  P=0.0 100 and P<0.000 1 after 
vaccination number 2, 3 and 4, respectively), patient 4 (P=0.00 16  after vaccination 
number 3) and 5 (P<0.000 1 ,  P=0.0270, P=0.000 1 ,  P=0.0004 and P=0.0007 after 
vaccination number 1 ,  2, 3, 4 and after 3 months of follow-up, respectively). 
Furthermore, transient Trojan-specific HLA class II responses were observed in 
PBMC from patient 3 after vaccination number 2 (P=0.002 1 )  and after vaccination 
number 3 in PBMC from patient 4 (P=0.0041) .  Examples ofMAGE-A3 (patient 3) 
and HPV-16  (patient 5) recall assays are shown in figure 3A and B, respectively. 
Trojan-specific immunity was significantly enhanced when PBMC were subjected 
to a single in vitro exposure with the respective Trojan-vaccine. Specifically, 
MAGE- or HPV-Trojan specific immunity was detected in four out of five 
immunized patients (P<0.000 1 in all four patients at any given time-point) after 
one single in vitro re-stimulation. Examples of MAGE-A3 (patient 3) and HPV- 16  
(patient 5) in vitro sensitization assays are shown in figures 3C  and D ,  respectively. 
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Table 4 Toxicity after the first immunization 









Pain - musculoskeletal 




Hemoglobin - low 
Total 3 11 0 0 
" BUN, blood urea nitrogen 
Table 5 Worst toxicity observed during any immunization 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 




Head/N eek edema 1 
Chills 
Neuropathy - motor 
Neuropathy - Cranial nerve 
Infection 
Pain - musculoskeletal 2 




Hemoglobin - low 
Diplopia 
Upper respiratory - fistula 
Total 1 10 7 4 
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Importantly, in vivo priming and additional ex vivo amplification also resulted in 
robust Trojan vaccine-induced responses to the HLA-11 peptide in these four 
patients (figure 3C and 3D). These responses appeared to peak after the second or 
third vaccination with P<0.0001 at any given time-point. Quantitative levels of 
immune responses observed at baseline, after the second immunization and after 
the fourth immunization in both patients who completed the full vaccination 
schedule are summarized in supplemental figure 3. To exclude non-specific 
immune responses, in two MAGE-A3 vaccinated patients (patients 1 and 2) the 
HPV-Trojan vaccines were added to the recall Elispot assay as an additional 
internal control. In these two assays, nonspecific responses were absent ( data not 
shown). In addition, the HIV-TAT sequence was tested in a re-stimulation HPV-16 
Elispot assay (patient 4 ), and no significant differences in SFC were observed 
between wells containing the HIV-TAT or negative control peptides ( data not 
shown). In contrast, by recall Elispot, no systemic responses could be detected to 
the HLA-I epitopes present in the Trojan vaccines. 
A. B. C. 
D. 
400 




MAGE- MAGE- MAGE- MAGE- Control 
Trojan HTL CTL I CTL: 
Antigen (10p g/ml) 
Figure 2. T2 weighted brain MRI images of patient 1 and Trojan vaccine-specific immunity. Left (A) image 
obtained eight weeks prior to vaccination (1 /30/06), middle (B) image obtained during neurological event 
(4/2 1/06), and right (C) image obtained following resolution of neurological symptoms (7/14/06). Arrows indicate 
the site of the cerebral metastasis. PBMC were re-stimulated once with MAGE-Trojan vaccine and cultured in the 
presence of IL-7 (5 ng/ml) and IL- 1 5  (5 ng/ml). After seven days, cells were evaluated for MAGE Trojan-specific 
HLA-1 and II peptide (D) specificity by IFNy Elispot assay. Number of spots per 1 00,000 PBMC is shown. 
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One transient Trojan-vaccine specific immune response was detected after in vitro 
re-stimulation in PBMC from patient 3 with P=0.0210 (MAGE-CTL1 ) and 
P=0.0430 (MAGE-CTL2) after receiving three immunizations. In general, the lack 
of response was not secondary to antigen specific T cell anergy, as tetramer 
analysis revealed no robust and long-lasting increase in the number of antigen­
specific CD8 T cells over time (supplemental figure 4). These data demonstrate 
that the Trojan peptide vaccines, when administered in combination with 
Montanide ISA 51 adjuvant and GM-CSF, induce systemic immunity to both the 
entire Trojan construct and the HLA-11 restricted epitopes. Furthermore, the fact 
that the responses to the intact Trojan constructs were higher than the responses to 
their constituent epitopes, suggests that natural cleavage of the Trojan peptides 
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H PV- Control 
HTL 
Figure 3. Trojan peptide-based vaccines induce Trojan-specific precursors in vivo. PBMC collected before 
immunization and at indicated time-points after immunization were evaluated for Trojan specificity by IFNy 
Elispot assay. Direct ex vivo measurement of T cell reactivity against MAGE-Trojan (A) HPV-Trojan (B) and 
individual Trojan-specific HLA-1 and II peptides (A+B). Number of spots per 200,000 PBMC is shown. Error bars 
represent SD from triplicate wells. Control values are shown without subtraction from experimental values. PBMC 
were re-stimulated once with MAGE-Trojan or HPV-Trojan vaccine and cultured in the presence of IL-7 (5 ng/ml) 
and IL-15 (5 ng/ml). After seven days, cells were evaluated for MAGE-Trojan (C), HPV-Trojan (D) and 
individual Trojan-specific HLA-1 and II peptide (C+D) specificity by IFNy Elispot assay. Number of spots per 
100,000 PBMC is shown. Error bars represent SD from triplicate wells. * P<0.05 
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Alternatively, it is possible that the observed responses were biased by our 
methodology, where we initially stimulated with the Trojan construct and used the 
HLA-I or II restricted peptides for re-stimulation. Further studies will be required 
to clarify this issue. 
Trojan peptide-based vaccines induce antigen specific lgG responses 
It is well established that, under most conditions antibody class switch 
recombination (CSR) requires T cell help. Furthermore, regulatory T cells are 
recognized to inhibit antigen specific CSR by both direct suppression of B cell 
function and indirect inhibition of the T helper response (23). Therefore, in order to 
understand the functional activity of the CD4 T cell responses, we interrogated the 
IgG titers to the Trojan peptide vaccines. Vaccine-induced immune responses were 
demonstrated in patient 3 (MAGE-A3 Trojan-specific IgG) and patient 5 (HPV- 1 6  
Trojan-specific IgG) (figure 4A and 4C, respectively). These responses were 
durable up to follow-up month 3 and, in one case, were observed even at a 1/5000 
dilution. Furthermore, IgG subtyping of the patient with the highest titers (patient 
5) revealed that these responses were IgG 1 ( data not shown). Interestingly, despite 
the presence of vaccine-induced T cell responses to the HLA-11 epitope in patients 
1 and 4, no Trojan-specific IgG was detected (figures 4B and 4D). These data 
demonstrate that the Trojan peptide vaccines are capable of eliciting high titer IgG 
responses in select patients, suggesting that the peptide-induced CD4 cell responses 
in these patients are capable of supporting antigen specific CSR. 
Antigen specific T cells accumulate at the site of vaccination 
In order to further define the nature of the immune response elicited by this 
vaccine, we next characterized the phenotype and function of cells located at the 
site of vaccination. Two patients developed palpable inflammatory lesions at the 
site of immunization (figure 5A). One patient consented to a biopsy of this region 
(performed 19 days after vaccine # 2), and the inflammatory nature of the response 
was characterized phenotypically by both immunohistochemistry and flow 
cytometry and functionally by IFNy Elispot. Analysis of H&E stained sections 
revealed granuloma formation, consistent with the well characterized association 
between Montanide ISA 5 1  adjuvant and granulomas (24). As demonstrated in 
figure 5B, the majority of cells recruited to the site of injection were CD68+ 
monocytes/macrophages, with a smaller population of CD3+ T cells. Subsequent 
flow cytometric analysis of these cells revealed that the majority of this CD3+ cell 
population was CD4+, with a limited number of CD8+ T cells (figure SC). 
Importantly, from a functional perspective, immune cells obtained from the 
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Figure 4. Vaccination with MAGE-A3 and HPV-16 specific Trojan vaccines elicits IgG antibody responses 
in patients with SCCHN. Trojan-specific IgG was quantified in plasma obtained before immunization and at 
various time-points after immunization as indicated. MAGE-A3 Trojan (A+B) and HPV Trojan (C+D) specific 
IgG was quantified by ELISA. Data represent mean OD readings from triplicate wells derived from three different 
plasma dilutions. 
vaccination site, specifically recognized the HPV-Trojan vaccine (P<0.0001) and 
HPV HLA-11 epitope (P<0.0001), as determined by an IFNy re-stimulation Elispot 
assay (figure SD). These data demonstrate that vaccination induces ongoing 
antigen specific immune responses at the site of vaccination. 
Antigen specific T cells accumulate within the tumor 
In order to understand the nature of the immune response within the tumor 
microenvironment, we analyzed the cells from an involved lymph node of one 
patient who underwent a neck dissection post treatment. Importantly, this patient 
had metastatic neck disease and refused standard of care treatment options prior to 
vaccination. In order to validate this decision, the patient met with physicians from 
medical oncology, radiation oncology and otorhinolaryngology-head and neck 
surgery, each of whom carefully explained the ramifications of this decision to the 
patient. Furthermore, the patient underwent a psychiatric evaluation and was 
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HPV-Trojan HPV-HTL Control 
Antigen (10ug/ml) 
Figure 5. Trojan-specific precursor frequency at the injection site exceeds precursor frequency in the 
peripheral circulation. Frozen section slides were generated from a granuloma derived from the site of 
immunization and stained by immunohistochemistry with a variety of leukocyte-specific markers. The granuloma 
was biopsied 1 9  days after the second vaccination. PET scan revealing high levels of inflammation at the injection 
sites as indicated by arrows (A); high numbers of antigen-presenting cells (CD68+) and CD3+ T cells infiltrated the 
site of immunization (B); part of the granuloma was enzymatically digested into a single cell suspension and 
evaluated for Trojan-vaccine specificity (C). As measured by flow cytometry, the majority of CD3+ T cells in the 
granuloma were found to be CD4+ cells. Next, cells were directly ex vivo evaluated for Trojan-specificity by IFNy 
Elispot. High numbers of Trojan-specific cells were found at the site of injection (D). In contrast, at the same time­
interval, no Trojan-specific responses were detected in cells (PBMC) derived from the peripheral circulation. 
Number of spots per 50,000 cells (granuloma) and 1 00,000 cells (PBMC) is shown. Error bars represent SD from 
triplicate wells. * P<0.05 
judged competent to decline treatment and sign informed consent. Two months 
after completing the full vaccine protocol, without an objective response as 
determined by RECIST criteria, the patient agreed to undergo a therapeutic neck 
dissection. Interestingly, in the pre-treatment biopsy, there was a notable absence of 
CD4+ T cell infiltration and a limited number of CD8+ cells. 
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In sharp contrast, in the post treatment biopsy there were abundant CD4 + and CD8+ 
cells throughout the specimen (figure 6A). Furthermore, there were a qualitatively 
greater number of apoptotic cells in the post treatment specimen as demonstrated 
by TUNEL staining. Importantly, these apoptotic cells were judged to be tumor, 
rather than infiltrating lymphocytes, by our head and neck pathologist (J.P.) who 
reviewed the slides. Because, it could be argued that these observed phenotypic 
differences were simply a result of sample error secondary to tumor heterogeneity, 
we sought to determine the antigen specificity of the TIL. A 48 hour recall 
experiment demonstrated no significant IFNy release in response to the peptide 
antigens and the more sensitive re-stimulation studies could not be accurately 
completed secondary to poor cell viability. Therefore, we employed tetramer 
staining as a surrogate to determine the presence of CD8+ cells specific for the 
HPV-CTL epitope (figure 6B). While the percentage of tetramer positive CD3 T 
cells in the peripheral blood was 0.4%, the percentage in the lymph node was 8.1 %. 
Interestingly, preliminary studies from this sample revealed that the majority of T 
cells had a senescent (CD2TCD28-) phenotype ( data not shown) (25). Taken in 
concert, these data indicate that vaccine-specific immune cells accumulate at the 
site of immunization and in the tumor micro-environment. Furthermore, the lack of 
a recall response to the peptides in combination with the presence of CD2TCD28-
senescent cells within the tumor microenvironment, suggests that the effector 
function of these antigen specific T cells might be impaired by tumor host 
interactions. 
Discussion 
This pilot study tested Trojan peptide-based vaccines in five patients with recurrent 
or metastatic SCCHN. This novel vaccine contains HLA-I and II restricted peptide 
epitopes from MAGE-A3 or HPV-16. This study is, to the best of our knowledge, 
the first to explore therapeutic vaccination with MAGE-A3 and HPV-16 derived 
HLA-I and II restricted T cell epitopes in recurrent or metastatic SCCHN, and the 
first to use Trojan constructs for the treatment of human malignancy. Several 
features of our study are important to consider, both as they relate to the 
interpretation of our results and to the design of subsequent clinical studies using 
Trojan peptide vaccines for the treatment of SCCHN. 
First, from a clinical perspective, none of the patients developed objective clinical 
responses by modified RECIST criteria. From a toxicity perspective, the Trojan 
vaccmes were well tolerated and toxicities in general did not require 
hospitalization. Furthermore, one patient developed significant cerebral edema 24 
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days after the first vaccination which was associated with hemiplegia and an 
immune response to both the Trojan and HLA-11 restricted peptides. These 
findings, while clinically intriguing, mandate caution in using Trojan vaccines in 
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Figure 6. CDS+ and CD4+ T cells infiltrate the tumor microenvironment during immunization and a subset 
appears to be HPV-specific. Photomicrographs of immunohistochemical staining of tumor tissue harvested 
before and after immunization with HPV-Trojan vaccine. High numbers of CD8+ and CD4+ cells were found in the 
tumor micro-environment after immunization (A). Representative sections from CD4 and CD8 staining of the 
neck metastasis slides before and three months after the last vaccination are shown. Positive controls were positive 
for all experiments (inset CD4). Part of the neck metastasis, collected at three months after immunization, was 
enzymatically digested into a single cell suspension (TIL). PBMC collected before and PBMC and TIL collected 
after three months of immunization were directly ex vivo stained with HPV-16 specific HLA-A*0201 tetramer and 
analyzed by flow cytometry for Trojan HLA-1 specificity (B). In comparison to PBMC collected at the same time­
interval, TIL derived from the tumor micro-environment after 3 months of immunization were found to be HPV-
16 specific, 0.4% and 8. I% respectively. 
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Second, in four out of five immunized patients, the Trojan-vaccines stimulated 
systemic T cell responses to both the whole constructs and the constituent HLA-II 
epitopes. Furthermore, Trojan vaccine-specific IgG antibodies were detected in 
plasma from two of these patients, suggesting that these CD4 T cells were able to 
support a humoral immune response. In contrast, the one HLA-I specific IFNy­
producing response was transient. Furthermore, staining of TIL from a tumor 
resected post-treatment from one patient, demonstrated a significant increase in the 
number of tetramer positive cells when compared with correlate PBMC. Taken in 
concert, our data suggest that Trojan peptide vaccines, when administered in 
combination with Montanide ISA 51 adjuvant and GM-CSF, induce both antigen­
specific cellular and humoral immunity, with a biased systemic response to the 
HLA-II epitopes. Furthermore, although there were no objective responses to the 
vaccine, it is notable that three patients survived for 24, 27 and 31 (still alive) 
months post-therapy, in a setting where the average survival is approximately six 
months. Enthusiasm for these clinical observations must be tempered by small 
numbers, a potential selection bias, and the fact that these patients received 
additional therapy after vaccination. 
The induction of functional systemic responses to the HLA-II peptides in four out 
of five patients without durable HLA-I responses in PBMC was surprising. These 
findings are particularly striking since in three patients, responses to the Trojan 
constructs were observed in primary recall assays without re- stimulation. 
Although patients with end stage disease are traditionally considered to be 
immunosuppressed by virtue of their large tumor burdens, this was not reflected by 
total white blood cell counts, levels of CD3+ cells, CD3+CD81 cells (supplemental 
table 1) nor the ability to develop Trojan-specific immune responses (table 3). 
While it is possible that these responses were predominated by the presence of 
regulatory T cells (Tregs), we do not think this is likely. Specifically, the Elispot 
assays used IFNy as a read out. While Tregs are recognized to be induced by this 
cytokine, they do not generally produce IFNy (26). Furthermore, although Tregs 
suppress CSR (24 ), two of the treated patients developed IgG antibody responses to 
the Trojan peptides. Thus, our findings demonstrate that this vaccine strategy may 
elicit functional cellular and humoral systemic immune responses to both the entire 
Trojan constructs and their constituent CD4 restricted epitopes. These observations 
are particularly relevant in light of a recent report demonstrating that adoptive 
transfer of antigen-specific CD4 cells can mediate regression of metastatic 
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melanoma (27) and animal studies showing that antigen-specific CD4 cells can 
effectively mediate direct regression ofHLA-11 positive melanomas (28, 29). 
Several possible explanations may account for the lack of durable HLA-1 responses 
in our study. First, recent data suggests that patients with SCCHN have a high 
frequency of HLA-11 precursors to MAGE-A3 in the absence of prior vaccination, 
suggesting that this cell population may be readily responsive to peptide 
stimulation (30). In addition, since SCCHN are recognized to escape the immune 
response through deletion/anergy of HLA-1 type effectors through Fas-FasLigand 
(Fas-FasL) interactions, it is likely that a limited number of antigen-specific 
precursors are available for subsequent expansion (31 ). Second, two of the four 
HLA * A02 positive patients were determined to be HLA * A0205 and HLA * A0206, 
respectively. Although data is limited, it is thought that HLA-1 epitope recognition 
is reduced in these patients, potentially influencing the development of HLA-1 
restricted T cell immunity (32). Finally, it is now well established that HLA-1 
immune responses are more prevalent in lymph nodes, suggesting that our decision 
to study PBMC may have biased our outcome (33). Further bias may have also 
been introduced in our experimental design, where we re-stimulated in vitro with 
the Trojan vaccine, rather than the individual epitopes. 
Interestingly, in the one patient from whom we were able to compare pre-and post 
treatment biopsies, there was a profound increase in both CD4+ and CD8+ T cell 
responses at three months following vaccination. Furthermore, TIL from this 
patient demonstrated a high percentage of antigen-specific T cells in the post­
vaccination biopsy. Importantly, the fact that these TIL did not secrete IFNy in a 
recall assay and demonstrated a largely CD2TCD28- phenotype ( data not shown), 
suggests that they were biologically exhausted or senescent (25). This idea is 
consistent with previous observations that CD27+/CD28+ T cells are responsible for 
the therapeutic effects in melanoma patients responding to adoptive T cell transfer 
(34). However, data from colon cancer patients, demonstrate that the presence of 
both CD27 /CD28 double negative and double positive CD8 cells in the tumor 
microenvironment are independently associated with reduced metastases (35). 
Further studies will be required to definitively characterize the function of these 
antigen-specific T cells. 
Two of the major difficulties experienced within patient accrual in this pilot study 
included the unexpected low frequency of HLA-A *02 expression among this 
patient population and relatively quick deterioration of most recurrent or metastatic 
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SCCHN patients. In fact, HLA-A *02 is frequent in all ethnic groups and is found 
in approximately 35% and 50% of African-Americans and Caucasians, respectively 
(36). Surprisingly, only 20% of African-Americans and 38% of Caucasians were 
found to be HLA-A *02 positive in our total study population (table 2). 
Interestingly, a clear increase in MAGE-A3 HLA-II specific T cells was observed 
in one study patient who was determined to express HLA-DR* l5. Although HLA­
DR*04 and HLA-DR*07 specificity for the MAGE-RTL epitope, incorporated in 
our MAGE-Trojan vaccine, has previously been reported (16), it suggests that this 
MAGE HLA-II epitope is promiscuous and immunogenic in patients who are not 
DR*04 and/or DR*07. Based on the low percentage of HLA-A*02 expression in 
this population, the limited tolerance of these patients to nearly four months of 
vaccine delivery and the induction of functional responses to both the Trojan 
vaccine and the HLA-II restricted epitopes, we are currently conducting a phase I 
clinical trial in which patients are immunized every two weeks and in which HLA­
A *02 is not required for study entry. We anticipate that these changes will increase 
the feasibility of our approach without inhibiting efficacy. 
In summary, this pilot study demonstrates the feasibility of using Trojan peptide 
vaccines in combination with Montanide ISA 51 adjuvant and GM-CSF for the 
treatment of patients with advanced SCCHN. These data add to a growing body of 
literature demonstrating the efficiency of using long peptides to prime antitumor 
immune responses (11). The fact that these Trojan constructs were effective in 
stimulating responses against both the parental vaccine as well as its HLA-II 
restricted epitopes, limits traditional feasibility concerns associated with the use of 
HLA-I restricted peptides. Furthermore, while our conclusions must be viewed in 
the context of limited sample size, the presence of antigen-specific cells both at the 
vaccine site and within the tumor microenvironment, suggests that these Trojan 
peptide-primed cells may home to the tumor site. From a clinical perspective, the 
ability of this vaccine strategy to induce humoral and cellular responses with 
limited toxicity, may allow it to serve as a solid foundation on which to add 
additional immuno-modulators. Alternatively, these Trojan peptides might be 
effective as "mono-therapy" to limit the risk of disease recurrence following 
standard therapy for patients with high risk SCCHN. Our ongoing studies are 
exploring both of these options as a means to both limit the treatment related 
morbidity and prolong the survival of our patients afflicted with SCCHN. 
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Chapter 8 Summary and discussion 
Conventional cancer therapies are valued for their antitumor effects. However, they 
lack tumor specificity, may reverse antitumor immunity ( e.g. by causing 
inflammation) and generally do not induce protective antitumor immune responses. 
Cancer immunotherapy is thought to facilitate long-lasting antitumor immune 
responses, which induce tumor regression and protection against recurrence. Since 
the discovery of naturally occurring cell-mediated immune responses in melanoma 
patients in the mid-1970s, and since the cloning of the first tumor-associated 
antigen in the mid-1990s, various strategies designed to induce or boost antitumor 
immunity have been developed (1,2). Currently, a total of eight 
immunotherapeutics have been approved for the treatment of solid malignancies 
and several others are currently under evaluation in various clinical trials. Despite 
these promising advances, cancer still contributed towards 571,950 deaths in the 
USA in 2011 (3) and to date, no cancer-specific immunotherapeutic agent used 
alone can permanently cure patients suffering from solid malignancies. Increasing 
evidence suggests that only the combined use of various immunotherapeutics can 
induce long-lasting, protective tumor regression and overcome tumor escape from 
immunosurveillance and immunosuppression. 
This thesis focuses on CD137-mediated co-stimulation (part A) and NK cell-based 
immunotherapy (part B) and their therapeutic potential in the treatment of patients 
with solid malignancies. Fundamental for NK cell-based immunotherapy is a 
sufficient ex vivo expansion of large numbers of cytotoxic NK cells which has 
previously been shown to be CD137-CD137L mediated (4). Therapeutic potential, 
challenges in clinical translation and possibilities for their combined use are 
discussed. In addition, results of a pilot study testing a MAGE and HPV peptide­
based vaccine are presented and discussed in the clinical perspective of the 
aforementioned immunotherapeutic strategies (part C). Overall, therapeutic 
strategies discussed in this thesis provide a foundation on which to add additional 
immunotherapies to facilitate improved treatment of select solid tumors. 
CD137 mediated co-stimulation: Lessons learned and hurdles 
to overcome 
Based on the therapeutic potential of anti-CD137 mAbs for the treatment of cancer 
and autoimmunity (5-9), the demonstrated importance of NK cells in CD137 
mediated antitumor responses in murine models (6,10) and the recognized 
importance of Fc-FcyR interactions on mAb function (11,12), we evaluated in 
chapter 2 the ability of two different glycoforms of a chimerized anti-human 
CD137 mAb, an aglycosylated (GA) and a low fucose form (GG), to react with 
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human NK cells. Because of the recognized role of NK cells in the antitumor 
function of anti-CD137 mAb in murine models, we initially hypothesized that IL-2 
stimulated human NK cells would express CD 13 7 and that ligation with chimeric 
anti-CD137 mAb would result in cytokine release and degranulation. Surprisingly, 
we found that, unlike their murine counterparts, human NK cells do not express 
high levels of CD137 following IL-2 stimulation and subsequent culture. In 
contrast, CD137 is stimulated on IL-2 activated human NK cells following culture 
in the presence of immobilized glycosylated mAb or papain cleaved Fe fragments. 
The inability to stimulate CD 13 7 expression was independent of the antigen 
specificity of the Fab region and the magnitude of CD 13 7 expression was 
associated with patterns of glycosylation known to enhance Fc-FcyR interactions. 
In addition, Fe dependent CD137 expression was associated with cell activation as 
demonstrated by enhanced CD69 and CD54 expression and the release of the pro­
inflammatory cytokines IFN-y and TNF-a. Furthermore, CD 13 7 expression was 
preceded by degranulation which results in reduced cytotoxicity of CD 13 7 
expressing NK cells against NK sensitive tumor targets. 
The unexpected findings in chapter 2 raised concerns whether murine-based 
animal models would accurately predict human immune responses to CD 13 7 
manipulation. Limited data exists on B cell associated CD137. This is surprising 
since their importance in antitumor immune-regulation and autoimmunity is well 
documented ( 13, 14) and CD 13 7 mediated T cell immunomodulation has been 
postulated to be mechanistically responsible for observed changes in B cell 
function, including diminished isotype-specific antibody responses and changes in 
B cell survival (15-17). Importantly, murine B cells do not express CD137, while 
human B cells are reported to up-regulate CD137 in response to anti-lgM 
stimulation (18-20) Therefore, in chapter 3, we performed in vitro studies to 
elucidate, which external signals regulated CD 13 7 expression on human B cells 
and defined the biological effect of CD 13 7-mediated co-stimulation on human B 
cells. Our studies revealed that despite the absence of CD 13 7 on murine B cells, 
CD137 is expressed on immunoglobulin (lg)-activated human B cells following B 
cell receptor (BCR) stimulation. Cognate help from T cells through CD40-CD40L 
interaction and cytokines are mandated since anti-CD40 stimulation or cytokine 
alone were not capable of inducing CD 13 7 expression in the absence of BCR 
stimulation. These findings suggest that CD 13 7 expression on human B cells is 
tightly controlled and strictly dependent upon antigen encounter while the BCR 
serves as the initial "switch", which enables CD 13 7 expression on the B cell 
surface. Importantly, CD137 ligation stimulated B cell proliferation, enhanced B 
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cell survival and induced TNF-a and TNF-B secretion. Furthermore, CD 13  7 
expression was preceded by CD137L expression when assessed in vitro. In 
addition, both CD 13  7+ and CD 13  7L + B cells were detected ex vivo in human 
tonsils, although receptor and ligand are primarily expressed on distinct 
populations. 
Events such as the TGN1412  trial in 2006, where healthy volunteers became 
critically ill following the first in-human administration of a super-agonistic anti­
CD28 mAb (21 ), underscore the importance of appropriate preclinical testing in 
vitro in human PBMC and in vivo in mice and non-human primate models. The 
disparity of CD 13  7 expression and function between human and murine NK and B 
cells challenges the use of murine-based disease models for the evaluation of 
CD137-mediated immune regulation and toxicity. To facilitate proper animal 
choice in preclinical animal testing, we performed binding studies of the chimeric 
glycosylated anti-CD137 mAb (GG) against activated PBMC from cynomolgus 
macaque and baboon (chapter 4). Surprisingly, the chimeric glycosylated anti­
CD137 mAb only bound human CD137, while a commercial mouse anti-human 
CD137-specific mAb bound activated CD137-expressing PBMC from both human 
and non-human primates. In order to understand the differences in binding affinity 
between these mAbs, we sequenced cynomolgus macaque and baboon CD 13  7 
specific cDNA and found that the amino acid sequence of CD137 is largely 
conserved between human and primate species, with the extracellular domain 
differing by only 9-1 0  amino acids. Glycosylation seemed not responsible for the 
observed binding differences since two potential amino acids highly suggestive for 
glycosylation (Asn 103 and Asn 1 1 5) did not differ between species. Subsequent 
replacement of cynomolgus macaque CD 13  7 sequences with human CD 13  7 
sequences identified the three amino acids Thr66, Pro67 and Phe69 as being critical 
for GG binding. In addition, these amino acids are likely involved in a 
conformational rather than a linear epitope, as an overlapping peptide was unable 
to inhibit GG recognition, even at excess molar concentrations. 
The findings in chapter 2 provide important insight into the design of antibodies 
intended to manipulate co-stimulatory pathways for clinical benefit. Although our 
studies did not elucidate if similar findings would apply for other co-stimulatory 
molecules, Maniar et al. recently published enhanced expression of OX40 on 
human NK cells in the presence of immobilized human IgG 1, whereas IgG I ­
mediated expression of CD28, CTLA-4, ICOS and PD-I was absent (22). The data 
presented in chapter 2 also support the idea that CD137 ligation may co-stimulate 
173 
Chapter 8 Summary and discussion 
antitumor function of Fe-primed NK cells. This hypothesis is supported by 
previous observations that human NK cells transfected with a construct containing 
the intracellular domain of CD 13 7 directly linked to an anti-CD3/CD 19 chimeric 
receptor were more effective than NK cells transfected with an anti-CD3/CD 19 
chimeric receptor alone, in both killing leukemic cells and producing IFN-y and 
GM-CSF (4). Additional studies by maniar et al. confirmed the notion that mAbs, 
which target tumor-associated antigens, when composed of the appropriate Fe, can 
also provide a first signal for NK cell-dependent CD137 expression since 
cocultures of human NK cells with mAb-opsonized head and neck cancer-derived 
tumor cells enhanced CD137 expression on human NK cells in vitro. Moreover, 
recent studies by Kohrt et al. demonstrated that sequential administration of anti­
CD20 and anti-HER-2/neu mAb followed by anti-CD137 mAb mediated co­
stimulation enhances NK cell-mediated cytotoxicity against lymphoma and breast 
cancer cells in murine models (23,24). Overall, the findings in chapter 2 shed new 
light onto a secondary function of Fc-FcyRIII ligation and demand caution when 
describing CD 13 7-specific mAbs as being "agonistic" if their function is assessed 
with intact Fe regions. Particularly, effects previously attributed to CD137 
interactions with the Fab region, must now be re-evaluated as potentially related to 
Fe induced expression of CD137 on NK cells with subsequent effects due to (i) 
direct interaction of CD137L with Fe induced CD137, (ii) direct stimulation of Fe 
induced CD137 by agonistic anti-CD137 mAbs or (iii) antibody blockade of 
interactions between Fe induced CD137 and CD137L. In addition, the findings in 
chapter 2 and 3 have important implications for the clinical translation of CD 13 7-
based immunotherapeutic strategies. The disparity of CD 13 7 expression and 
function between human and murine NK and B cells challenges the use of murine­
based disease models for the evaluation of CD137-mediated immune regulation. 
As a result, targeting the CD 13 7 pathway with therapeutic intent may have 
unanticipated consequences on human B and NK cell function. 
Importantly, CD137 is recognized for the treatment of both cancer and 
autoimmunity (5-9). This dual function should be taken into account when 
analyzing the direct effect of anti-CD137 targeting immunotherapeutics in clinical 
cancer studies. Specifically, CD137-mediated B cell proliferation and survival are 
likely to positively affect antitumor immunity. However, CD137 stimulation 
greatly enhanced TNF-a and TNF-� secretion by anti-Ig/anti-CD40 activated B 
cells. These cytokines independently or complementarily enhance immune 
responses and augment inflammation by targeting various immune cells which may 
negatively affect antitumor immune responses. TNF-a and TNF-� act both 
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stimulatory and inhibitory depending on the site and time of activation. It has been 
shown to be important in the early phase of inflammation (25,26) which promotes 
tumor cell growth, survival and angiogenesis (27). In contrast, failure to regulate 
TNF production induces chronic inflammation which may inhibit immune 
responses (28). In addition, TNF-a has been shown to play a role in cytokine­
induced apoptosis of NK cells (29). Only outcome analysis of phase I/II clinical 
studies can define which function will be more prominent. Finally, Fe stimulated 
NK cells did not express CD137L. However, B cells were found to express 
CD137L during the early stages of B cell activation followed by the up-regulation 
of CD 13 7. This may suggest that reverse signaling plays a role in B cell function, 
since CD 13 7L has been shown to also reverse signal in other cell types (30,31 ). 
Safe and effective translation of antibodies designed to manipulate co-signaling 
pathways requires in depth preclinical non-human in vivo assessment. The 
translational relevance of such in vivo studies is largely dependent upon the ability 
of the study drug to elicit similar functional responses in the animal chosen. The 
findings presented in chapter 4 underscore the importance of careful animal 
selection before preclinical in vivo testing is initiated. This became clear by the in 
depth in vitro studies performed shortly after the TGN1412 trial. The extensive 
cytokine release in this in-human trial was not foreseen by thorough in vitro 
(human PBMC) and in vivo (mice and cynomolgus macaque) preclinical studies 
which excluded differences in the extracellular domain, intracellular domain and 
binding affinity of cynomolgus macaque CD28 (32). However, post-clinical re­
evaluation demonstrated various differences in CD28-mediated immune reactivity 
between human and cynomolgus macaque PBMC (33). In particular, murine Treg 
were found to efficiently prevent CD28-triggered cytokine production (34) and 
cynomolgus macaque CD4+ T cells loose CD28 expression during differentiation 
into effector T cells, in contrast to human CD4+ T cells, which maintain CD28 
expression (35). Ideally, safety studies of the presented CD137 antibodies should 
be performed in chimpanzees since this animal is the only animal that possesses 
Thr66, Pro67 and Phe69 responsible for GG binding. However, research using 
chimpanzees is profoundly restricted. In addition, inherent polymorphisms for 
CD 13 7 within individuals of a species should be taken into account since they have 
been reported in cynomolgus macaques (36). In this regard, only in-human studies 
will provide definitive proof of safety. 
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NK cell-based immunotherapy in patients with solid 
malignancies: Lessons learned and hurdles to overcome 
The pivotal role of NK cells in CD137 mediated antitumor immunity, the reported 
success of NK cell-based immunotherapy in patients affected by hematological 
malignancies and the importance of CD 13 7-CD 13 7L ligation in ex vivo NK cell 
expansion formed the foundation of the studies presented in chapter 5. This 
chapter extends the results presented in chapter 2. We found that NK cells from 
normal individuals and patients affected by gastric cancer, lung cancer, colon 
cancer and hepatocellular cancer rapidly expand ex vivo from PBMC in the 
presence of exogenous IL-2 and K562 cells expressing membrane-bound IL-15 and 
CD137L. Based on CD3 and/or CD56 phenotype, the majority of cells in the 
expanded cell product represented NK cells while a much smaller proportion 
represented NKT and T cells. Ex vivo expansion tended to alter the balance of NK 
cell receptor expression towards those that activate and mediate cytotoxicity. 
Additional studies confirmed their lytic activity, both directly and indirectly 
through ADCC, against autologous tumor targets while sparing autologous PBMC. 
Immunomagnetic bead separation confirmed that little to no cytotoxictity was 
mediated by the T and NKT cell population. To facilitate clinical translation, we 
also confirmed that NK cells can be expanded from lymphocyte-enriched cell 
fractions obtained from PBMC by GMP compliant counter current elutriation and 
that these NK cells are able to lyse allogeneic prostate-derived tumor cell lines in a 
similar fashion. 
The interaction of Fe fragments of antibodies with Fey receptors is an essential 
checkpoint in ADCC. Specific polymorphisms at amino acid position 158 enhance 
FcyRIII affinity for IgG 1 and are associated with improved clinical outcome in 
lymphoma patients treated with anti-CD20 antibody (12). Based on the previous 
findings that (i) patterns of Fe glycosylation known to impact Fe interactions with 
FcyRIII directly affect CD137 expression and NK cell activation (chapter 2) and 
(ii) that the cytolytic capacity of expanded autologous NK cells is enhanced in the 
presence of the chimeric anti-epidermal growth factor receptor (EGFR) 
monoclonal antibody cetuximab ( chapter 5), we extended our studies to define the 
importance of FcyRIII polymorphisms in cetuximab-mediated ADCC and used 
various head and neck derived tumor targets as an in vitro study model in chapter 
6. Polymorphism frequency at amino acid 158 from 45 healthy individuals was 
51.1 % for F IF, 3 7 .8% for V IF and 11.1 % for VIV. ADCC assays against three 
different head and neck carcinoma cell lines confirmed that cetuximab-mediated 
ADCC in vitro is enhanced in individuals possessing at least one V allele. In 
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addition, we found evidence that NK cells containing a single V allele mediate 
better direct cytotoxicity in an antibody-independent manner since donor NK cells 
possessing at least one V allele showed significantly enhanced cytotoxicity against 
NK sensitive K562 targets. These findings have significant implications for the 
identification of solid tumor patients, including head and neck cancer patients, 
which are most likely to respond to anti-EGFR antibodies and/or NK cell-based 
immunotherapy. 
The use of NK cells as a treatment modality in solid tumors requires that large 
numbers of NK cells are generated that kill tumor cells directly or augment the 
cytotoxic effect of tumor directed monoclonal antibodies. In general, NK cell 
mediated cytotoxicity requires HLA class I and KIR mismatching to overcome 
natural inhibition. For that reasons, allogeneic NK cells are postulated to be more 
cytotoxic than their autologous counterparts. For clinical translation of allogeneic 
treatment protocols in solid malignancies, cell products have to contain pure NK 
cell populations free of contaminating T and NKT cells in order to prevent graft­
versus-host disease (GvHD) (37). Although unwanted allogeneic T and NKT cells 
can now be depleted by human-grade and GMP conform magnetic bead 
procedures, single contaminating T and NKT cells may still persist. Depletion of 
contaminating T and NK cells is likely to be less critical in an autologous treatment 
setting. Under the ex vivo expansion conditions presented in chapter 5, NK cells 
up-regulated various receptors associated with activation and cytotoxicity. This 
resulted in natural cytotoxicity against autologous gastric tumor cells partially 
mediated through NKp46 and NKp30. In general, data on NK cell mediated 
autologous tumor cell killing in solid malignancies is limited, although autologous 
NK cell mediated cytotoxicity has recently been shown in melanoma (38). 
To facilitate clinical translation, current clinical cellular therapy protocols were 
adapted to explore the possibility to serve in future NK cell-based immunotherapy 
studies. The Elutra® cell separator uses counter-flow elutriation technology to 
separate PBMC primarily by size and secondarily by specific gravity. This 
generates five separate cell fractions including platelets (fraction 1), erythrocytes 
mixed with lymphocytes (fractions 2), lymphocytes (fractions 3), lymphocytes 
mixed with monocytes (fraction 4) and monocytes (fraction 5). Currently, 
monocytes obtained from fraction 5 are used to generate dendritic cells for cancer 
immunotherapy while the cells from fractions 2, 3 and 4 are usually "archived" in 
liquid nitrogen. Studies in chapter 5 confirm that NK cells could also be expanded 
from elutriated cell fractions. Although variability in expansion rates between 
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healthy individuals was observed, these data provide a foundation for the large­
scale production of cytolytic NK cells from elutriated cell fractions. Expanded NK 
cells could be employed alone or in combination with other cellular components 
such as DC generated by fraction 5 for application in cellular therapy of cancer. 
Importantly, we demonstrated that the receptor-ligand pairs mediating autologous 
NK cell toxicity is patient dependent. These differences likely reflect variation in 
expression of receptor-ligand combinations in human that are known to be 
operative in the control of NK cell cytotoxicity. These variations include HLA and 
KIR polymorphisms as well as tumor type and tumor origin ( e.g. primary versus 
metastatic tumor cells; lymph node metastases versus organ metastases) (38,39). 
Instruments to easily identify patients who are likely to have optimal cytotoxic 
receptor-ligand combinations are lacking and this should be taken into account 
when data from phase I toxicity trials is interpreted in terms of clinical benefit. The 
finding that ex vivo expanded NK cells mediate ADCC, which significantly 
improved overall NK cell-mediated cytotoxicity, implicates that the combined 
strategy of adoptively transferred ex vivo expanded NK cells with concurrent 
infusion of a mAb that is approved for cancer immunotherapy may provide clinical 
benefit for the treatment of select solid tumors. Enhancement in cytotoxicity was 
far more dramatic in the autologous setting if compared to the allogeneic setting 
suggesting that Fe receptor ligation augments ongoing receptor-ligand interactions 
or alternatively, triggers additional receptor-ligand interactions associated with 
natural cytotoxicity. Importantly, efficient tumor cell killing is highly dependent on 
the potential of adoptively transferred NK cells to home and infiltrate into solid 
tumor tissue. This may be directed by opsonizing tumor cells with a cancer cell 
directed mAb although clinical studies are needed to confirm this hypothesis. 
Moreover, the findings presented in chapter 6, confirm the impact of Fe 
polymorphisms in ADCC against EGFR expressing tumor targets. Careful pre­
entry patient selection is likely to enhance clinical outcome in future phase 1/11 
clinical trials testing tumor-specific mAb in solid tumor patients. In addition, Fe 
polymorphism screening may prove useful in defining the patients, who are likely 
to respond to treatment with currently approved tumor-specific mAbs. Importantly, 
effects of tumor-antigen density, also reported to affect EGFR-specific ADCC (40), 
were not taken into account in the studies presented in chapter 6. 
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Scientific possibility and clinical reality: Lessons learned and 
hurdles to overcome 
Chapter 7 summarizes a clinical study on the safety and immunogenicity of a 
MAGE-A3 and HPV-16 peptide-based vaccine for the treatment of head and neck 
cancer patients. Both vaccines were composed of HLA class I and HLA class II 
restricted MAGE-A3 or HPV-16 derived peptides, joined by furin-cleavable linkers 
which enable release of the individual peptide-epitopes in the Golgi where furin 
endopeptidase resides ( 41 ). In addition, a "penetrin" peptide sequence derived from 
HIV-TAT was added, which allows the entire peptide-vaccine to translocate 
through the cell membrane and penetrate directly into the ER and Golgi where they 
can form peptide-HLA complexes ( 42). In this clinical study, we screened 31 
patients with recurrent or metastatic squamous cell carcinoma of the head and neck 
(SCCHN) and five patients were treated. Three patients received the MAGE-A3 
peptide vaccine composed of two HLA class I epitopes and one HLA class II 
epitope and two patients received the HPV-16 peptide vaccine composed of one 
HLA class I epitope and one HLA class II epitope. In four out of five immunized 
patients, the Trojan-vaccines stimulated systemic T cell responses to both the 
whole construct and the constituent HLA class II epitopes and Trojan vaccine­
specific IgG antibodies were detected in plasma from two of these patients. In 
addition, one transient HLA class I specific immune response was observed and 
staining of tumor-infiltrating lymphocytes (TIL) from a tumor resected post­
treatment from one patient demonstrated a significant increase in the number of 
vaccine-specific HLA class I restricted T cells when compared with correlate 
PBMC. Furthermore, vaccine-specific HLA class II specific T cells were found at 
the site of immunization. Importantly, from a toxicity perspective, the Trojan 
vaccines were well tolerated and toxicities in general did not require 
hospitalization. One patient with a known brain metastasis developed significant 
cerebral edema 24 days after first vaccination with the Mage-Trojan vaccine, which 
was associated with hemiplegia and an immune response to both the whole 
construct and HLA class II restricted peptides. In addition, from a clinical 
perspective, none of the patients developed clinical responses by modified RECIST 
criteria. 
Several features of the Trojan pilot study are important to consider, both as they 
relate to the design of clinical studies in general and to the design of subsequent 
clinical studies using Trojan vaccines for the treatment of SCCHN. First, the lack 
of induction of durable HLA class I responses was surprising, yet explainable. 
Recent data suggests that cancer patients possess HLA class II precursors to 
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MAGE-A3 in the absence of prior vaccination (43), suggesting that this cell 
population may readily respond to peptide stimulation. In addition, immune escape 
through deletion/anergy of HLA class I effector T cells through Fas-FasL 
interactions may result in limited numbers of antigen-specific precursors available 
for subsequent stimulation. Furthermore, two of the four HLA * A02+ patients were 
determined to be HLA *0205 and HLA * A0206, respectively. These HLA * A02 
epitopes are associated with reduced HLA class I restricted T cell immunity (44). 
Finally, tumor specific immune responses are more prevalent in lymph nodes (45), 
suggesting that the immunomonitoring studies using PBMC may have biased 
immunological outcome. 
Importantly, despite the lack of CTL responses, T helper cell responses were 
elicited even in patients with end-stage disease, who are traditionally considered 
immunosuppressed by virtue of their large tumor burdens. Moreover, the 
stimulation of T helper cell responses is particularly relevant in light of a recent 
report demonstrating that adoptive transfer of antigen-specific T helper cells can 
mediate regression of metastatic melanoma ( 46) and animal studies showing that 
antigen-specific T helper cells can effectively mediate direct regression of HLA 
class II positive melanoma ( 4 7 ,48). 
Two of the major hurdles experienced in this pilot study relate to patient accrual. 
These included the unexpected low frequency of HLA-A *02 expression among this 
patient population and the relatively quick deterioration of clinical performance 
status. HLA-A *02 is frequent in all ethnic groups and is found in approximately 
35% and 50% of African-Americans and Caucasians, respectively (49). Among our 
patients, only 20% of African-Americans and 38% of Caucasians were found to be 
HLA-A *02+. Further studies in a larger patient cohort are needed to confirm this 
finding which implies that the HLA-A *02 allele might be of prognostic relevance 
in SCCHN. 
Although there were no objective (RECIST) responses to the vaccine, it is notable 
that three patients survived for 24, 27 and 31 months post-therapy, in a setting were 
the average survival is approximately six months. The ability of the Trojan 
vaccines to induce humoral and cellular responses with limited toxicity, may allow 
them to serve as a solid foundation on which to add additional immune-modulators 
such as CD137 mAb. Alternatively, the Trojan vaccines might be effective as 
monotherapy to limit the risk of disease recurrence following standard therapy for 
patients with high risk SCCHN. 
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Future perspectives 
In the past 20 years, immunotherapy has found its place into the daily treatment of 
patients suffering from various hematological and solid malignancies. Progress in 
the understanding of its mode of action has accelerated clinical interest and resulted 
in numerous ongoing immunotherapy-based clinical studies targeting various 
tumor-specific antigens (www.clinicaltrials.gov). In addition, immunotherapeutic 
strategies were extended towards the direct manipulation of immune-modulatory 
pathways. First clinical success of an immune-modulatory immunotherapy was 
achieved almost a year ago when a CTLA-4 blocking mAb, ipilimumab, 
demonstrated effective in enhancing overall survival in metastatic melanoma (50). 
This thesis provided various approaches of cancer immunotherapy which can be 
used alone, in combination, or in conjunction with currently approved treatment 
modalities. Several findings in this thesis justify further investigation. 
First, CD137 ligation has been shown to promote both T cell (51) and B cell (this 
thesis; (52)) proliferation and survival. Therefore, studies that further elucidate the 
functional relevance of CD 13 7 expression on human NK cells are highly needed. If 
proven equal, their in vivo persistence after adoptive transfer may be enhanced 
through CD 13 7 targeting. Furthermore, activated NK cells up-regulate HLA class 
II and co-stimulatory molecules (unpublished data) and their ability to internalize, 
process and present influenza-derived antigens to CD4+ T cells has been described 
(53). Extended studies are of clinical interest to define if T cell responses directed 
against tumor cells are optimized by NK cell mediated antigen presentation. 
Second, the concurrent expansion of NKT cells from PBMC during ex vivo NK cell 
expansion sets the stage for their clinical translation into new cellular therapy 
protocols. Specifically, y8-TCR+ T cells possess strong lytic potential after 
activation with isopentenyl pyrophosphate (IPP) and IL-2 (54) and they have been 
shown to enhance NK cell mediated cytotoxicity through CD 13 7-CD 13 7L 
interactions (22). Infusion of y8-TCR+ T cells alone or in combination with NK 
cells in newly proposed immunotherapy protocols may induce favorable clinical 
responses. Also, the preliminary findings that Fe polymorphisms may also play a 
role in natural cytotoxicity should be further studied in order to clarify the direct 
association of a V allele with enhanced expression of natural cytotoxicity and 
activating receptors. If confirmed, stringent patient selection will become possible 
in future clinical studies testing adoptive NK and/or y8-TCR+ T cells transfers or 
tumor antigen-specific mAb which in turn, may positively affect clinical response 
rates and select for patients who benefit the most. However, optimism should be 
181 
Chapter 8 Future perspectives 
dampened since a VIV phenotype is relatively rare in the general population (this 
thesis; (12,40,55)). This may impact patient accrual rate and should be taken into 
account when proposing a clinical trial. In addition, some combined strategies may 
not prove to be optimal since the addition of a gp 100 peptide vaccine to 
ipilimumab treatment increased the risk of tumor progression and shortened tumor 
responses (56). 
Finally, immunotherapy-induced clinical benefit reqmres the induction of an 
equilibrium in which tumor-specific immune cells constantly overrule or at least 
equal tumor cell growth. To establish such an equilibrium is likely to require less 
time in patients who are tumor free or have minimal residual disease, compared to 
patients with large tumor burdens. Therefore, tumor mass reduction through 
surgery and/or radiation should be considered as a complementary entry criteria in 
studies evaluating immunotherapeutic strategies in patients with metastatic disease 
who failed therapy with approved treatments. This could reduce the number of 
patients who have to be excluded from study protocols due to rapid disease 
progression. In addition, the approval of ipilimumab demonstrated the 
insufficiency of conventional RECIST to evaluate clinical success in terms of 
objective tumor responses, which led to the incorporation of immune-related 
response criteria (irRC). These response criteria should now be extended and 
define an equilibrium ( e.g. stable disease) as a positive responses criteria. 
Importantly, applying irRC on previously ran clinical studies will likely re-identify 
various immunotherapeutic strategies with proven favorable toxicity profiles and 
potential clinical benefit for patients with solid tumors. It might be more cost­
effective to first reconsider the potential of these previously tested options before 
proposing to test others. 
In conclusion, the field of immunotherapy is rapidly expanding treatment 
possibilities for patients with malignancies. These treatments require a more 
"personalized medicine" approach and novel evaluation criteria. A combination of 
therapy options is probably the most effective and could exist of vaccination, 
adoptive cell transfer and modulation of the response by therapeutic antibodies. 
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Chapter 9 Nederlandse samenvatting 
Achtergrond 
In het dagelijks leven staan we continu bloot aan potentiele ziekteverwekkers, zoals 
bacterien en virussen. Ons lichaam wordt beschermd tegen deze ziekteverwekkers 
door een leger aan witte bloedcellen die gezamenlijk het afweersysteem, ook wel 
immuunsysteem genoemd, vormen. Het afweersysteem zorgt ervoor dat alles wat 
niet in ons lichaam thuis hoort, wordt herkend en opgeruimd. Het bestaat uit twee 
verschillende delen. Het eerste deel, het aangeboren afweersysteem, wordt 
gevormd door neutrofielen, macrofagen, natural killer (NK) cellen, y8 T cellen, 
monocyten en dendritische cellen. Het aangeboren afweersysteem reageert direct 
na het binnendringen van een ziekteverwekker, waarbij de afweerreactie niet 
specifiek en slechts van korte duur is. Echter, het aangeboren afweersysteem 
activeert het tweede deel van ons afweersysteem, het verworven afweersysteem. 
Dit deel komt langzaam op gang, herkent specifiek de lichaamsbedreigende 
aanvaller en beschermt voor langere tijd tegen de betreffende ziekteverwekker. Het 
verworven afweersysteem wordt gevormd door T cellen en B cellen. Als een 
gezonde eel geYnfecteerd wordt door een ziekteverwekker worden delen van de 
ziekteverwekker (peptiden) via de HLA moleculen op het celoppervlak van de 
geYnfecteerde eel aan het afweersysteem gepresenteerd. Hierdoor wordt de 
aangeboren en verworven afweer op gang gebracht. Op het moment dat een 
gezonde eel in een tumorcel verandert, worden delen van het tumorunieke 
materiaal (tumorspecifieke peptiden) ook via de HLA moleculen op het 
celoppervlak van de tumorcel aan het afweersysteem gepresenteerd. Dit betekent 
<lat in principe ook kankercellen door het afweersysteem kunnen worden herkend 
en opgeruimd. Immuuntherapie bij kanker (tumorspecifieke immuuntherapie) is 
een behandeling die erop is gericht het afweersysteem te stimuleren om 
tumorcellen te herkennen en op te ruimen. 
Aangeboren afweer 
NK eel/en 
Binnen de aangeboren afweer spelen NK cellen een belangrijke rol in de 
herkenning en vemietiging van tumorcellen. Hun functie wordt gereguleerd door 
een complex netwerk van celstructuren (receptoren) welke diverse 
"tegenstructuren" (ligands) op een tumorcel kunnen herkennen. De interactie 
tussen een receptor en zijn specifieke ligand resulteert in een afweer remmende 
reactie als het gaat om een gezonde lichaamseigen eel, welke niet opgeruimd hoeft 
te worden. Daarentegen resulteert de interactie tussen een receptor en zijn 
specifieke ligand in een afweer activerende ( cytotoxische) reactie als het om een 
geYnfecteerde eel of een tumorcel gaat, welke opgeruimd moet worden. 
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Dendritische eel/en 
Dendritische cellen bezitten de unieke eigenschap dat ze kankerspecifieke 
eiwitstructuren (antigenen) opnemen en in brokjes (peptiden) presenteren aan T 
cellen. De presentatie van de opgenomen peptiden vindt voomamelijk in de 
lymfklieren plaats, via zogenaamde HLA moleculen. Dit zijn speciale 
presentatiemoleculen welke zich op bijna alle cellen in het lichaam bevinden. Er 
worden twee soorten presentatiemoleculen onderscheiden; HLA klasse I en II 
moleculen. Ook tumorcellen bezitten HLA moleculen, voomamelijk HLA klasse I 
moleculen. Tot nu toe is aangenomen dat vooral de HLA klasse I moleculen van 
belang zijn voor de afweer tegen tumorcellen. 
Verworven afweer 
Ten grondslag aan de verworven afweer tegen tumorcellen ligt de herkenning van 
peptiden afkomstig van tumorspecifieke eiwitten die via HLA-moleculen op het eel 
oppervlak gepresenteerd worden aan cellen van het afweersysteem 
Teel/en 
T cellen kunnen gepresenteerde peptiden op het celoppervlak van tumorcellen 
herkennen met behulp van een bepaald eiwit, de T eel receptor (TCR). Elke T eel 
heeft een TCR waarmee het een soort tumorpeptide kan herkennen. Een verworven 
afweerreactie wordt in gang gezet op het moment dat een tumorcel, bijvoorbeeld 
door de opruimreactie van het aangeboren afweersysteem, afsterft en zijn 
tumorspecifieke eiwitten in de bloedbaan vrij komen. De dendritische cellen nemen 
de vrijgekomen tumorspecifieke eiwitstructuren op en presenteren deze in de vorm 
van tumorspecifieke peptiden via de HLA moleculen op hun celoppervlak aan de T 
cellen. Dit resulteert in activatie en vermenigvuldiging van de tumorspecifieke T 
cellen en uit een tumorspecifieke T eel ontstaan vervolgens meerdere 
tumorspecifieke T cellen. Deze tumorspecifieke T cellen verlaten vervolgens de 
lymfklier om op zoek te gaan naar tumorcellen met dezelfde tumorpeptiden op hun 
celoppervlak. Op het moment dat een tumorspecifieke T eel een via de HLA 
moleculen gepresenteerde tumorpeptide herkent, wordt de tumorspecifieke T eel 
opnieuw geactiveerd. In plaats van zich te delen, scheidt de tumorspecifieke T eel 
cytotoxische granula uit, welke de tumorcel vemietigen. T cellen worden 
onderverdeeld in cytotoxische T cellen en helper T cellen. Cytotoxische T cellen 
herkennen peptiden die via HLA klasse I moleculen worden gepresenteerd, zijn 
cytotoxisch en kunnen met hun toxische granula tumorcellen vemietigen. Helper T 
cellen herkennen peptiden die via de HLA klasse II moleculen worden 
gepresenteerd en ondersteunen de cytotoxische T cellen, dendritische cellen en B 
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cellen bij het uitvoeren van hun functie. Daarnaast spelen helper T cellen een rol 
bij de "geheugenvorming" (memory) van het verworven afweersysteem. Dit is 
belangrijk, aangezien bij een eerste contact met een ziekteverwekker, het 
afweersysteem pas na enkele dagen op gang komt. Bij een tweede contact wordt 
het "geheugen" geactiveerd en verloopt de afweerreactie sneller. De memory van 
het afweersysteem is een belangrijke voorwaarde voor het langdurig "aanslaan" 
van tumorspecifieke immuuntherapie bij patienten met kanker. 
B cellen 
Via de helper T cellen worden de B cellen aangezet tot de productie van 
antilichamen. Antilichamen zijn eiwitstructuren die onder andere specifieke 
eiwitten herkennen op het celoppervlak van ziekteverwekkers, geYnfecteerde cellen 
en tumorcellen. Op het moment dat antilichamen aan kankereiwitten binden, 
worden de kankercellen voor het afweersysteem zichtbaar en worden deze 
opgeruimd. Daarnaast stimuleren B cellen op hun beurt de T cellen doordat ze, net 
zoals dendritische cellen, antigenen opnemen en als peptiden via de op hun 
celoppervlak bevindende HLA klasse II moleculen aan de T cellen aanbieden. 
Co-stimulatie 
Ben optimale T eel activatie ligt aan de basis van een optimale afweerreactie. T eel 
activatie is in de eerste plaats afhankelijk van de via de HLA moleculen 
gepresenteerde antigenen en in de tweede plaats afhankelijk van co-stimulatie. Co­
stimulatie vindt plaats via unieke receptor-ligand combinaties en draagt bij aan het 
activeren en vermenigvuldigen van afweercellen of juist aan het afremmen van 
afweercellen, bijvoorbeeld om te voorkomen dat lichaamseigen cellen worden 
gedood (auto-immuunziekten). Zonder co-stimulatie kan het afweersysteem niet 
functioneren. Ben belangrijke rol bij het herkennen en bestrijden van tumorcellen 
wordt vervuld door co-stimulatie-specifieke receptor-ligand interacties. Daarom 
staan co-stimulatie moleculen momenteel in de belangstelling van artsen en 
wetenschappers. 
In dit proefschrift wordt veel aandacht besteed aan het co-stimulatie molecuul 4-
1 BB (CD137) omdat is aangetoond dat dit molecuul zowel een rol speelt bij tumor­
specifieke afweerreacties als ook bij het ontstaan van verschillende auto­
immuunziekten. De CD 13 7-specifieke co-stimulatie receptor bevindt zich bij 
mensen op het celoppervlak van geactiveerde T cellen, NK cellen (dit proefschrift) 
en B cellen (dit proefschrift), terwijl de ligand (CD137L) zich op het celoppervlak 
van monocyten, dendritische cellen, B cellen en natural killer-like T (NKT) cellen 
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bevindt. CD 13 7-CD 13 7L interacties stimuleren de vermenigvuldiging en verlengen 
de levensduur van T cellen. Daamaast spelen CD 13 7-CD 13 7L interacties een rol in 
de NK celspecifieke afweer tegen tumorcellen. 
Actuele mogelijkheden van tumorspecifieke immuuntherapie 
Antilichamen 
Antilichamen zi jn opgebouwd uit twee delen, een Fab-gedeelte en een Fc-gedeelte. 
Het Fab-gedeelte is antigeenspecifiek en kan een tumorspecifieke structuur op het 
celoppervlak van de tumorcel herkennen. Het Fc-gedeelte van een antilichaam kan 
door NK cellen via de Fe-receptor gebonden warden waardoor vervolgens 
antilichaamafhankelijke eel cytotoxiciteit (ADCC) gestimuleerd wordt. 
Antilichamen hebben dus grofweg drie functies: (i) door het binden aan 
tumorspecifieke structuren op het celoppervlak van de tumorcel wordt de tumorcel 
zichtbaar voor het afweersysteem en kan vervolgens vemietigd warden door NK 
cel-gemedieerde ADCC, (ii) door het binden aan tumorspecifieke structuren op het 
celoppervlak wordt de groei-impuls van de tumorcel geremd en (iii) door het 
binden aan specifieke structuren op het celoppervlak van afweercellen worden deze 
geactiveerd (bijvoorbeeld bij CD 13 7-specifieke co-stimulatie) of juist geremd (bij 
het voorkomen van auto-immuunziekten). 
Cytokinen 
Cytokinen zijn eiwitten die het afweersysteem en mogelijk ook de al bestaande 
afweerreactie tegen tumorcellen kunnen activeren. 
Vaccinatie 
Tumor-specifieke vaccinatie was in eerste instantie gericht op de presentatie van 
tumorspecifieke eiwitstructuren aan T cellen door (i) tumorspecifieke peptiden, (ii) 
tumorspecifieke eiwitten, (iii) bestraalde tumor cellen of (iv) tumor eel lysaten te 
injecteren. De gedachte was dat op deze manier de dendritische cellen de 
geYnjecteerde eiwitstructuren zouden opnemen en presenteren aan de T cellen. 
Later werden behandelingsstrategieen ontwikkeld waarbij dendritische cellen 
beladen met tumorspecifieke eiwitstructuren of getransfecteerd met tumorspecifiek 
materiaal werden geYnjecteerd. In dit geval konden de opgenomen tumorspecifieke 
eiwitstructuren via de op de dendritische eel aanwezige HLA moleculen aan het 
afweersysteem gepresenteerd worden. Deze strategie vormde in 2010 de basis voor 
de eerste op afweercellen gebaseerde behandeling van patienten met prostaatkanker 
(Sipuleucel-T; Provenge®). 
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Adoptieve eel transfer 
Bij adoptieve eel therapie (ACT) worden afweercellen uit de bloedbaan gersoleerd 
en buiten het lichaam achtereenvolgens geselecteerd, geactiveerd en 
vermenigvuldigd. Nadat de betreffende afweercellen voldoende geactiveerd en 
vermenigvuldigd zijn, worden ze via een infuus direct in de bloedbaan van de 
patient terug gegeven. Op <lit moment ligt het zwaartepunt bij de 
vermenigvuldiging en infusie van T cellen ( al dan niet genetisch gemodificeerd). 
De interesse in selectie, activatie en vermenigvuldiging van NK cellen voor 
adoptieve NK eel therapie staat echter ook in de belangstelling ( <lit proefschrift). 
Hindernissen bij de toepassing van tumorspecifieke 
immuuntherapie 
Voor een succesvolle vemietiging van tumorcellen is het noodzakelijk <lat het 
afweersysteem voldoende geactiveerd wordt en <lat de geactiveerde afweercellen 
de tumorcellen herkennen. Helaas is aangetoond <lat de afweercellen van mensen 
met kanker afwijken van de afweercellen van mensen zonder kanker. 
Kankerpatienten hebben bijvoorbeeld minder co-stimulatie en HLA klasse II 
moleculen op het celoppervlak van hun dendritische cellen. Ook is aangetoond <lat 
de TCR bij kankerpatienten minder goed functioneert en dat kankerpatienten 
verhoogde aantallen van afweerremmende T cellen bezitten (regulatoire T cellen). 
Daamaast bezitten tumorcellen de mogelijkheid om zich tegen het afweersysteem 
te beschermen door zelf afweerreacties af te remmen of door zich onzichtbaar te 
maken. Dit gebeurt bijvoorbeeld door het uitscheiden van afweerremmende stoffen 
door de tumorcel, door het tot expressie brengen (up-regulatie) van 
afweerremmende ligands op het celoppervlak van de tumorcel en door een 
verminderde expressie van HLA moleculen ( down-regulatie) op het celoppervlak 
van de tumorcel. 
Het is dus duidelijk dat tumorspecifieke immuuntherapie verschillende afwijkingen 
in het afweersysteem moet omzeilen, alvorens het afweersysteem te kunnen 
activeren. Daamaast is het aannemelijk dat het na elkaar of gelijktijdig toepassen 
van verschillende vormen van immuuntherapie een grotere kans op genezing biedt. 
Dit proefschrift 
Op dit moment is tumorspecifieke immuuntherapie vooral gericht op de 
vemietiging van tumorcellen door antilichamen en op de activatie van cytotoxische 
T cellen binnen de verworven afweer. Relatief weinig therapieen richten zich op de 
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optimalisatie van co-stimulatie, de aangeboren afweer en helper T cellen. Om de 
invalshoeken van tumorspecifieke immuuntherapie verder uit te breiden, mede met 
het doel om bestaande immuuntherapeutische mogelijkheden verder te 
optimaliseren, wordt in <lit proefschrift de therapeutische potentie van CD 13 7-
specifieke co-stimulatie ( deel A) en NK eel therapie ( deel B) voor de behandeling 
van patienten met solide tumoren beschreven. Daamaast worden de eerste klinische 
resultaten van vaccinatie met HLA klasse I en II specifieke MAGE- en HPV­
peptiden bij patienten met hoofd-hals tumoren besproken. 
Deel A: CD137-specifieke co-stimulate 
Het eerste deel van dit proefschrift richt zich op de rol van CD137 op menselijke 
NK cell en, B cell en en de toepassing van diermodellen op de translatie van CD 13 7-
specifieke antilichamen naar bruikbare medicijnen in klinische studies voor 
patienten met solide tumoren. 
Hoofdstuk 2 
Gebaseerd op (i) de in muismodellen aangetoonde rol van CD137-specifieke 
antilichamen in de afweerreactie tegen tumorcellen, (ii) de cruciale rol van muizen 
NK cellen in CD137-gemediieerde afweerreacties tegen tumorcellen en (iii) de 
belangrijke rol van Fc-receptoren in het functioneren van antilichamen in het 
algemeen, hebben we in hoofdstuk 2 van dit proefschrift de uitwerking van 
CD 13 7- specifieke antilichamen op menseli jke NK cellen bestudeerd. Vanwege de 
aangetoonde rol van NK cellen in de door CD 13 7-specifieke antilichamen 
gestimuleerde tumorspecifieke afweerreactie in muizen, gingen we ervan uit dat 
Interleukine-(IL )2 geactiveerde menselijke NK cellen het molecuul CD 13 7 tot 
expressie zouden brengen. Ook gingen we ervan uit dat binding van het CD 13 7-
specifieke antilichaam aan het molecuul CD 13 7 zou leiden tot NK eel gemedieerde 
cytotoxiciteit. De resultaten lieten echter zien dat menselijke, IL-2 geactiveerde NK 
cell en geen tot zeer weinig CD 13 7 tot expressie brengen. In tegendeel, voor het tot 
expressie brengen van CD137 op menselijke NK cellen, diende de Fe-receptor van 
de NK eel het Fc-gedeelte van het antilichaam te binden. Daamaast toonden we aan 
dat het tot expressie brengen van CD137 niet afhankelijk is van het Fab-gedeelte 
van het antilichaam en dat de hoeveelheid CD 13 7 expressie geassocieerd is met het 
aantal aanwezige glucosemoleculen (suikers) in het Fc-gedeelte van een 
antilichaam. Deze bevindingen zijn belangrijk voor de juiste interpretatie van 
gepubliceerde experimenten met CD 13 7-specifieke antilichamen in muizen. 
CD137-specifieke afweerreacties, welke geYnterpreteerd werden als Fab­
gemedieerd kunnen door onze resultaten evenwel Fc-gemedieerd zijn. 
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Hoofdstuk 3 
Op basis van de bevindingen in hoofdstuk 2 ontstond er twijfel over de relevantie 
van muismodellen om menselijke afweerreacties op CD 13 7-specifieke 
antilichamen te voorspellen. B cellen spelen een duidelijke rol in de afweer tegen 
tumorcellen en aangenomen wordt dat de stimulatie van CD 13 7 op T cell en 
verantwoordelijk is voor de veranderingen in B cel-gemedieerde afweer en de 
overleving van B cellen. Er is echter weinig bekend over de directe rol van CD 13 7-
gemedieerde co-stimulatie op menselijke B cellen. Hier is ook van belang dat 
muizen B cellen geen CD 13 7 tot expressie brengen en dat menselijke B cellen 
CD 13 7 tot expressie brengen na stimulatie met antilichamen. In hoof dstuk 3 
hebben we eerst geevalueerd welke signalen verantwoordelijk zijn voor de 
expressie van CD 13 7 op menselijke B cellen. Daama hebben we bekeken welke 
invloed CD137 heeft op de functie van menselijke B cellen. Onze experimenten 
toonden aan dat antilichaamgeactiveerde menselijke B cellen, CD 13 7 tot expressie 
brengen op het moment dat de B eel receptor (BCR) gestimuleerd wordt. 
Stimulatie van het CD 13 7 molecuul op menselijke B cellen leidde tot B eel deling 
en een betere B eel overleving. Uit deze experimenten konden we concluderen dat 
de expressie van CD 13 7 op menselijke B cellen zeer nauwkeurig geregeld wordt, 
afhankelijk is van stimulatie met antilichamen en dat de BCR de uiteindelijke 
expressie van CD 13 7 op menselijke B cellen bepaald. 
Hoofdstuk 4 
Nieuwe behandelingsmogelijkheden mogen alleen aan mensen met kanker warden 
aangeboden als de uitwerking van het nieuwe medicijn op proefdieren als "veilig" 
kan warden aangenomen. Normaal gesproken moeten nieuwe medicijnen zowel op 
muizen als apen op veiligheid warden getest. Om in proefdieren te kunnen 
vaststellen of een medicijn als "veilig" kan warden beschouwd, is het noodzakelijk 
dat de afweercellen van het proef dier of de tumor van het proef dier het te testen 
medicament herkent en kan binden. De in hoofdstuk 2 en 3 aangetoonde 
verschillen in CD 13 7 expressie tussen muizen en menselijke NK cell en en B cell en 
brengen duidelijk de grenzen van het voorspellend vermogen van muismodellen op 
de invloed van CD137-specifieke co-stimulatie op het menselijke afweersysteem 
naar voren. Om vast te kunnen stellen welk proefdier voor het testen van de 
CD 13 7-specifieke antilichamen geschikt is, hebben we in hoofdstuk 4 gekeken of 
de CD137 moleculen op het celoppervlak van witte bloedcellen van mensen, 
resusapen en bavianen het CD 13 7-specifieke antilichaam herkenden en konden 
binden. Dit bleek een waardevolle test, aangezien het CD 13 7-specifieke 
antilichaam het CD 13 7 molecuul op de witte bloedcellen van apen niet bond. Dit 
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was uiteindelijk terug te voeren op een klein, maar essentieel, genetisch verschil 
tussen witte bloedcellen van mensen en apen. Alleen chimpansees hebben de 
gelijke genetische CD 13 7 codering en onderzoek met deze apen is streng 
gelimiteerd. 
Deel B: NK eel therapie 
Hoofdstuk 5 
Voor celtherapie met NK cellen is het essentieel om deze cellen buiten het lichaam 
te kunnen vermenigvuldigen. Eerder onderzoek heeft aangetoond dat CD 13 7-
CD 13  7L interacties het vermenigvuldigen van NK cellen buiten het menselijk 
lichaam stimuleert. In hoofdstuk 5 beschrijven we de succesvolle 
vermenigvuldiging ( expansion) van NK cellen uit het bloed van patienten met 
maagkanker, longkanker, darmkanker en leverkanker. Ook toonden we aan dat ze 
NK celspecifieke cytotoxische moleculen op hun celoppervlak tot expressie 
brengen, waarmee ze in staat zijn om lichaamseigen tumorcellen te herkennen en 
op te ruimen. Ook lieten de experimenten in dit hoofdstuk zien dat de 
vermenigvuldigde NK cellen in staat zijn tot ADCC, aangezien hun cytotoxisch 
vermogen duidelijk toenam in de aanwezigheid van een antilichaam welke het 
molecuul EGFR op tumorcellen herkent en bindt. De op het celoppervlak van de 
NK eel tot expressie gebrachte cytotoxische moleculen speelden hierbij een 
cruciale rol. Daamaast werd een eerste stap naar de klinische toepassing van deze 
cellen in NK celtherapie gezet door aan te tonen <lat een reeds bestaande techniek 
voor de isolatie van monocyten ter voorbereiding van celtherapie met dendritische 
cellen ook toegepast kan worden voor het op grote schaal produceren van 
cytotoxische NK cellen voor NK celtherapie. Tevens kan de gecombineerde 
toepassing van de NK cellen, beschreven in <lit hoofdstuk, met al bestaande 
tumorspecifieke antilichamen het therapie-effect van deze antilichamen versterken. 
Hoofdstuk 6 
Voor NK eel gemedieerde ADCC is de interactie tussen het Fc-gedeelte van een 
antilichaam en de Fe-receptor op de NK eel essentieel. Eerder onderzoek heeft 
aangetoond dat specifieke genetische veranderingen (polymorphismen) in de Fe­
receptor geassocieerd zijn met een verhoogde kans op slagen van een behandeling 
met antilichamen bij patienten met een lymfoom. Omdat in hoofdstuk 5 kon 
worden aangetoond <lat door ADCC de cytotoxiciteit van de vermenigvuldigde NK 
cellen duidelijk toenam, hebben we in hoofdstuk 6 bepaald of de eerder 
aangetoonde Fc-polymorphismen bij patienten met bloedkanker ook een rol spelen 
bij patienten met solide tumoren. Om dit te onderzoeken hebben we in hoofdstuk 6 
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het effect van verschillende Fc-polymorphismen op EGFR-gemedieerde ADCC in 
hoofd-hals tumoren met elkaar vergeleken. Uit de experimenten bleek dat bij 
patienten met hoofd-hals tumoren Fc-polymorphismen niet alleen een rol spelen bij 
ADCC maar ook bij het antigeen-onfhankelijke vermogen van NK cellen om 
tumorcellen te herkennen en te vemietigen. Dit is een belangrijke bevinding, 
aangezien op deze manier vooraf bepaald kan warden bij welke patienten een 
behandeling met tumorspecifieke antilichamen of NK cellen een hoge kans van 
slagen heeft. 
Deel C: Van de theorie naar de praktijk 
In eerste instantie werd aangenomen dat HLA klasse I moleculen en cytotoxische T 
cellen onmisbaar zijn in de verworven afweer tegen tumorcellen. Door het op grote 
schaal "falen" van vaccinatiestudies, waarbij alleen de cytotoxische T cellen 
geactiveerd werden, werd de noodzaak tot het activeren van zowel cytotoxische T 
cellen als ook helper T cellen aannemelijk. Hoofdstuk 7 bevat de eerste klinische 
resultaten van de behandeling van patienten met hoofd-hals tumoren met Trojan­
peptiden. Trojan-peptiden zijn opgebouwd uit verschillende HLA klasse I en II 
peptiden met het doel cytotoxische T cellen en helper T cellen te activeren. Bij vier 
van de vijf behandelde patienten konden we aantonen dat de helper T cellen door 
vaccinatie met de Trojan-peptiden geactiveerd werden. Daamaast werden bij een 
patient ook de cytotoxische T cellen geactiveerd. De vaccinaties werden door de 
patienten goed verdragen en drie van de vijfbehandelde patienten leefde langer dan 
24 maanden in een situatie waar normaal gesproken de levensverwachting onder de 
zes maanden ligt. 
Verschillende aspecten van deze klinische studie zijn van belang voor de toekomst 
van tumorspecifieke immuuntherapie. Zoals eerder beschreven moeten 
verschillende afwijkingen in het afweersysteem omzeilt warden, alvorens het 
afweersysteem geactiveerd kan warden. De Trojan-peptiden zijn in eerste instantie 
gericht op de activatie van het afweersysteem en omzeilen niet de eventueel 
bestaande afwijkingen in de afweercellen van een patient. Aangezien het 
aannemelijk is dat alleen het, na elkaar of gelijktijdig, toepassen van verschillende 
vormen van immuuntherapie een kans op genezing biedt, kan de werking van de 
Trojan-peptiden geoptimaliseerd worden door bijvoorbeeld gelijktijdig met 
CD 13 7-specifieke antilichamen te behandelen. Ook het aantal aanwezige 
tumorcellen bepaald sterk de kans van slagen van tumorspecifieke immuuntherapie 
aangezien een patient met een groot aantal tumorcellen (uitzaaiingen) zeer 
waarschijnlijk ook meer tumorspecifieke T cellen nodig heeft om alle tumorcellen 
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te kunnen vemietigen. Vaccineren in een vroeg, nog beter "tumor vrij", stadium is 
dus noodzakelijk. 
Conclusies 
In de afgelopen 20 jaar heeft tumorspecifieke immuuntherapie een plaats 
ingenomen in de behandeling van patienten met kanker. De toegenomen 
duidelijkheid over de interactie tussen het afweersysteem en tumorcellen heeft 
ertoe bijgedragen dat op dit moment verschillende potentiele 
behandelingsmogelijkheden in klinische studies aan patienten met kanker warden 
aangeboden (www.clinicaltrials.gov). Samengevat bouwt dit proefschrift de 
bestaande invalshoeken van tumorspecifieke immuuntherapie verder uit. Het 
beschrijft de potentie, uitdagingen in klinische translatie en mogelijkheden tot het 
gecombineerd inzetten van CD 13 7 -specifieke co-stimulatie en op NK cell en 
gebaseerde celtherapie met het doel bestaande mogelijkheden verder te 
optimaliseren. Met het gegeven dat iedere patient met kanker unieke afwijkingen in 
het afweersysteem heeft, waardoor in de eerste plaats de ziekte kanker heeft 
kunnen ontstaan, is het aannemelijk dat alleen het gecombineerd inzetten van 
vaccinatie, adoptieve eel therapie en manipulatie van het afweersysteem door ( co­
stimulatie-specifieke) cytokinen en antilichamen, kan leiden tot een succesvolle 
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Figure 3. CD137 is preferentially expressed on activated B cells of naive origin 




Purified human B cells were activated with anti-Ig/anti-CD40. After 3 days, B cells were harvested and CD137  
expressing B cells and non-CD1 37 expressing B cells were assessed for  cell surface phenotype by flow cytometry 
(A). Histograms show surface expression of indicated markers on CD1 37+ B cells and CD1 3T B cells. Filled 
peaks represent isotype controls. Data are representative of 5 individual experiments. Purified human B cells were 
separated into nai've (CD 1 9+CD2T) and memory (CD19+CD271 B cells and subsequently stimulated with anti­
Ig/anti-CD40. CD1 37 surface expression was determined at indicated time-points (B). Data shown are 
representative of 5 individual experiments. *P<0.05. 
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Tonsillar mononuclear cells were analyzed for CD137 expression on B cells by FACS. B cells (CD19+CD3") were 
gated and the percentage of CD I 3 7 expression on B cells is indicated in a dot plot (A). Data are representative of 6 
individual experiments from different donors. The phenotype of CD137+ B cells was analyzed in comparison to 
CD13T B cells (B). Filled peaks indicate isotype controls. Data are representative of 5 individual experiments. 
Three-color immunohistochemistry of human tonsil sections was used to identify the localization of CD137 
expressing B cells. The upper panel shows a tonsillar germinal center ( original magnification x20; CD20, green; 
CD137, red; DAPI, blue) (C) and follicular mantle zone (IgD, green; CD137, red; DAPI, blue) B cells (D). The 
indicated area from germinal centers and follicular mantle zones were enlarged to identify the CD20+/CD1 3 7+ and 
Ign•;cD137+ cells (lower panel). 
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Figure 5. Trojan-specific precursor frequency at the injection site exceeds precursor frequency in the 
peripheral circulation. Frozen section slides were generated from a granuloma derived from the site of 
immunization and stained by immunohistochemistry with a variety of leukocyte-specific markers. The granuloma 
was biopsied 19 days after the second vaccination. PET scan revealing high levels of inflammation at the injection 
sites as indicated by arrows (A); high numbers of antigen-presenting cells (CD68+) and CD3+ T cells infiltrated the 
site of immunization (B); part of the granuloma was enzymatically digested into a single cell suspension and 
evaluated for Trojan-vaccine specificity (C). As measured by flow cytometry, the majority of CD3+ T cells in the 
granuloma were found to be CD4+ cells. Next, cells were directly ex vivo evaluated for Trojan-specificity by IFNy 
Elispot. High numbers of Trojan-specific cells were found at the site of injection (D). In contrast, at the same time­
interval, no Trojan-specific responses were detected in cells (PBMC) derived from the peripheral circulation. 
Number of spots per 50,000 cells (granuloma) and I 00,000 cells (PBMC) is shown. Error bars represent SD from 
triplicate wells. * P<0.05 
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Figure 6. CD8+ and CD4+ T cells infiltrate the tumor microenvironment during immunization and a subset 
appears to be HPV-specific. Photomicrographs of immunohistochemical staining of tumor tissue harvested 
before and after immunization with HPV-Trojan vaccine. High numbers of CD8+ and CD4+ cells were found in the 
tumor micro-environment after immunization (A). Representative sections from CD4 and CD8 staining of the 
neck metastasis slides before and three months after the last vaccination are shown. Positive controls were positive 
for all experiments (inset CD4). Part of the neck metastasis, collected at three months after immunization, was 
enzymatically digested into a single cell suspension (TIL). PBMC collected before and PBMC and TIL collected 
after three months of immunization were directly ex vivo stained with HPV-16  specific HLA-A*0201 tetramer and 
analyzed by flow cytometry for Trojan HLA-1 specificity (B). In comparison to PBMC collected at the same time­
interval, TIL derived from the tumor micro-environment after 3 months of immunization were found to be HPV-
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CAAAGCCTCTGAGTCCTTGCAGCTGGTCTTTGGCATTGACGTG 69 7 
CAAAGCCTCCGAGTCCCTGAAGATGATCTTTGGCATTGACGTG 7 1 9  
CAAAGCCTCCGAGTCCTTGCAGCTGGTCTTTGGCATTGACGTG 7 0 3  
CAAAGCTTCCGATTCCTTGCAGCTGGTCTTTGGCATCGAGCTG 6 9 2  
CAAAGCCTCCGAGTACTTGCAGCTGGTCTTTGGCATCGAGGTG 642 
CAAAGCCTCCGAGTACTTGCAGCTGGTCTTTGGCATCGAGGTG 9 7 7  
* * * * * *  * *  * * * *  * *  * *  * * * * * * * * * *  * *  * *  
Supplemental figure 1 .  Specific Amplification of MAGE-A3. RNA was extracted from cell lines TU1 59 (lanes 
2,3), 0 12SCC (lanes 4,5) and HW12 (lanes 6,7) which express multiple MAGE proteins. PCR was then performed 
with the previously published MAGE-A3 primers (A) or with primers MA3 _F4 and MA3 _R4 (B). PCR products 
from both sets of primers were subjected to restriction digestion with Eco RI and then separated by agarose gel 
electrophoresis [(-) undigested, (+) digested]. PCR products that were amplified with MA3-F4 and MA3-R4 
resulted in complete digestion of the product (B) while PCR products amplified by the previously published 
MAGE-A3 primers resulted in incomplete digestion, suggesting of non-specific amplification (A). Direct 
sequencing of the MA3_F4 and MA3_R4 PCR products confirms the specificity of the amplified sequence as 
demonstrated by the chromatogram and multiple sequence analysis of the homologous MAGE genes are the 
region of the Trojan peptide (C). 
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H&E H LA-A2 
Supplemental figure 2. Loss of HLA-A *02 expression in SCCHN. {Top) H&E stain of the tumor shows sparse 
keratinization (left) and complete loss of HLA-A *02 staining, whereas the interstitial fibrous tissue shows intense 
staining (right). (Bottom) H&E stain of the tumor shows extensive keratinization (left) and intense tumor cell 
staining for HLA-A *02 (right). 
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Supplemental figure 3. Quantitative immune responses. Quantitative immune responses as measured by re­
stimulation Elispot of both patients who completed the full vaccination schedule are presented for MAGE­
A3/patient 3 (A) and HPV-16/patient 5 (B). White bars indicate responses against the Trojan vaccine; black bars 
indicate responses against the RTL-peptide; dotted bars indicate responses against the CTL peptides. Error bars 
represent SD from triplicate wells 
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Supplemental figure 4. Trojan peptide-based vaccines fail to induce robust immunity to the HLA-1 
restricted epitope. Percentage of circulating MAGE-A3 and HPV-16 specific cos+ T cells were determined by 
staining of peripheral blood mononuclear cells obtained before and after immunization with control CTL 
(YIGEVLVSV), MAGE-CTL 1 (KVAELVHFL) and MAGE-CTL2 (FLWGPRALV) or HPV-CTL (TLGIVZPI) 
specific tetramer. Percentage of vaccine-specific cos+ T cells was calculated by subtracting the number of cells 
which stained positive with control tetramer. Percentage of CDS4Tetramer T cells is shown at indicated time­
points for patient 1 (A), patient 2 (B), patient 3 (C) and patient 5 (D). 
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Supplemental table 1 CD3+, CDS+ and total white blood cell counts before treatment 
Value8 Patient 
1 2 3 
WBC (K/mcL) 4.8 9.4 7.2 
CD3+ (%) 44.1 5.1 29.2 
CD3+CD8+ (%) 42. 25.2 31.5 
"WBC; white blood cell count (normal range 4.0-1 0.0 K/mcL) 
bsingle use exemption, due to a secondary diagnosis of myelodysplastic syndrome 
n/a, not applicable 
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